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ABSTRACT
The SLC6 family of secondary active transporters is made up of integral membrane
solute carrier proteins characterized by the Na+-dependent translocation of small amino acid or
amino acid-like substrates. SLC6 transporters, particularly the monoamine transporters (MATs)
of serotonin, dopamine and norepinephrine, are some of the most heavily studied proteins today
due to their association with a number of human diseases and disorders, making MATs a critical
target for therapeutic development. In addition, MATs are directly involved in the action of
drugs of abuse such as cocaine, amphetamines, and ecstasy.
Following the first cloning of a MAT gene in the early 1990s, much has been uncovered
about the structure and function of these proteins. Early studies developed an understanding of
the kinetic parameters by which MATs operate and also yielded enough information to model the
basic structural characteristics of MATs. This was greatly improved upon within the last decade,
as crystallographic and computational advances have provided structural insights that have vastly
accelerated our ability to study these proteins and their involvement in complex biological
processes. However, despite a wealth of knowledge concerning the structural and kinetic
characteristics of MATs, little is understood as to how these features are interrelated and much is
still unclear as to the how regulation (and maybe more importantly, dysregulation) of MATs
alters the functionality of these proteins at the molecular and synaptic levels.
The overall goal of this dissertation was to comprehensively examine the relationship
between MAT structure and the ions and ligands that bind to MATs to promote/prevent
xviii

transporter function. This was done using a comprehensive approach that included biological,
electrophysiological and computational techniques to target and elucidate the roles of specific
amino acid residues in ion/ligand binding and/or mediation of the substrate translocation process.
In successfully examining a number of specific MAT residues, this work has lead to the
deduction of basic roles for each of the ion binding sites in the translocation mechanism
(chapters II and III), as well as detailed the importance of specific structural components of
MATs that are vital for functionality (chapters IV and V). Furthermore, this dissertation includes
work highlighting the development of several photo-labeled, radio-iodinated antagonist
analogues that will be used to further improve the understanding of how inhibitors bind to and
block MAT function at the molecular level (chapter VI). In total, the work outlined in this
dissertation provides a clearer understanding as to the molecular interactions that are necessary
for MAT function and contributes an improved appreciation for the underlying mechanisms of
substrate translocation and pharmacological intervention.
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CHAPTER I
INTRODUCTION
The Solute Carrier Super-family of Proteins
The solute carrier (SLC) transporter super-family is comprised of approximately 350
transporters organized into 55 families. A majority of SLC members are integral, plasmalemmal
proteins that are responsible for the transport of a wide range of impermeant solutes across cell
membranes. SLC transporters have an extraordinarily diverse range of substrates that include
both charged and uncharged organic molecules along with inorganic ions and the gas ammonia.
However, despite such a large array of functions, the overall tertiary structure of SLC
transporters has been shown to be remarkably similar, with all the solved SLC structures
exhibiting a 5 + 5 arrangement of α-helices that have been termed the “LeuT-fold,” after an
amino acid transporter from the bacterium A. aeolicus that was the first SLC transporter to have
a high-resolution crystal structure solved. This 5 + 5 arrangement consists of two bundles of 5
transmembrane helices (TMs) that are bundled together and exhibit inverted symmetry in
relation to each other, supporting the idea of a conserved mechanism throughout the SLC family.
This similarity in the “super-structure” of SLC proteins is especially surprising, given that very
little homology is found in the primary amino acid sequence of SLC transporters from different
sub-families.
The SLC6 family is among the largest and most studied of the SLC class, containing 20
genes that encode a group of structurally similar transporter proteins. These proteins transport
1

amino acids and amino acid derivatives across the plasma membrane against a concentration
gradient by coupling substrate movement to the extracellular electrochemical Na+ gradient.
Whereas SLC6 transporters are found from bacteria to man, the vast majority of information
concerning the SLC6 family comes from studies of the glycine, γ-amino-butyric acid (GABA),
serotonin, norepinephrine and dopamine neurotransmitter transporters, due to their importance in
mental health and addiction. In the CNS of higher order species, the cognate substrates for
neurotransmitter tranporters are all common neurotransmitters that transmit chemical messages
that are critical for a range of essential brain functions. Whereas the neurotransmitters glycine
and GABA are considered inhibitory transmitters, as they are associated with the regulation of
neuronal excitability throughout the CNS, the monoamine neurotransmitters serotonin (5-HT),
dopamine (DA) and norepinephrine exhibit an increased amount of diversity in terms of the roles
that each pathway performs. My work will focus primarily on the monoamine neurotransmitter
transporters (MATs), with particular emphasis on the serotonin transporter (SERT) and the
dopamine transporter (DAT).

The Neurophysiologic Role of MATs
The expression of MATs is primarily associated with their respective monoaminergic
neurons, and thus the presence of MATs is typically used as a marker for specific
monoaminergic systems (Huang and Lin 2015). MATs are distributed in both the dendrites and
along the axons of presynaptic monoaminergic neurons (Figure 1). Here, the MATs mediate the
rapid reuptake of neurotransmitter released into the synapse during chemical neurotransmission
and also play a role in neurotransmitter recycling, as transport of neurotransmitter back into the
2

Figure 1. Role of MATs in synaptic transmission. Cartoon depicting a
chemical synapse during signal transduction. Neurotransmitter (black dots) is
cleared from the synapse by MATs. Once transported back into the presynaptic
neuron, neurotransmitter can then be repackaged back into vesicles by VMAT.
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pre-synaptic neuron thereby allows for the sequestration of neurotransmitter back into synaptic
vesicles by vesicular monoamine transporters (VMAT1 and VMAT2) (Iversen 1971; Anne and
Gasnier 2014). Thus, MATs have a critical regulatory influence on the process of synaptic
transmission by both terminating receptor-mediated signaling events and replenishing vesicular
neurotransmitter pools.
Due to their crucial role of keeping basal extracellular concentrations of
neurotransmitters low, malfunction or improper regulation of MATs contributes to a number of
neurological and neuropsychiatric disorders (Gether et al. 2006; Pramod et al. 2013). MATs
alone have been implicated in a variety of mental illnesses including (but not limited to), major
depression, anxiety, addiction, autism, attention deficit disorder, schizophrenia and obsessive
compulsive disorder (Hahn and Blakely 2002; Sakrikar et al. 2012; Hamilton et al. 2013; Pramod
et al. 2013; Hansen et al. 2014). Given their clinical significance, it is unsurprising that MATs
are targets for a number of therapeutic and illicit compounds. These include tricyclic
antidepressants, selective serotonin reuptake inhibitors and the drugs of abuse cocaine,
methamphetamine and methylene-dioxymethamphetamine (MDMA, ecstasy) (Tatsumi et al.
1997; Amara and Sonders 1998; Kristensen et al. 2011). Despite the importance of MATs as
drug targets however, surprisingly little is known about their molecular pharmacology, including
localization and structure of drug binding sites along with the molecular mechanism of action.
Recent progress provided by crystal structures of a single eukaryotic and several prokaryotic
SLC6 transporters has provided a new level of insight into the structural biology of the MATs
that presents new opportunities to interpret existing knowledge, as well as guide new studies
aimed at better understanding how drugs bind, interact with and functionally modulate MATs.
4

Monoamine Transporter Structure
Following the first cloning of a MAT gene in the early 1990s (Blakely et al. 1991;
Hoffman et al. 1991; Pacholczyk et al. 1991), much has been uncovered about the structure and
function of MATs. Early studies used extensive biochemical and mutagenesis studies to develop
an understanding of the kinetic parameters by which MATs operate and provide indispensable
insight into transporter topology and secondary structure. However, this work was limited as it
was not able to successfully produce much information on the tertiary structure of MATs. This
was greatly improved upon within the last decade, as a number of prokaryotic as well as a single
eukaryotic SLC family member have been crystallized.
The first crystal structure of an SLC6 family member was reported by Yamashita et al. in
2005, whereby a high-resolution X-ray crystallographic structure of a prokaryotic homolog to the
SLC6 transporters, dubbed the leucine transporter (LeuT), was obtained from the thermophile
bacterium A. aeolicus. This first crystal structure provided unambiguous insight into central
aspects of the structural biology of SLC6 transporters, including long-sought details for how
SLC6 transporters accommodate substrate and ions. Importantly, this crystal structure displayed
features that closely matched what the previous biochemical analysis had predicted, suggesting
that LeuT was a useful structural and functional template for understanding MATs (Singh et al.
2008). This has since been confirmed with the successful crystallization of the first eukaryotic
SLC6 protein, a dopamine transporter from Drosophila melanogaster (dDAT) (Penmatsa and
Gouaux 2013). In addition, the discovery of a remarkable structural conservation between LeuT
and secondary active transporters from other transporter families, not originally thought to be
structurally or mechanistically related to SLC6 transporters (Abramson and Wright 2009), have
5

further strengthened the validity of using LeuT as a structural template for understanding
fundamental aspects of MAT function.
In general, SLC6 proteins have twelve defined TMs with intracellularly-facing N- and Ctermini (Figure 2). Unlike the prokaryotic SLC6 family members, MATs feature N- and Ctermini that are significantly longer and have been shown to mediate complex regulatory
processes, such as transporter trafficking, ion stoichiometry and protein function (Kristensen et
al. 2011; Pramod et al. 2013; Vaughan and Foster 2013). Moreover, MATs also feature a number
of intracellular sites for post-translational modifications such as phosphorylation and
palmitoylation and an extended extracellular loop 2 domain (EL2) between TMs 3 and 4 which
contains a several glycosylation sites as well as a critical disulfide bond (discussed further in
chapter V) (Vaughan and Foster 2013) (Figure 2). Nevertheless, MATs and LeuT share only a
modest 20-25% overall sequence identity that increases to greater than 50% identity when
focusing on the core binding region where the bound substrate is located in the LeuT crystal
(Yamashita et al. 2005). The LeuT and dDAT crystal structures have revealed that SLC6
transporters are based on a 5 + 5 helical architecture where TMs 1–5 and TMs 6–10 form two
pentihelical bundles aligned antiparallel to one another yielding a pseudo-twofold axis of
symmetry (Figure 3A). TMs 11 and 12 in LeuT lie peripheral to the 5 + 5 core and may play a
less critical role in transport but important functions in other aspects of structure or regulation.
The substrate permeation pathway is formed almost exclusively by TM1, TM3, TM6, and
TM8 and holds a central substrate-binding site (S1) in which the substrate and two Na+ ions are
accommodated (Figure 3, A and B) (Yamashita et al. 2005). Directly above the binding site is an
external “lid” formed by the aromatic side chains of Y108 on TM3 and F253 on TM6. This
6

Figure 2. Basic structure of a MAT. Cartoon representing a simplified layout of a
MAT's structure. There are 12 transmembrane-spanning helical domains, as well as intraand extracellular loop regions (glycosolation sites in extracellular loop 2 are represented
as Ys) including both N- and C-termini that face intracellularly.
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hydrophobic lid is supported by the presence of a water-mediated ionic interaction between R30
on TM1 and D404 on TM10 (Figure 3B). In a LeuT crystal structure with the noncompetitive
inhibitor tryptophan complexed, a direct interaction between the inhibitor and the side chains of
R30 and D404 is observed, suggesting that this ionic interaction may be important for proper
function of the translocation mechanism (Singh et al. 2007; Zhou et al. 2007; 2009). Importantly,
this ionic interaction at the outer gate is conserved in MATs (although the Asp is replaced by a
Glu in SERT). The importance of the formation of this putative salt bridge in AMPH recognition
and translocation by SERT is the topic of chapter V.
The intracellular gate found just below the binding site is much thicker than its
extracellular counterpart. This structure is stabilized mainly by an interaction network formed
between the ionic pairing of R5 and D369, as well as by S267 and Y268 (Figure 3B). Adjacent to
these residues is a bulky side chain of a tryptophan (W8), which has also been suggested to
provide strength to the substructure (Yamashita et al. 2005; Singh et al. 2007; Zhou et al. 2007;
Singh et al. 2008; Zhou et al. 2009).
The extracellular and intracellular gating regions prevent access to the binding region
when in an occluded or closed conformation, eliminating the non-specific movement of substrate
or ions in either direction and forcing the substrate to move into the cell following translocation
(Yamashita et al. 2005; Kanner 2008; Singh et al. 2008). This crucial role is supported by the
observation that all residues participating in the two networks are strictly conserved across the
MATs except for D404, which is conservatively substituted by a Glu in SERT (Beuming et al.
2006).
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The Substrate Binding Pocket
LeuT and the MATs share a remarkably high sequence similarity (upwards of 65%) in the
regions that contain core transport machinery, especially within TMs 1, 3, 6 and 8, which
makeup the substrate permeation pathway and house the substrate binding site (S1) along with
the Na+ binding sites (Yamashita et al. 2005; Beuming et al. 2006)(Figure 3B). Consequently,
the LeuT crystal structures provide sound templates for which homology models of MATs can
be constructed (Yamashita et al. 2005; Beuming et al. 2006; Rudnick 2006; Henry et al. 2006a).
In general, the high degree of sequence similarity observed between the core region of LeuT and
the MATs produce models with very similar overall structure. By contrast, some of the more
variable loop regions have little to no homology and are therefore more difficult to align with the
LeuT template (Beuming et al. 2006). Similarly, LeuT has considerably shorter N- and C-termini
and thus these regions have also been very difficult to recreate computationally. However, the
recent solving of the dDAT crystal structure does provide a more detailed look into some of the
regions that previously were unsolved, with the caveat that several point mutations, a large
deletion in EL2 and use of a Fab fragment were needed in order to thermo-stabilize dDAT for
crystallography (Penmatsa et al. 2013).
Due to the large number and variety of crystal structure conformations available for LeuT,
much of this introduction will focus on the particular structural features that are important for
substrate/ion binding and the translocation machinery of LeuT. Importantly, many of the amino
acids that are functionally important for LeuT are conserved in MATs. Likewise, important
functional residues that are not highly conserved between LeuT and the MATs generally suggest
an evolutionary reason for this discrepancy. Throughout this introduction I will highlight these
10

divergent residues in order to emphasize the structural nuances between LeuT and the MATs that
are vital for their contrasting cellular responsibilities.
The S1 binding site of LeuT. In all substrate-bound LeuT structures reported, a single
substrate molecule is accommodated in a common binding site, designated S1, which is located
centrally within the permeation pathway (Figure 4A) (Yamashita et al. 2005; Singh et al. 2008;
Krishnamurthy and Gouaux 2012; Piscitelli and Gouaux 2012). The S1 pocket is composed
almost entirely of TMs 1, 3, 6 and 8, whereby residues from these TMs that face the permeation
pathway create a lining of aromatic, aliphatic and polar amino acid side chains. In addition, the
backbone amide groups from the unwound regions of TMs 1 and 6 also contribute to the S1
binding site (Yamashita et al. 2005; Singh et al. 2008)(Figure 4A).
The S1 pocket of LeuT can be divided into two regions: a polar region formed
exclusively by the unwound regions of TM1 and TM6 that accommodates the α-amino and αcarboxylate groups of the amino acid substrates, and a hydrophobic pocket formed by aliphatic
side chains from TM1, TM3, and TM6 accommodating the hydrophobic side chain of the
substrate (Yamashita et al. 2005; Singh et al. 2008) (Figure 4A) Within the polar region, the
hydrophilic components of the substrate form hydrogen bonds with backbone amide groups of
TM1 and TM6. The α-amino group of the substrate interacts with backbone carbonyls from A22
in TM1, along with F253 and T254 in TM6, and with a side-chain hydroxyl from S256 in TM6.
The α-carboxyl group of the substrate interacts with a backbone amide nitrogen from L25 and
G26 in TM1, a phenolic hydroxyl moiety from Y108 in TM3 and with one of the bound Na+ ions
(Na1) (Yamashita et al. 2005). The hydrophobic region accommodating the aliphatic portion of
the substrate is formed by the side chains of residues from TM3 (V104 and Y108), TM6 (F253,
11

Figure 4. The S1 binding site of LeuT, dDAT and hSERT. Pictured are three-dimesional
representations of the S1 binding sites of (A) LeuT, (B) dDAT and (C) hSERT with their
respective substrates bound. Panels (A) and (B) are taken from occluded or semi-occluded
crystal structures, respectively, whereas panel (C) is a computational homology model of
hSERT based off of the structure of LeuT. Each substrate is depicted as a yellow space-filling
molecule (with hydrogens capable of hydrogen bonding included) and the bound Na+ and Cl–
ions are represented as purple and green spheres, respectively. Amino acid side chains that
makeup the substrate binding site are shown as colored sticks, with their respective colors
illustrating whether they are in TMs 1(purple), 3 (pale brown), 6 (green), or 8 (lavender).
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S256 and F259) and TM8 (S355 and I359). This region is a major determinant for substrate
specificity of the MAT binding pocket (Gouaux 2009). Lastly, the position of the side chains
from residues Y108 and F253 are oriented above the bound substrate and thus these side chains
form a pseudo-barrier between the binding site and the extracellular vestibule. It is important to
note that these two aromatic side chains are part of the predicted extracellular gate that separates
the substrate from the extracellular vestibule (Figure 4B) (Singh et al. 2008).
The sharing of upwards of 65% sequence identity between the core binding regions of
LeuT and the MATs, along with the high degree of conservation between substrate coordinating
residues, strongly suggests that the S1 site is structurally conserved between LeuT and MATs.
This is consistent with a large amount of biochemical evidence that has identified S1 residues
that alter substrate affinity in MATs (Beuming et al. 2006; Rudnick 2006; Henry et al. 2007) and
has since been confirmed by the dDAT crystal structure (Wang et al. 2015).
The S1 binding site in MATs. For the MATs, docking 5-HT and DA into homology
models of the S1 site in SERT and DAT, respectively, have obtained strikingly similar poses of
the substrates (Huang and Zhan 2007; Beuming et al. 2008; Celik et al. 2008; Field et al. 2010).
Importantly, these homology models not only look highly similar to the LeuT crystal structure,
but they have also been corroborated by the recent crystal structure obtained for dDAT
(Penmatsa et al. 2013; Wang et al. 2015) (Figure 4B). The aromatic moieties of the substrates are
accommodated in a hydrophobic region of the pocket, formed by hydrophobic and aliphatic
residues in TM1, TM3, and TM6 (Figure 4, B and C), whereas the alkylamine side chains of
dopamine both occupy a region equivalent to the polar region in LeuT that accommodates the αcarboxyl group on its amino acid substrates. An important feature in this region of SERT, DAT,
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and NET is the presence of an Asp residue close to the TM1 helical break (D46 in dDAT, D98 in
hSERT) at a position where LeuT contains a Gly (G24). The acidic side chain in this position is
strictly required for the function of the MATs (Kitayama et al. 1992; Barker et al. 1999; Henry
2003; Celik et al. 2008; Andersen et al. 2010), leading to the early suggestion that this residue is
involved in a critical interaction with the monoamine substrate, possibly by a direct interaction
with the amino group of the substrate (Kitayama et al. 1992; Barker et al. 1999). This has since
been validated in the crystal structure of dDAT (Penmatsa et al. 2013; Wang et al. 2015), as well
as mutational studies of SERT showing that the loss of affinity observed when shortening the
alkyl-amine side chain of 5-HT derivatives by one methyl can be compensated for by extending
the amino acid side chain by one methyl via substitution of Asp with Glu at this position (Barker
et al. 1999; Celik et al. 2008). Thus, as the monoamine substrates lack a negatively charged
carboxylate group, the unique presence of an Asp residue in this position in the MATs is present
to compensate for the inability of the monoamine substrates to coordinate with one of the Na+
ions.
The S2 binding site in the extracellular vestibule. Several reports have suggested that
the extracellular portion of the substrate permeation pathway (often referred to as the
extracellular vestibule) contains a second substrate binding site in LeuT, designated the S2 site
(Shi et al. 2008). The S2 site is located just above the extracellular gate, in an amorphous region
housed near the bottom of the extracellular vestibule (Figure 5). Substrate binding to the S2 site
was first suggested by Shi et al. (2008), who used molecular dynamics (MD) simulations in
combination with biochemical experiments on reconstituted LeuT to propose that occupation of
the S2 site is required to trigger conformational changes that releases substrate from the S1 to
14

Figure 5. The location of the S1 and S2 binding sites in LeuT. A crystal structure of LeuT
with the inhibitor clomipramine bound to the S2 binding site in the extracellular vestibule.
The substrate, leucine is bound at the S1 binding site in the central binding region, while both
sodium sites are occupied by Na+ (purple spheres). TMs 1 (purple), 3 (pale brown), 6 (green)
and 8 (lavender) are colored to outline the general substrate permeation pathway.
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intracellular side (Quick et al. 2012). These results remain controversial, as other reports refute
the existence of the S2 site in LeuT (Piscitelli et al. 2010).
Although the S2 site has not been found to occupy substrates in any structure of LeuT
crystallized in presence of substrates, other structures of LeuT crystallized in presence of certain
LeuT inhibitors or detergents have found that these molecules bind within the S2 site (Figure 5)
(Zhou et al. 2007; Singh et al. 2008; Quick et al. 2009; Zhou et al. 2009), hereby preventing
conformational changes necessary for substrate translocation (Singh et al. 2007; Quick et al.
2009; Zhou et al. 2009), a mechanism that might be relevant for the mechanism of action of
MAT inhibitors (Zhou et al. 2007; 2009). This model has been supported by a wealth of
biochemical evidence from SERT, whereby site-directed mutagenesis was used to identify a lowaffinity S2 binding site whereby both TCAs (Sarker et al. 2010) and SSRIs (Chen et al. 2005b;
Plenge et al. 2007) can occupy. Binding of an antagonist in the S2 site is thought to produce an
allosteric effect on the S1 binding site, whereby the S1 site exhibits an increased affinity for a
bound antagonist while the S2 site also acts as a functional lid that further decreases the
likelihood that the antagonist bound to S1 will dissociate (Chen et al. 2005b; Neubauer 2006;
Plenge et al. 2012). Recently, the synthesis of several novel citalopram analogues that favor the
S2 site over the S1 site has been reported (Banala et al. 2013). Similarly, the lab of Amy
Newman has recently developed three photo-tagged, radiolabeled citalopram analogues that are
capable of creating a covalent attachment to within its SERT binding site when flashed with UV
light (chapter VI). Both these sets of citalopram analogues could be used as tools to elucidate the
residues that are critical for binding of an antagonist at the S2 site.
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Ion Binding Sites in MATs
The cotransport of Na+ ions with the substrate molecule is a principal characteristic of the
SLC6 subfamily. It is the utilization of the chemiosmotic Na+ gradient that contributes the
energy needed to complete the thermodynamically-unfavorable movement of substrate across the
plasma membrane. Furthermore, binding and, in some cases, cotransport of additional Na+, Cl–,
K+ and/or H+ ions is necessary for the function of most SLC6 transporters (Kristensen et al.
2011). For instance, SERT contains two putative Na+ binding sites and one Cl– binding site
within close proximity to the substrate-binding site. Interestingly, the SERT translocation
shoichiometry requires the symport of one Cl– and only one Na+ (despite the purported presence
of two bound Na+) with one 5-HT molecule, while the antiport of one K+ ion is also required to
complete one transport cycle. By contrast, DAT transport stoichiometry consists of the symport
of two Na+ and one Cl– per molecule of DA and does not require intracellular K+ antiport. Since
the first crystal structures of LeuT were solved (and especially with the recent crystallization of
dDAT), a considerable amount of structural knowledge has been gained concerning the overall
structural components of the ion binding sites in MATs. This has ushered in a new understanding
of how ions interact with MATs and thus has allowed for considerable investigation into the
mechanism by which ions couple to and drive substrate transport by MATs, a feature of much of
my work discussed in this dissertation (chapters II and III).
The Na+ binding sites. One of the primary features of all of the outward-facing and
occluded LeuT structures is the presence of two distinct ion-binding sites in the S1 pocket that
are occupied by Na+ ions, designated Na1 and Na2 (Yamashita et al. 2005; Zhou et al. 2007;
Singh et al. 2008; Zhou et al. 2009). Both Na+ binding sites are believed to be important in the
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stabilization of the unwound regions of TMs 1 and 6, which contain several residues purported to
coordinate the binding of substrate (Figure 6A). In addition, the Na+ ion located in Na1 interacts
directly with substrate bound to LeuT, further corroborating the importance of the Na+ ions in the
proper organization of the binding region and explaining the strict selectivity of Na+ over
similarly charged but different sized cations by SLC6 transporters.
In the Na1 and Na2 sites, six and five backbone carbonyls or side-chain oxygens
coordinate Na+, respectively (Figure 6A). The residues forming the Na1 site are highly
conserved across the SLC6 family, strongly indicating that an equivalent site is present in MATs
(Rudnick 2006; Singh et al. 2008; Gouaux 2009). The only major difference among these
residues when comparing LeuT and MATs is the substitution of an Asp (D98 in SERT) at the
position equivalent to G24 in LeuT (Figure 6, B and C). As mentioned previously, it has been
shown that this variation in MATs is important in order to compensate for the lack of a carboxyl
group in the structure of monoamine neurotransmitters.
Of the five residues that coordinate Na2 in LeuT, one is identical and three are highly
similar to the equivalent residues in MATs. The single nonconserved residue is T354 in LeuT,
which has an Asp (D437) at the homologous position in the MATs. Despite this variation
between LeuT and MATs in the constituents that form the putative Na2 site, a number of studies
supplied evidence supporting the presence of two Na+ binding sites, even in those MATs that
only cotransport a single Na+ (Rudnick 2006; Singh et al. 2008).
Although Na+ binding sites similar to Na1 and Na2 exist in the mammalian MATs, as
demonstrated in the dDAT crystal structure, the exact role of Na+ at each of these sites is largely
uncertain. For example, it has been suggested that MATs translocating one Na+ (SERT and NET)
18
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Figure 6. The ion binding sites in LeuT, dDAT and hSERT. Ions and their respective
coordination sites are represented for (A) LeuT, (B) dDAT and (C) hSERT. Sodium and chloride
ions are depicted as purple and green spheres, respectively. Bound substrate in each model is
represented as a yellow sticks with those hydrogens capable of hydrogen bonding included. Side
chains from amino acids that makeup part of an ion coordination network are depicted as sticks
(note that some interactions are from the amino acid backbone of labeled residues, however for
clarity these were not included).
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use only the Na1 site, whereas the transporters that translocate two Na+ per substrate also use the
Na2 site (Rudnick 2006; Singh et al. 2008). However, in direct opposition to this hypothesis, a
crystal structure has been characterized for a bacterial galactose transporter (vSGLT) that is very
similar structurally to LeuT but only has a single Na+ binding site, of which is found in a
homologous position to the Na2 site in LeuT (Faham et al. 2008). This would suggest that only
the Na2 site is conserved throughout the LeuT super-family, and given the fact that the Na1 site
is not present in vSGLT, this would suggest that Na2, and not Na1, may be the Na+ of action in
MATs that only cotransport a single Na+ (Watanabe et al. 2010).
In chapter III, I will present work that utilizes a mutation at one of the Na1 coordinating
residues (N101) in the human (h)SERT which changes the selectivity of this site and thereby
allows for the parsing of roles between the Na1 and Na2 sites. There I will also present a
mechanism by which the Na+ at Na2 is cotransported with 5-HT and the Na+ at the Na1 site
plays more of a regulatory role, thereby mediating the cascade of conformational changes that
triggers the translocation mechanism (Felts et al. 2014).
The Cl– binding site. The majority of mammalian SLC6 transporters, including the three
MATs, are dependent on the symport of one Cl–. This is not the case for the prokaryotic SLC6
homolouges, including LeuT, which are characterized by a Cl–-independent mechanism (Zomot
et al. 2007; Kanner 2008; Zhao et al. 2010). Given the lack of a Cl–-binding site in LeuT, the
characterization of the Cl binding site in mammalian SLC6 transporters was instead successfully
mapped via two independent biochemical studies using site-directed mutagenesis and
computational modeling (Forrest et al. 2007; Zomot et al. 2007). Comparative sequence analysis
of mammalian SLC6 transporters and LeuT provided hints that eventually lead to identification
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of Glu290 in TM7 of LeuT as a candidate position for the Cl–-binding site in mammalian
transporters. Importantly, this negatively charged residue is conserved in Cl–-independent
prokaryotic SLC6 transporters but not in the Cl–-dependent mammalian SLC6 transporters
(Forrest et al. 2007; Zomot et al. 2007).
Computational homology models of SERT and the GABA transporter revealed that with
Cl– docked into the equivalent position of Glu290 in LeuT, that this positioning could
accommodate the Cl– ion via coordination by Y121, S336, N368, S372, along with possible
additional coordination by Q332 and C369 (hSERT numbering; Figure 6C). The essential role of
Cl– at this site was further supported by site-directed mutagenesis targeting Cl– coordinating
residues, where mutation of these residues resulted in considerable alteration of transport activity
and a subsequent elimination of Cl– dependence (Forrest et al. 2007; Zomot et al. 2007).
Recently, several groups have shown that mutation of the negatively-charged residue
demonstrated to take the place of Cl– in prokaryotic SLC6 transporters results in a Cl– dependent
transporter with a Cl binding site coordinated by many of the residues associated with Cl–
coordination in MATs (Kantcheva et al. 2013). Moreover, the acquisition of the dDAT crystal
structure has similarly confirmed the residues originally forwarded as Cl– coordinating residues
in MATs (Figure 6B) (Penmatsa et al. 2013). However, despite the wealth of both biological and
structural data that outlines the positioning of the Cl binding site, little remains know as to the
actual function of this Cl site during the translocation mechanism (Erreger et al. 2008). This gap
in knowledge is the basis for the project outlined in chapter II, where use of a mutant associated
with the Na1 site (N101) alters the dependence of the transporter for extracellular Cl–, without a
relative diminishment in transport activity. This work better describes the selectivity of the Cl
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site and speculates on a functional role of Cl– binding (Henry et al. 2011).

Chemiosmotic Coupling and the Translocation Mechanism
The Alternating Access Mechanism of Substrate Transport
The main mechanistic theory for how secondary-active transport selectively moves
substrate across the membrane is known as the alternating access mechanism (Jardetzky 1966).
The basic concept of this model is that transporters function by having a central core region
where substrate binds that can be sealed off from both the extracellular and intracellular faces of
the membrane (Figure 7). This is managed by the existence of substructures of the protein that
can be sequentially rearranged in order to allow or prevent access to the protein’s core, thereby
acting as functional gates. The gates can both be closed to form an occluded binding pocket,
however the sequential closing off of one gate generally results in the rearrangement and opening
of its counterpart, thereby alternatively granting access of the binding region to the opposing
faces of the membrane. In the case of ion-coupled transporters, such as MATs, the toggle
between extracellular and intracellular facing conformations is determined by the binding of
substrate and ions.
Prior to the availability of crystal structures, numerous biochemical studies identified that
there is a considerable amount of structural rearrangement of many of the TMs and extracellular
loops during transport (Loland et al. 1999; Androutsellis-Theotokis et al. 2001; Ni 2001;
Androutsellis-Theotokis and Rudnick 2002; Zomot 2003; Loland et al. 2004). However, despite
this wealth of information a mechanistic model remained impossible to generate without a
structural template by which to base it on.
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Figure 7. The alternating access model of transport. Cartoon depicting the basic stages of
the alternating access model of transport. Substrate (red diamond), two sodium ions (blue
circles) and a chloride ion (green triangle) bind to the outward facing structure (1). This
causes a cascade of confomational changes that closes the extracellular gate (2), placing the
transporter in the occluded state, and then continues in opening the intracellular gate (3).
Substrate and ions are then released into the cell (4; note that only one sodium is
cotransported with the substrate by SERT and NET, while two are cotransported by DAT).
For SERT, a potassium ion (orange square) binds to the intracellular facing conformation (5),
causing the rectification of the transporter to the outward facing conformation (note that no
ion antiport is needed for rectification of DAT or NET to the outward facing conformation).
In returning to the outward facing conformation, the potassium ion is released (6) and a new
cycle can begin.
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The emerging crystal structures of the LeuT-fold family of proteins have since provided
snapshots of the transporter in various stages of substrate translocation, such as the outwardfacing, occluded and inward-facing conformations (Figure 8, A–C) (Yamashita et al. 2005;
Singh et al. 2008; Krishnamurthy and Gouaux 2012). By assuming that the conformational
changes necessary to move substrate will be conserved among the LeuT-like transporters, several
groups have put the snapshots together to describe the alternating access system in these
proteins. Two prevalent models are the “rocking bundle” (Forrest and Rudnick 2009), where a
bundle (TMs 1, 2, 6 and 7) and scaffold (TMs 3, 4, 5, 8, 9 and 10) rock in relation to one another
resulting in transition from outward to inward facing conformations, and the “hinge” model
(Krishnamurthy et al. 2009), where flexing movements in TMs 1 and 6 followed by side chain
rearrangement is sufficient to open and close the outer and inner gating densities and allow the
subsequent passage of substrate. A relatively complete set of crystal structures for the transporter
Mhp1, representing the outward-facing, occluded and inward-facing conformations, have
demonstrated that the transporter undergoes rigid body movements similar to those proposed in
the rocking bundle model (Shimamura et al. 2010; Weyand et al. 2010). Recently, using antibody
stabilization and mutagenesis primarily at the Na2 binding site, a set of LeuT crystals were
generated that captured a substrate-free outwards-facing and apo-inward facing set of
conformations (Krishnamurthy and Gouaux 2012) (Figure 8, A and C). In this report, the authors
propose these new structures reveal a hybrid mechanism of transport for LeuT that involves a
combination of both hinge and rigid-body movements to permit substrate and ion passages
across the membrane. Indeed, as more LeuT-fold crystal structures are resolved, inevitably a
clearer picture of the transport mechanism by this family will emerge. However, even with an
24
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Figure 8. Three distinct structural conformations of LeuT provide a general outline of the alternating access mechanism of
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increasing number of crystal structures captured in various states of mechanistic movement, it is
important to remember that each structure represents a simple snapshot of an incredibly dynamic
process. As such, much of our understanding of the mechanistic interworkings of MAT
machinery remains elusive.
Kinetic and Electrogenic Properties of MATs
The primary role of the MATs is to mediate the rapid removal of neurotransmitter from
the synapse, a process that requires transport against very large concentration gradients. Studies
using radiolabeled substrates have been the gold standard for the study of the kinetic properties
of MATs. These studies have shown that the relationship between concentrations of substrate,
along with Na+ and Cl−, and transport activity follows Michaelis-Menten kinetics with Km values
in the lower micromolar range for the substrate (Sneddon 1973; Humphreys et al. 1994) and
millimolar range for the two ions (Sneddon 1969; Nelson and Rudnick 1979; 1982). However,
despite a wealth of knowledge concerning the structural and kinetic characteristics of MATs,
little is understood as to how these features are interrelated and much is still unclear as to the
how regulation (and maybe more importantly, dysregulation) of MATs alters the functionality of
these proteins at the molecular and synaptic levels. My work on the characterization of the role
that the ion binding sites play in the SERT transport mechanism can be found in chapters II and
III.
Along with defining the kinetic properties of the MAT transport process, flux
experiments have also determined that the process of stoichiometric substrate translocation is
electrogenic for some MATs (DAT and NET) and electroneutral for others (SERT) (Rudnick and
Nelson 1978; Mager et al. 1994; Sonders and Amara 1996). As MAT transport can produce
26

membrane potential-dependent currents, transporters operating via an electrogenic mechanism
therefore also add conductance to the membrane. However, several studies have shown the
conducting properties of MATs can be considerably larger than the electrogenic values predicted
by the stoichiometric transport mechanism (Sonders et al. 1997; Carvelli et al. 2004). Moreover,
in addition to this substrate-dependent ion flux there also exists an uncoupled, substrate
independent ion flux. In fact, MATs are thought to exhibit at least four distinct conducting states
(Mager et al. 1994).
The mechanism by which these distinctive conducting states operate is yet to be
elucidated, however several studies have demonstrated that interacting proteins, such as the
SNARE protein syntaxin1A, can bind to and regulate MAT activity and conducting states (Quick
2003; Carvelli et al. 2008). These studies have demonstrated that the interaction between MATs
and their binding partners can result in the toggling between the uncoupled and coupled ion
conducting states of MATs, and thus that both cell excitability and ligand-mediated effects may
be dependent on the association of MATs and their respective interacting proteins (Quick 2003).
Moreover, electrogenic substrate transport and inward currents have also been described for
other SLC6 members who do not necessarily translocate neurotransmitters (i.e. amino acid,
creatine and taurine transporters), thus it is conceivable that in addition to moving substrates
across membranes this protein family also controls ion concentrations within cellular
microdomains. For example, data from native neurons suggest that DAT-mediated conductances
generated by DA or AMPH increase excitability of midbrain dopaminergic neurons (Ingram et
al. 2002; Carvelli et al. 2004).
These transport-associated currents provide useful tools for quantitative functional
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characterization, as well as for qualitative distinctions between substrates and blockers. For
example, amphetamine-like dopamine-releasing drugs produce transport-associated currents at
dopamine transporters, but cocaine-like drugs block such currents (Galli et al. 1995; Sonders and
Amara 1996). Furthermore, it has been postulated that dysregulation of these MAT conducting
states may result in alteration of the firing rates of MAT-associated neurons, possibly explaining
disease states such as depression and anxiety (Ingram et al. 2002; Carvelli et al. 2004).

Pharmacological Intervention and MATs
Given the critical role that MATs play in the regulation of neurotransmission, it is
unsurprising that these proteins are attractive pharmacologic targets for both therapeutic and
illicit substances. Decades ago, MATs were found to be important for the mechanism by which
classic mood stabilizers produce their effects (Brill and Patton 1957; Iversen 2000). Since this
discovery, the pharmaceutical industry has initiated an extensive drug discovery campaign in
order to develop and synthesize compounds that selectively target DAT, NET and SERT. This
has led to the successful development of an abundance of ligands for MATs, including
compounds that exhibit both high affinity and selectivity for each of the three transporters
(Figure 9).
The first class of ligand developed for use as MAT antagonists was the tricyclic
antidepressants (TCA)(Marshall et al. 1960), including imipramine (Trofanil) and desipramine
(Norpramin), however TCAs demonstrate activity across a variety of different receptors along
with MATs (Gillman 2007). A further, more specific set of antagonists have since been
developed that exhibit far more selectivity for target protein(s) (Tatsumi et al. 1997). These new
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Figure 9. - Chemical structures of classic MAT substrates and inhibitors. Depicted are
the chemical structures and names of classic MAT agonists (top) and antagonists (bottom).
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classes are termed selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine (Prozac),
citalopram (Celexa) and paroxetine (paxil), norepinephrine reuptake inhibitors, such as
reboxetine (Vestra), and selective dopamine reuptake inhibitors, such as bupropion (Wellbutrin).
Two classes of dual-acting antagonists with affinity for two of the three MATs have also been
developed, including serotonin-norepinephrine reuptake inhibitors, such as duloxetine
(Cymbalta), and norepinepherine-dopamine reuptake inhibitors, such as nomifensine (Merital).
Many of these drugs have various authorized clinical usages, however knowledge of the
structural features of the binding sites for many of these ligands or overall mechanism by which
these drugs modulate neurotransmission remains undetermined. Research into defining the
binding site(s) of the SSRI citalopram is discussed in chapter VI.
Along with therapeutic compounds, there are also a host of illicit substances, both natural
and synthetic, that target MATs (Figure 9) (Rothman and Baumann 2003; Baumann et al. 2014).
For instance, cocaine, one of the most abused drugs of addiction, is a potent inhibitor of DAT,
NET and SERT. As DAT has been suggested to be the source of the rewarding properties of
cocaine (Giros et al. 1996; Chen et al. 2006), the DAT-cocaine interaction has been of particular
interest for researchers. Recently, a photo-tagged, radiolabeled cocaine analogue called RTI-82
was used to biochemically determine a specific ligand attachment point when binding to DAT.
This allowed for an increase in the constraints used for the development of computational
docking studies and resulted in an eloquent prediction of the relative positioning of cocaine
bound to DAT (Dahal et al. 2014). Furthermore, a recent crystal structure of a cocaine-bound
dDAT revealed a highly similar molecular arrangement (Wang et al. 2015) to that predicted by
the work of Dahal et al. This exemplifies the power of the combination of biochemical and
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computational approaches to determining structural features of the interactions between MATs
and their respective ligands. This is critical, as much of my work utilizes this comprehensive
approach to obtain structural insights as to the importance of specific binding domains or critical
coordinating residues.
Despite cocaine being the most studied MAT ligand and many of the therapeutic
compounds having a similar antagonistic effect of MATs, not all drugs act as functional
antagonists of MAT transport. In fact, multiple synthetic substrates are available for all three of
the MATs (Rothman and Baumann 2003; Baumann et al. 2014). The best examples of these
synthetic substrates are amphetamine and a number of amphetamine-like derivatives. This
includes one of the most problematic drugs of abuse in today’s society, methamphetamine, as
well as methylphenidate, which is used to treat attention deficit hyperactivity disorder, and 3,4methylenedioxymethamphetamine (MDMA or ecstasy), which is an increasingly popular club
drug. Moreover, a new class of banned substances known as bath salts target MATs, with some
acting as antagonists and other being functional substrates to MATs (Baumann et al. 2014).
Critically, each of these synthetic substrates are thought to not only compete with primary
neurotransmitters for reuptake by MATs, but they are also thought to induce reverse transport, or
efflux, of neurotransmitter back into the synapse, thereby causing an even more pronounced
increase in synaptic neurotransmitter levels. How ligands are recognized as substrates and the
mechanism by which substrate-induced efflux occurs both remain poorly understood. Research
into the importance of an acidic amino acid at the external gate of SERT and the role it plays in
substrate recognition and the transport/efflux mechanisms of MDMA is the topic of chapter V.
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CHAPTER II
A CONSERVED ASPARAGINE RESIDUE IN TRANSMEMBRANE SEGMENT ONE
OF THE SEROTONIN TRANSPORTER DICTATES CHLORIDE-COUPLED
NEUROTRANSMITTER TRANSPORT
Introduction
The human (h)SERT, like other neurotransmitter transporters of the SLC1 and SLC6
families, displays secondary-active substrate transport (Mitchell 1961), coupling the
concentrative movement of neurotransmitter to the transmembrane gradients of Na+ and other
ions (Humphreys et al. 1994; Rudnick 2002). A distinguishing feature of neurotransmitter
transport by the SLC6 family relative to the SLC1 family is a strong dependence on extracellular
Cl– for transport (Lingjærde 1971; Nelson and Blaustein 1982). During a single cycle of
substrate transport in hSERT, a stoichiometry of 1-5-HT+in:1-Na+in:1-Cl–in:1-K+out has been
advanced on the basis of ion dependence studies in cells and resealed membrane vesicles that
predicts an overall electroneutral coupling mechanism. Such studies have led to the belief that
the energy stored in the Cl– concentration gradient contributes directly to transmembrane 5-HT
flux (Rudnick 2002; Quick 2003). However, electrophysiological experiments reveal that SERT
can exhibit nonstoichiometric flux states where additional 5-HT-induced charge movements
occur (Lin et al. 1996; Adams and DeFelice 2002; Ramsey 2002; Quick 2003). For the dopamine
transporter, a homologue of hSERT, Cl– has been implicated as a charge carrier in
nonstoichiometric flux states (Ingram et al. 2002; Carvelli et al. 2004), suggesting that the role of
Cl– in neurotransmitter transport is more complex than originally suspected. Interacting proteins,
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including syntaxin 1A, can modulate the stoichiometry of charge movements across hSERT and
other monoamine transporters (Ingram et al. 2002; Quick 2003; Binda et al. 2008; Carvelli et al.
2008), changes that can alter neuronal firing rates (Ingram et al. 2002; Carvelli et al. 2008). In
addition, SERTs are expressed early in the embryo (Hoffman and Mezey 1989; Schroeter and
Blakely 1996), and in many distinct membrane environments (e.g. neurons, placenta,
lymphoblasts, platelets, and epithelial cells), where Cl– gradients can change over time (Jang et
al. 2001; Adragna et al. 2004). Together these findings indicate that the contribution of Cl– to
neurotransmitter transport deserves further investigation.
High-resolution structures of a Cl–-independent SLC6 family member, the leucine
transporter from Aquifex aeolicus (LeuT) (Yamashita et al. 2005), have afforded opportunities to
elucidate details of neurotransmitter transporter ionic coupling. Although overall sequence
identity between LeuT and neurotransmitter transporters is low, amino acid identity approaches
50% for residues surrounding the binding sites for leucine and Na+, propelling homology-guided
structural studies. In addition, crystal structures of the transporters ApcT (Shaffer et al. 2009),
BetP (Ressl et al. 2009), vSGLT (Faham et al. 2008), and Mhp1 (Weyand et al. 2008) that have
no significant sequence homology to SLC6 family members exhibit the same helical packing
pattern as LeuT (Abramson and Wright 2009). Therefore, a model-guided study of SLC6 family
members may identify important mechanisms that are likely difficult to derive from patterns of
sequence conservation.
In a prior study (Henry 2003), we demonstrated that an asparagine (N101) in hSERT
transmembrane segment (TM) 1 tolerates substitution by cysteine and that cells transfected with
N101C are sensitive to transport inactivation by positively charged cysteine-directed MTS
33

reagents. Because this inactivation was largely eliminated by the presence of 5-HT, we proposed
that N101 might lie at or near the substrate-binding site.
The following work demonstrates that the N101 residue, homologous to the sodiumcoordinating residue N27 in LeuT, contributes an important role in facilitating the coupling of
Cl– to 5-HT transport. Rather than directly coordinating Cl– binding, our evidence indicates that
N101 translates Cl– binding to the stabilization of a TM1–TM6 interhelical network, with the
participation of TM6 residue S336, to promote efficient coupling between 5-HT and Na+.

Methodology
Site-directed Mutagenesis and Construction of Mutant Plasmids
Mutation of hSERT cDNA in pcDNA3.1 or pOTV to generate N101A, N101C, and
S336C constructs in hSERT and hSERT C109A backgrounds was performed using the
Stratagene QuikChange kit, as described previously (Henry 2003), with confirmation of all
mutants by DNA sequencing (Center for Molecular Neuroscience Neurogenomics, Vanderbilt
DNA Sequencing Core Facility or Northwoods DNA, Inc., Bemidji, MN). For cysteine
modification studies to probe for N101-sensitive conformational movements, rSERT N101
mutants were generated in the background of Cys substitutions S277C and S404C using a Cys
reduced transporter (X5C; C15A/C21A/C109A/C357I/C622A).
5-HT and NE Transport Measurements
HeLa and HEK-293 cells, maintained at 37 °C in a 5% CO2-humidified incubator, were
grown in complete medium (DMEM, 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin, and
100 µg/ml streptomycin). For initial evaluation of mutant transporter activity, cells were plated at
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a density of 50,000 cells/cm2 in 96- or 24-well culture plates. Cells were transfected with
hSERT, rSERT, or hNE transporter constructs with TransIT transfection reagent (Mirus Inc.,
6µl/µg of DNA), also in OptiMEM medium as described previously (Henry 2003), or with
Lipofectin followed by infection with vTF7-3 vaccinia virus as described (Blakely et al. 1991).
Following transfection (20–48 hours), cells were washed with one of the following buffers:
MKRHG

assay

buffer

(120mM

NaCl,

4.7mM KCl,

2.2mM CaCl2,

1.2mM MgSO4,

1.2mM KH2PO4, 10mM glucose, 10mM HEPES, pH 7.4); chloride-containing assay buffer
(5.4mM potassium gluconate, 1.2mM calcium gluconate, 7.5mM HEPES, and either NaCl or
NMDG-Cl at 120mM) chloride-free assay buffer (same as chloride-containing buffer except
120mM NaCl is replaced with 120mM NaX (X= Br, I, NO2, NO3, thiocyanate, acetate,
methanesulfonate, or gluconate) and assayed for [3H]5-HT (5-hydroxy[3H]tryptaminetrifluoroacetate, (121 Ci/mmol) Amersham Biosciences) transport as described previously
(Henry 2003). For Na+ replacements assays, NMDG-Cl was used in place of NaCl. Transport
was linear with time under these conditions for up to 15 minutes. Saturation kinetic profiles for
derivation of 5-HT Km and Vmax values were established in 24-well plates as described above
except 2-fold serial dilutions were used maintaining 5-HT-specific activity, starting at 5µM of a
mixture of labeled and unlabeled 5-HT. Transport assays were terminated by washes with icecold assay buffer, and cells were then dissolved in MicroScint 20 (Packard) scintillant. Uptake
from parental cells was subtracted from transporter-transfected cells to determine specific
uptake. Nontransfected cells exhibited comparable uptake to assays performed in the presence of
1µM paroxetine, 1µM RTI-55, or 100nM cocaine. Km and Vmax values were derived using a
nonlinear curve fit as a function of 5-HT or NE concentration (40nM to 5µM) (Prism 4,
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Graphpad). All experiments were performed in triplicate and repeated in three or more separate
assays.
Spontaneous 5-HT Efflux
Cells were loaded as described above for transport studies with 40nM [3H]5-HT. Loading
was allowed to proceed for 30 or 90 minutes at 37 °C and was terminated by aspiration of assay
buffer and a single wash with 0.5ml of ice-cold MKRHG buffer. MKRHG buffer (0.5ml) was
added to one-half of the wells and returned to 37 °C for 30 minutes. The wells that did not
receive buffer represent the total 5-HT taken up at T = 0. Buffer from the efflux wells
(representing 5-HT efflux) was collected, transferred to scintillation vials with 5ml of EcoScint
H, and counted. 5-HT remaining in the cells at T = 30 or 90 minutes was assessed by scintillation
photometry. Percent efflux was calculated as the ratio (×100) of 5-HT efflux divided by 5-HT
accumulated in parallel plates, not subjected to efflux, at T = 0. No difference was observed in %
efflux for plates pre-loaded for 30 or 90 minutes (data not shown).
Total and Cell Surface Expression Protein Analysis
To determine total and surface expression of hSERT with wild type and/or mutant
constructs, HeLa cells were plated in 24 or 12 well dishes at 100,000 or 500,000 cells per well,
respectively, and transfected 18–24 hours later as detailed above. Seventy two hours after
transfection, cell surface proteins were biotinylated and analyzed via Western blotting as
described previously (Henry 2003). Oocyte biotinylation experiments to quantitate surface
expression of hSERT and hSERT mutants were performed as described previously (Ramsey
2002) using 1.5 ng of cRNA and substituting EZ-Link Sulfo-NHS-biotin (Pierce) with EZ-Link
Sulfo-NHS-SS-Biotin. Blots of total and surface protein were probed with ST-01 from Mab
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Technologies., Inc. (Stone Mountain, GA), and developed using Western Lightening
Chemiluminescent Plus reagent (PerkinElmer Life Sciences).
Evaluation of Cysteine Accessibility
To probe for ion-dependent hSERT conformational movements, HeLa cells were plated
on poly-D-lysine-coated 24-well TopCount plates at a density of 50,000 cells/well and
transfected as described above. Twenty four hours post-transfection, cells were washed one time
with 2 ml, one time with 1 ml, and one time with 500µl of MKRH (MKRHG without glucose) ±
120mM Cl− and ± 50µM 5-HT. Following a 5-minute incubation, solutions were aspirated and
replaced with 500µl of 2mM MTSET in MKRH. MKRH alone was added to one set of wells as a
control. MTSET-treated wells were washed twice with 750µl of MKRH followed by aspiration
and addition of 225µl of MKRHG. Cells were allowed to equilibrate to 37°C for 10 minutes
followed by addition of [3H]5-HT containing ascorbic acid and iproniazid phosphate. After 10
minutes at 37°C, wells were washed three times with 500µl of ice-cold MKRH. MicroScint 20
(0.5ml) was added to each well, and the accumulated 5-HT was quantified.
rSERT N101A/S404C accessibility was examined using MTSEA. HeLa cells were plated
in 96-well plates at a density of 50,000 cells/well transfected and infected with vTF7-3 as
described above. Twenty hours post-transfection, cells were washed three times with phosphatebuffered saline with magnesium and calcium (PBS: 137mM NaCl or equimolar concentration of
NMDG-Cl or sodium isethionate, 2.7mM KCl, 4.3mM Na2HPO4, and 1.4mM KH2PO4, pH 7.3)
containing 0.1mM CaCl2 and 1mM MgCl2 (PBSCM). Following a 5-minute incubation,
solutions were aspirated and replaced with 50µl of MTSEA in the indicated concentrations in
50µl of PBSCM. After 10 minutes, the cells were washed five times with 100µl of PBSCM
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followed by incubation with 20nM [3H]5-HT for 10 minutes in 50µl of PBSCM. After 10
minutes, wells were washed three times with 100µl of PBSCM. Optifluor (PerkinElmer Life
Sciences) (150µl) was added to each well, and accumulated 5-HT was measured in a Wallac
MicroBeta plate counter. Cells transfected with S404C was used as the control.
hSERT Expression in Xenopus laevis Oocytes
Oocytes were isolated, and cRNA was prepared as described previously (Ramsey 2002;
Adams and DeFelice 2003). cRNA was injected on the day of oocyte harvest. hSERT, N101A,
N101C, S336C, N101A/S336C, and N101C/S336C cRNA were transcribed from NotI-linearized
constructs in pOTV vector (a gift of Dr. Mark Sonders, Columbia University) using Ambion
mMessage Machine T7 kit (Ambion, Austin, TX). Each oocyte was injected with 1.5ng of cRNA
and incubated at 18°C for 4–6 days in Ringer's buffer (100mM NaCl, 2mM KCl, 5mM MgCl2,
5mM HEPES, pH 7.4) supplemented with 550µM/ml sodium pyruvate, 100µg/ml streptomycin,
50µg/ml tetracycline, and 5% dialyzed horse serum. Whole-cell currents were measured by twoelectrode voltage clamp techniques using a GeneClamp 500 (Molecular Devices, Palo Alto, CA).
Microelectrodes were pulled using a programmable puller (Model P-87, Sutter Instrument,
Novato, CA) and filled with 3M KCl (0.5–3-megohm resistance). A 16-bit A/D converter
(Digidata 1322A, Molecular Devices) interfaced to a PC computer running Clampex 9 software
(Molecular Devices) was used to control membrane voltage and to acquire data. To induce
hSERT-associated current, oocytes were perfused with 5-HT (typically 5µM) in buffer (120mM
NaCl,

5.4mM

potassium-gluconate,

1.2mM calcium-gluconate,

7.2mM HEPES,

0.1mM iproniazid, pH 7.4) using a gravity flow system (4–5ml/minute). Buffer pH was adjusted
with KOH or KHPO4. The 5-HT-induced current was defined as current in the presence of 5-HT
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minus current in the absence of 5-HT. Substitution of Cl− was performed as with the tissue
culture studies above and is indicated in the text and figures. To minimize liquid junction
potentials, Cl− substitution experiments were performed using a 1M KCl, 2% agar salt bridge to
isolate the Ag-AgCl electrode from the bath. For constant voltage recordings, data were low pass
filtered at 10Hz and digitized at 20Hz. For current-voltage (I-V) recordings, the voltage was
changed stepwise every 500ms. Currents were low pass filtered at 100Hz and digitized at 200Hz.
All analyses were performed using Origin 7 (OriginLab, Northampton, MA) and GraphPad
Prism (GraphPad software, San Diego).
Simultaneous Measurement of 5-HT Uptake and 5-HT-induced Currents
Simultaneous measurement of 5-HT uptake and 5-HT-induced current was performed
under voltage clamp conditions, using techniques described previously (Petersen and DeFelice
1999). Oocytes were perfused for 150s under voltage clamp with 1µM [3H]5-HT (specific
activity = 3.12Ci/mmol). To minimize loss of 5-HT, oocytes were perfused with ice-cold buffer
for 250s prior to removal from the chamber. The total charge movement was calculated by time
integration of 5-HT-induced inward currents and related to the amount of 5-HT taken up in the
same oocyte. Nonspecific 5-HT uptake was determined using water-injected control oocytes
analyzed under the same conditions. Oocytes were solubilized with 200µl of 0.1% SDS and 10ml
of EcoScint H (National Diagnostics, Atlanta, GA), and 5-HT accumulation was quantified by
liquid scintillation photometry (Packard Instrument Co.).
hSERT Molecular Modeling
Molecular models for hSERT were generated using the template structure of LeuT
(PDB_ID 2A65) as detailed elsewhere (Kaufmann et al. 2009). The binding mode for 5-HT
39

identified as the one most consistent with available experimental data by Kaufmann et
al. (Kaufmann et al. 2009) was taken as the starting point for model refinement using the
AMBER forcefield. Briefly, ions were added to the energy-minimized model of 5-HT in
complex with hSERT to generate refined models that either contained NaCl or omitted Cl−
(Na+ only). Two Na+ ions were added to both the Na+ (without Cl−) and NaCl models by
superimposing the hSERT model reported by Kaufmann et al. (Kaufmann et al. 2009) with the
x-ray structure of LeuT and utilizing the coordinates of atom NA 752 (Na1-binding site) and NA
751 (Na2-binding site). For the NaCl model, a single Cl− ion was centered on the region of the
hSERT model occupied by the side-chain carboxyl group of residue E290 in LeuT, as recently
validated in studies of SERT and GAT (Forrest et al. 2007; Zomot et al. 2007). Models of the
hSERT ion-binding sites were then refined with 50 steps of “steepest descents” and 450 steps of
gradient-based minimization in AMBER9 (Kaufmann et al. 2009) followed by brief (1ns) low
temperature (50K) molecular dynamics simulations in vacuo, using a distance-dependent
dielectric constant and 12Å cutoff for non-bonded interactions to energetically relax the system.
The resulting structures were then subjected to an additional round of energy minimization as
described above to generate the reported models. Partial charges for 5-HT were ascribed using
the atom-centered point charge method of Bayly and Kollman (Bayly and Kollman 1994). All
other molecular mechanics parameters for 5-HT and ions were taken from the standard AMBER
force field with the exception of acetate. Acetate parameters were derived by analogy to the
ionized form of the carboxylic acid side chain of aspartate from the standard AMBER9 database
truncated at the CB atom with total partial charge equal to −1.0). Two-dimensional schematics of
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the refined hSERT ion-binding sites were generated with ChemDraw 10.0 (Cambridge Soft), and
three-dimensional representations were rendered with PyMol (Schrödinger, LLC).
Molecular Dynamics and Free Energy Perturbation (FEP) Simulations
Molecular models of a protonated 5-HT were developed where the geometry parameters
(bond lengths and angles) were obtained by quantum mechanics minimization at the B3LYP/6–
31G* level of theory using the restrained electrostatic potential fitting approach described by
Anisimov et al. (Anisimov et al. 2005). The net charge of 5-HT molecule was set to +1 with the
side-chain nitrogen protonated based on the reported pKa values. Parameters for deprotonated
cysteine (thiolate ion) for pKa computations have been validated and published before by
Foloppe and Nillson (Foloppe and Nilsson 2007). For equilibrium MD simulations, the starting
configuration for SERT complexed with the 5-HT, two sodiums, and one chloride ion was taken
from the minimized molecular model described above. The S352C, S336C, and N101A mutants
were obtained with a side-chain rotamer library search using SCWRL3.0 software (Canutescu et
al. 2003). The complexes were next embedded into a lipid membrane using a multiple step
membrane building procedure used in previous studies (Jo et al. 2009). The simulation box
contains the 5-HT transporter, bound sodium ions with (or without) chloride/acetate ions, one
serotonin substrate, and 204 1-palmitoyl-2-oleoylphosphatidylcholine lipid molecules solvated in
an explicit 150mM NaCl aqueous solution. All computations were carried out by NAMD version
2.7b1 (Phillips et al. 2005), and analysis was done with CHARMM version c36b2 with the
CHARMM27 force fields for proteins and lipids (Brooks et al. 2009). MD simulation methods
used here are similar to those used in previous studies of membrane systems (Caplan et al. 2008;
Noskov 2008). Briefly, constant temperature/constant pressure algorithms were applied (with
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pressure at 1 atm and temperature at 315K). Electrostatic interactions were treated with the
Particle Mesh Ewald algorithm with a 104/104/96-Å grid for fast Fourier transform, κ = 0.34Å−1,
and a 6th order spline interpolation. The nonbonded interactions were smoothly switched off at
12–14Å. All simulation systems were equilibrated for 5 ns each without any constraints, and the
production was run for another 15 ns.

Results
hSERT N101 Mutation Eliminates Cl− Dependence of 5-HT Uptake
To examine a role of hSERT N101 in the Cl− dependence of 5-HT transport, we
transfected HeLa cells with hSERT or hSERT N101A and N101C mutants and measured the
effect of extracellular Cl− on 5-HT transport saturation kinetics (Figure 10). As described
previously (Chang and Lam 1998), removal of external Cl− from the medium of hSERTtransfected cells resulted in a significant (5-fold) decrease in 5-HT transport Vmax (NaCl, 0.068 ±
0.006 fmol/cell/minute; sodium gluconate, 0.014 ± 0.002) and a significant (3.6-fold) increase in
5-HT Km (NaCl, 0.9 ± 0.2µM; sodium gluconate, 3.2 ± 0.36µM, one-way ANOVA, Dunnett's
post hoc, p < 0.002). Remarkably, the hSERT N101A and N101C mutants were largely
insensitive to Cl− substitution with gluconate (Figure 10, B and C). Moreover, the 5HT Km values of N101A and N101C were not influenced by the presence of Cl−, unlike hSERT,
and were comparable with the 5-HT Km values obtained for hSERT in the presence of Cl−
(N101A+Cl 1.45 ± 0.4µM, N101A-Cl 1.66 ± 0.2µM; N101C+Cl 1.20 ± 0.3µM, N101C−Cl 1.4 ±
0.2µM; hSERT+Cl 0.87 ± 0.2µM, hSERT−Cl 3.2 ± 0.4µM). The rate of 5-HT transport by hSERT
was a monotonic function of extracellular Cl− concentration (Hill = 0.8 ± 0.1) with an EC50 of
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D

Figure 10. Kinetic analysis and Cl– dependence of 5-HT uptake in hSERT N101
mutants. HeLa cells transiently expressing the hSERT (A), hSERT N101A (B), or hSERT
N101C (C) were evaluated for dose-dependent 5-HT uptake after 10 min in the presence
(solid line/filled circles) or absence (dashed line/open circles) of Cl–. Dependence of 5-HT
uptake on Cl– concentration is lost in N101 mutants (D). HeLa cells transiently expressing
hSERT (open circles), hSERT N101A (filled boxes), or hSERT N101C (filled triangle) were
incubated with increasing concentrations of Cl– and assayed for uptake of [3H]5-HT for 10
min. Remaining anion concentration was accounted for by addition of methanesulfonate.
Different amounts of plasmid DNA were used to transfect hSERT, N101A and N101C to
account for differences in surface expression.
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7.5mM (Figure 10D), in line with previous studies of rSERT (Barker et al. 1999). Across the
same Cl− concentration range, the N101C and N101A mutants exhibited virtually no further
stimulation of 5-HT transport.
N101 Dictates Cl−-dependent Conformational Changes in TM1 and EL4
N101 could dictate the Cl− sensitivity of hSERT simply by stabilizing binding of the
anion. Alternatively, N101 may be required to translate anion binding into critical
conformational changes linked to the Na+-coupled, 5-HT transport process. To examine these
issues, we first examined the ability of Cl− to alter aqueous exposure of three residues proposed
to report steps in the transport cycle, C109, S404, and S277 (Figure 11). Each of these positions
is distant from the 5-HT- and Cl−-binding sites, so changes in their accessibility are likely to
reflect conformational changes because of ligand binding rather than direct binding itself. C109
lies at the extracellular end of TM1 and is the major determinant of wild type SERT sensitivity to
MTS reagents (Figure 11) (Chen 1997; Chen et al. 1997). MTS-mediated inactivation of C109 is
sensitive to Na+ replacement with Li+ and is also modulated by 5-HT (Chen et al. 1997; Ni
2001), possibly a sign that this residue sits within a conformationally-active domain that is
mobilized by ion and neurotransmitter binding. We found that the presence of Cl− significantly
protected C109 against inactivation by the positively charged MTSET (Figure 12A), independent
of the presence of 5-HT. In contrast, hSERT N101A was not protected against MTSET
inactivation by Cl−, consistent with the lack of Cl− dependence measured for N101A in 5-HT
transport assays (Figure 10). As C109 was the target for inactivation by MTSET in hSERT
N101A, as opposed to another endogenous cysteine, we found that the C109A/N101A double
mutant was insensitive to MTSET (data not shown). Strikingly, whereas 5-HT had little or no
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Figure 11. Mapping of MTSET probes and Cl–-binding site from hSERT onto the LeuT
crystal structure. Illustration shows hSERT features discussed in this study as follows: 1)
MTSET targeted cysteine mutants (magenta spheres numbered with the corresponding
hSERT residue and their respective domains (TM1, blue; TM5, orange; EL4, yellow, and
TM6, green); 2) space filling model of substrate in the binding site (sub); 3) ions Na+ and Cl–
(purple and green spheres, respectively); and 4) stick representation of the N101 side chain.
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Figure 12. Assessment of MTSET accessibility of targeted cysteines as a prediction of
conformation change. Tissue culture cells expressing hSERT or hSERT N101A (A), rSERT
S404C or rSERT N101A/S404C (B), and rSERT S277C or rSERT N101A/S277C (C) were
pretreated with MTSET in the absence (open bars) or presence (black bars) of 5-HT (50µM)
and in the absence or presence of Cl– as indicated. Following treatment, 5-HT uptake assays
were performed in normal uptake buffer to quantitate activity. Percent remaining activity is
plotted and is defined as the amount of 5-HT uptake of MTSET- (A) or MTSEA- (B & C)
treated cells as a percent of untreated cells. A two-tailed t test was performed on sample sets
as indicated with brackets; * = p≤0.05; ** = p≤0.01; *** = p≤0.001. n.s., not significant.
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ability to protect wild type hSERT against MTSET inactivation in Cl−-free conditions, 5-HT
provided significant protection to hSERT N101A (Figure 12A) in the absence or presence of the
anion. These data suggest that N101 is required to transduce Cl− binding to allow 5-HTdependent conformational changes that involve TM1 and associated elements, as reported by
C109 modification. In the N101 mutants, 5-HT induced a similar conformational change, but this
effect did not require the presence of Cl−. S404, located in the middle of EL4 (Figure 11), has
been proposed to report reorientation of another external component of the 5-HT permeation
pathway (Mitchell et al. 2004). Unlike C109 in hSERT, however, Cl− substitution in the absence
of 5-HT does not afford protection of S404C (in a C109A background) to the membranepermeant MTSEA (Figure 12B), although Cl− and 5-HT together do induce protection. We found
that, just as with C109, the aqueous accessibility of S404C in an N101A background is sensitive
to 5-HT in either Cl−-containing or Cl−-free medium. These studies confirm previous data
(Mitchell et al. 2004) that transport-linked conformational changes in EL4 are associated with
the loading of all three substrates and demonstrate that mutation of N101 allows just 5-HT and
Na+ to trigger conformational changes in EL4. C109 and S404 are external reporters of
conformational changes arising with substrate binding. In contrast, S277 in TM5 (Figure 11) is
positioned to contribute to the cytoplasmic permeation pathway for 5-HT. Indeed, increased
S277 accessibility is believed to report an “open-to-in” conformation of the transporter (Zhang
and Rudnick 2006; Forrest et al. 2008). Na+ and Cl− are required for the 5-HT-dependent
exposure of residues in the cytoplasmic permeation pathway of SERT (Zhang and Rudnick 2006;
Forrest et al. 2008). Figure 12C demonstrates that 5-HT increases the extent of MTSEA
inactivation in rSERT S277C only when Cl− is present. In the N101A/S277C double mutant,
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however, 5-HT alone increased the extent of MTSEA inactivation demonstrating
Cl− independence. As the sensitization of S277C afforded by 5-HT in the N101A background
still required the presence of Na+ (data not shown), the cytoplasmic pathway appears to still be
coupled to Na+ with N101 substitution, reinforcing a specificity for disruption of Cl− coupling in
N101 mutants.
hSERT N101 Dictates Ion Selectivity of 5-HT-independent Charge Flux
hSERT expressed in X. laevis oocytes (Cao et al. 1998) and mammalian cells (Hilber et
al. 2005) conducts both 5-HT-independent and -dependent currents, in addition to transporting 5HT. Both 5-HT-independent (“leak current”) and -dependent currents require extracellular
Na+ and Cl− (Corey et al. 1994; 1998), although it is unknown whether the 5-HT-dependent and independent currents share a common pathway and/or molecular contacts as they permeate
SERT. To assess whether mutation of N101 removes the Cl− dependence of SERT currents or
affects stoichiometric charge movements, or both, we monitored hSERT-mediated currents in
oocytes recorded under two-electrode voltage clamp. Prior to measuring currents, we determined
the abundance of wild type and N101 mutant hSERT expressed on the oocyte surface by
biotinylation. Consistent with prior measurements of hSERT N101C surface expression in HeLa
cells (Henry 2003), whole-oocyte biotinylation studies revealed reduced cell surface expression
of N101 mutants (N101A and N101C, 61 ± 5.7 and 32 ± 8.7% of hSERT, respectively; Figure
13D), although SERT-dependent transport and currents were readily detectable. In the oocyte
biotinylation studies, a band was observed in the total (uninjected) control lane similar in size to
mature hSERT. However, the band appears to be nonspecific as the same control lane lacks the
immature and oligomeric hSERT bands observed in the hSERT-expressing oocytes, and this
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band is not observed in the surface control lane. As shown in Figure 13A, 5-HT induced larger
currents in N101 mutants compared with wild type hSERT despite reduced surface expression.
These currents were absent from mock-injected oocytes and were blocked by co-application of
SERT antagonists (data not shown). Additionally, as first described by Mager et al. (Mager et al.
1994), antagonist (RTI-55) treatment of hSERT-expressing oocytes revealed a 5-HT-independent
current that appears as an outward current at −60mV (Figure 13A) and that reverses at
approximately +30mV (Figure 13B). The apparent outward current is interpreted as RTI-55
block of inward leak current. In contrast to 5-HT transport (Mager et al. 1994), the hSERT leak
current was insensitive to extracellular Cl−, except at high positive potentials where a slight
reduction in maximal outward current was evident (Figure 13B). These data indicate that
Cl− flux does not constitute a significant fraction of the 5-HT-independent current, consistent
with the reversal potential of +30mV. Like hSERT, the N101A mutant was insensitive to
external Cl−. However, in this mutant, the reversal potential for these currents (using RTI-55 to
define the leak) shifted from approximately +30 to approximately +70mV (Figure 13C). The
movement of ions during these experiments is insufficient to alter the internal ionic
concentration of the oocyte, even less so in the presence of endogenous ion pumps. Thus, the
shift in reversal potential we observe toward ENa is most likely an inherent effect of the mutant
on the ion selectivity of 5-HT independent currents. In support of this hypothesis, replacing all
Na+ with NMDG in normal Cl− buffer shifts the hSERT reversal negative by 40.1 ± 3.8mV, p <
0.05, n = 7, whereas N101A shifts by 52.6 ± 3.3mV (p < 0.05, n = 6). These changes are
consistent with a shift toward a greater contribution of Na+ to 5-HT independent currents in the
N101A mutant than in hSERT.
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Figure 13. Current-voltage relationship analysis of the hSERT leak conductance of
N101A mutant. (A) Current traces of 5 HT-induced (5µM 5-HT) and leak current (revealed
by application of the SERT antagonist RTI-55 (5 µM)) from oocytes expressing hSERT
mutants. Oocytes were injected with equimolar amounts of cRNA. Steady-state I/V analyses
of leak currents for hSERT (B) and N101A (C) recorded in Ringer’s buffer containing either
120mM NaCl (open circles) or 120mM sodium methanesulfonate (filled boxes). Values
plotted represent the difference between conductances in buffer alone versus addition of 5µM
RTI-55. Because of the low levels of leak current observed in the hSERT-expressing oocytes
compared with the N101 mutants, only hSERT-expressing oocytes showing relatively higher
leak currents were used to have sufficient signal for the I/V analysis.
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D

Figure 13 (continued). Current-voltage relationship analysis of the hSERT leak
conductance of N101A mutant. (D) Western blot analysis of total and surface expression of
hSERT detected with hSERT-specific monoclonal antibody ST-51. Equal amounts of protein
were loaded in each lane. A band of similar size to mature hSERT was noted in the total
(uninjected) control lane. However, the band is nonspecific as the total control lane lacks the
immature and oligomeric hSERT bands observed in the hSERT-expressing oocytes, and no
bands are observed in the surface control (CTL) lane.
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N101 Dictates Cl− Dependence of 5-HT-induced Currents
Similar to leak currents, currents elicited by 5-HT were significantly larger in the N101
mutants than in wild type hSERT when normalized for surface expression (Figure 14A). Even
more striking was the loss of Cl− dependence for these currents in N101 mutants (Figure 14, A–
D). In the hSERT N101C mutant, 5-HT actually induced slightly larger current (Imax) at negative
potentials in the absence of Cl− and current decreased in response to increasing
Cl− concentrations (Figure 14D). These data can be explained if Cl− is still transported through
the N101C mutant, offsetting the Na+ current. As described previously, 5-HT-induced currents in
hSERT and rSERT did not reverse at positive potentials (Cao et al. 1998) because of outward
leak currents that begin to dominate at positive potentials (Figure 14B) (Sonders et al. 1997). In
contrast, a reversal of 5-HT-induced currents is evident at approximately +75mV for both
hSERT N101A and N101C. This finding is consistent with the loss of outward leak currents in
the N101 mutants at positive potentials (Figure 14, C and D). Analysis of the Cl− concentration
dependence of 5-HT-induced currents (−60mV, 5µM 5-HT) confirms that although 5-HTactivated current in hSERT required Cl− (EC50 = 0.5mM), N101 mutants did not require Cl− over
the same concentration range (Figure 14E). Unlike the shifted Km value for 5-HT transport in the
absence of Cl− (Figure 10A), the EC50 values for 5-HT-elicited currents in hSERT were
unaffected by external Cl− (1.6 versus 1.8µM, respectively) (Figure 14F). The 5-HT EC50 values
for N101A and N101C were also Cl−-insensitive but were significantly decreased relative to
hSERT values (N101A-Cl 0.78 ± 0.14µM, N101A+Cl 0.64 ± 0.11µM; N101C−Cl 0.72 ± 0.13µM,
N101C+Cl 0.39 ± 0.05µM, p < 0.05 one-way ANOVA, Dunnett's post hoc test) consistent with
the lower Km value for 5-HT measured in the mutants (Figure 10).
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Figure 14. TEVC analysis of N101 mutants. (A) Raw traces of Cl– dose-dependent 5-HTinduced currents (5-HT, 5µM). Cl– addition is designated by bars along with concentration used.
Anion concentration was adjusted with 120mM with methanesulfonate. Current-voltage
relationship for the 5-HT-induced current reveals a reversal equilibrium for N101 mutants.
Steady-state currents evoked upon application of 5µM 5-HT in the presence (filled circles) or
absence (empty circles) of Cl– and normalized to % current obtained with 120mM Cl– at –60mV
are plotted in relation to membrane potential for hSERT (B), N101A (C), and N101C (D). (E)
Plot of induced current amplitudes from hSERT (open circles), N101A (filled boxes), and N101C
(filled triangles) from (A). Currents were normalized to current obtained at 120 mM Cl–. Cl– was
replaced with 120mM MS. (F), plot of induced current as a function of 5-HT concentration in the
presence (filled circles) or absence (empty circles) of Cl– and normalized to percent current at
saturation conditions in the presence of Cl–.
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N101 Dictates hSERT Coupling and Stoichiometry
To investigate the larger 5-HT-induced currents exhibited by the N101 mutants, we
determined 5-HT flux and total charge movements in hSERT and hSERT N101 mutants in single
voltage-clamped (−600mV) oocytes (Ramsey 2002). As shown in Figure 15A, in normal
extracellular Cl− hSERT supported the net inward movement of ~7 positive charges per 5-HT
molecule, consistent with previous studies (Mager et al. 1994; Quick 2003). Removal of
Cl− caused a modest but significant increase in the flux ratio (~10 charges/5-HT), arising from a
relative retention of 5-HT-gated currents despite a reduction in 5-HT transport. Charge/5-HT
flux ratios in the N101 mutants were significantly greater than for hSERT, in the presence or
absence of Cl−, with ~40 charges moved per 5-HT. When normalized for transporter surface
expression, this dramatic increase in the charge/5-HT flux ratio resulted from increased charge
movement (rather than a reduction in 5-HT transport; data not shown), suggesting a disruption of
coupling between transmembrane flux of Na+ (or other ions) and 5-HT. To test this idea, we
returned to mammalian cells where the smaller internal volume facilitates an assessment of
equilibrium accumulation of 5-HT. After 2 hours of incubation in 50nM 5-HT, hSERTtransfected HeLa cells established a 281-fold (±14) gradient of 5-HTin/5-HTout (Figure 15B). In
contrast, the N101 mutants concentrated 5-HT to a significantly lesser extent (N101A, 18-fold
(±1); N101C, 31-fold (±1); p < 0.01, one-way ANOVA and Dunnett's post hoc analysis).
Removal of the Cl− gradient as a driving force in platelet plasma membrane vesicles led to a
much smaller (∼50%) decrease in 5-HT accumulation (Nelson and Blaustein 1982), consistent
with an important role for N101 in optimal coupling of 5-HT transport to the Na+ gradient.
Moreover, when transfected cells with accumulated 5-HT were washed and then incubated in 554
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Figure 15. Ion-substrate coupling analysis of hSERT N101 mutants. (A) TEVC analysis of
charge-to-substrate flux ratio: TEVC oocytes expressing hSERT or the N101 mutants were
exposed to [3H]5-HT in the presence or absence of Cl–. Induced current was monitored during the
incubation period followed by quantization of total 5-HT incorporated. Total current was
converted to charge. The net charge movement per 5-HT molecule translocated was plotted for
both presence (filled bars) and absence (open bars) of Cl–. (***=p≤0.001). (B) Steady-state
uptake kinetics: [3H]5-HT (20 nM) uptake in NaCl-containing assay buffer by HeLa cells
transiently transfected with hSERT (open circles), N101A (filled boxes), N101C (filled triangles)
or nontransfected (filled diamonds) is monitored over 120 min. Data are normalized by
calculating the concentration ratio of [3H]5-HT inside the cell over the concentration in the buffer.
The data were fit to a Michaelis-Menten nonlinear regression equation. (C) Substrate efflux from
cells preloaded with [3H]5-HT: HeLa cells transiently transfected with hSERT, N101A, or N101C
are incubated with 20 nM [3H]5-HT for 30 min washed and allowed to efflux for 30 min in
MKRH buffer. % [3H]5-HT efflux is plotted and determined by comparing [3H]5-HT remaining
in the cells from efflux assay to duplicate samples halted prior to the efflux step. (***=p≤0.001).
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HT-free medium, hSERT N101 mutant cells exhibited significantly more efflux of 5-HT (hSERT
31 ± 1.3% in 30 minutes; N101A 76 ± 1.7% (p < 0.001); N101C 71 ± 1.1% (p < 0.001, one-way
ANOVA and Dunnett's post hoc analysis) (Figure 15C). Together, these data reveal that
mutation of N101 disrupts the ability of hSERT to utilize energy stored in transmembrane ion
gradients to support the intracellular accumulation of 5-HT.
Molecular Modeling Suggests a Mechanism for N101 Participation in Ion-coupled 5-HT
Transport
The lack of evidence for direct interaction between N101 and Cl− (Forrest et al. 2007;
Zomot et al. 2007; Ben-Yona et al. 2011; Tavoulari et al. 2011) suggests that N101 effects derive
not from Cl− binding. We investigated the possibility that N101 served an essential role in
propagating Cl− binding at nearby sites to other critical determinants of 5-HT transport using
RosettaLigand (Meiler and Baker 2006) to dock 5-HT into an hSERT homology model and
performed relaxation and energy minimization in vacuo with AMBER (Kaufmann et al. 2009).
Subsequently, models of wild type hSERT and the N101A mutant were evaluated both in the
absence and in the presence of the Cl− and acetate ions using the same protocol. The placement
of 5-HT in our model is consistent with biochemical data that indicate coordination of the 5-HT
amine by D98 as well as sensitivity of 5-HT to substitution at various positions around the indole
ring (Barker et al. 1998; Adkins et al. 2001). In hSERT, with Na+, Cl−, and 5-HT bound, our
depiction illustrates these three substrates co-localized around the Na1 binding pocket through
their coordination by residues of TM1, -2, -6, and -7 (Table 1). These four helices have been
proposed to form a bundle whose movement within the protein closes the extracellular
permeation pathway and opens a pathway to the cytoplasm (Forrest et al. 2008). Our minimized
structures also predict that Cl− and Na+ coordination is linked via dual interacting residues S336
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hSERT WT:
Na1: A96 O, D98 Oδ-, N101 Oδ, S336 O, S336 Oγ; n=6
Na2: G94 O, V77 O, L434 O, D437Oδ-, S438 Oγ, n=5
Cl: Y121 HH, Q332 He, S336 Hγ1, N368 Hδ, S372 Hγ; n=5
hSERT WT: No Cl–
Na1: A96 O (0.3), D98 Oδ1 Oδ2, N101 Oδ, F335 O, S336 O, n=5.1
Na2: G94 O, V77 O, L434 O, D437 Oδ1 Oδ2; n=5
N101A: Cl–
Na1: A96 O, D98 Oδ1 Oδ2, S336 O, Oγ, N368 Oδ n=5.8
Cl: Y121 HH, Q332 He, S336 Hγ1, N368 Hδ, S372 Hγ; n=5
N101A: No Cl–
Na1: A96 O, D98 Oδ1 Oδ2, S336 O, Oγ, N368 Oδ n=6
Na2: G94 O, V97 O, L434 O, D437 Oδ1 Oδ2; n=5
Table 1. Ion coordination in the presence or absence of Cl– for hSERT and N101. The
table presents data from computation models of hSERT WT and N101A with and without Cl–
included in the system. Listed are the residues within range of forming a hydrogen bond to
each respective bound ion. For each ion-binding site, coordinating residues are listed along
with the respective chemical component of the residue that forms a hydrogen bond with the
ion. The total number of coordinating interactions is listed at the end of each row. Those
residues with low occupancy have their occupancy values included in parentheses.
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Figure 16. Molecular models of putative hSERT ion-binding sites. The top panels (A-C) are
2.5-dimensional representations emphasizing differences in ion coordination geometry observed
after a 20-ns MD simulation of computational models of hSERT and hSERT N101A in the
presence and absence of Na+. Residues participating in the ion-binding site of each model are
color coded blue (TM1), green (TM6), and yellow (TM7). Note the apparent importance of
residue Ser-336 in stabilization of favorable ion-coordination geometry in both the models for
hSERT with NaCl (A) and the N101A mutant without Cl– (C). This positioning of S336 is not
found in the model of hSERT without Cl– (B). (D-F) A three-dimensional rendering of (D)
hSERT with NaCl, (E) hSERT without Cl–, and (F) hSERT N101A without Cl– superimposed on
top of hSERT WT without Cl– (black). All dashed lines represent stable hydrogen bonds observed
after 20 ns of MD simulation in lipid membrane and aqueous solution.
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(TM6) and N368 (TM7). 5-HT engages both the Na+ and Cl− coordination networks via a salt
bridge provided by its ethylamine nitrogen. N101 participates in Cl− interactions in these models
through stabilization of N368 in TM7 and Na1. To test predictions from the gas-phase
computations, we constructed a solvated lipid membrane system with our SERT models and
performed all-atom MD simulations with the CHARMM-27 force field (data not shown; see
(Henry et al. 2011)).
Using different methods (comparative modeling, docking, minimization, and then allatom MD simulations), we consistently observed distinct backbone conformational shifts at
residue S336 in response to Cl− removal (Figure 16, A, B, D and E) that result in a shift of
hydrogen-bonding interactions of the S336 side-chain OH away from interaction with the N368
side-chain amide (Figure 16, A and D), where many residue contacts in TM1, -2, -6, and -7 are
affected, including Y121 and S372. The multiple interactions of N101 observed in hSERT are
likely critical to coupling as they lead to an extensive hydrogen bond and coordination network
around the bound ion substrates. Conversely, Cl− coordination by N368 permits an interaction of
the S336 side-chain OH with N368 via an improved geometry for coordination of the Na1 site
Na+ ion. In turn, these interactions link TM2 and TM7 to TM1, where critical aspects of 5-HT
coordination are located (residue D98 and the backbone carbonyl of Y95) (Figure 16, A and D).
Notably, our recent substituted cysteine accessibility method analysis of TM6 (Field et al. 2010)
revealed S336C exhibits the same phenotype as the N101C mutant in that it is sensitive to (+)charged MTS reagents and insensitive to (−)-charged MTS reagents.
Importantly, analyses of MD trajectories allow us to predict the residue interaction
changes likely to arise in N101 mutants that allow for Cl−-independent 5-HT transport. Analysis
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of the inter-residue contacts from MD simulations predicted that the N101A mutation could
considerably disrupt the H-bond interaction network found in the hSERT substrate-Na1 ionbinding pocket (Table 1). Coordination of Na+ by the N101 side-chain amide oxygen is predicted
to be lost as is the H-bond between 5-HT and S336. A number of long lived (stable) bonds
connecting TM2 and -7 are also lost in the hSERT WT models absent of Cl– (Figure 16, B and
E). However, the A101 side chain, being considerably smaller than N101, permits a local
repacking of the residues forming the Na1-binding site and displacement of the Na+ ion by ~2.0Å
(Figure 16F, gray and magenta spheres). This change allows formation of a novel Na+
coordination site in which the backbone carbonyl of S336 supplements the S336 side chain,
restoring WT-like ion coordination number (n = 6) with the backbone carbonyl of L337 (TM6)
forming an H-bond with the 5-HT ethylamine moiety. Interestingly, a conservative but bulkier
N101Q mutation results in almost complete loss of function (data not shown), suggesting side
chains larger than Asn may significantly impact interactions in the binding site. The Na1 site is
further stabilized by S336 forming an H-bond to the side chain of the N368 amide. There is also
a long living hydrogen bond (>80% of all analyzed MD frames) between Y121 and S372 (TM6).
These interactions effectively mimic the relative positioning of the same residues from TM1, -2,
-6, -7 found in the WT hSERT Cl− ion coordination models (Figure 16, A, D, E and F)).
Effect of Cl− and Different Mutations on Ion and Solute Binding to the Transporter
To better understand the role of Cl− in binding of Na+ and 5-HT, we computed binding
enthalpies using MM/PBSA approximation (Swanson et al. 2004). The evaluation of binding
enthalpies for mutants (101A and 336C) may help highlight the role of the anion in the transport
cycle and its modulation by N101 and S336. The ΔΔH for the Cl−-free WT protein shows
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significant inhibition of both Na+ and 5-HT binding to the transporter indicating an important
role of Cl− in the stabilization of the entire binding pocket. The analysis of the ion coordination
within the Na1 site shows that the anion-depleted transporter displays different ion coordination
for Na1 than the anion-bound complex. In particular, the hydroxyl oxygen from the side chain of
S336 no longer coordinates the Na+ ion, and the Na1 coordination number is reduced from ~6 to
~5 ligands producing an immediate effect on ion binding affinity to Na1. In contrast, removal of
Cl− from the N101A mutant led to relatively modest changes in the binding enthalpies for solute
and ions to the Na1/Na2 sites as compared with WT. In the N101A system, both side-chain
carboxylate oxygens of D98 and the side-chain OH and backbone carbonyl oxygen of S336 are
now participating in the coordination shell for the Na+ ion bound to the Na1 site thereby
compensating for the substitution at N101 (Figure 16F). S336 contributes both main chain and
side-chain oxygens to ion coordination in the N101A mutant (with and without Cl− bound).
However, binding of Cl− to the N101A mutant destabilizes ion coordination at the Na2 site such
that the affinity of Cl− for the transporter is reduced relative to that of a wild type transporter.
Thermodynamic analysis of binding enthalpies suggest that N101 plays an important role in
modulation of binding affinity at the Na1 and Na2 sites as well as a contribution to the
modulation of Cl− binding.
Validation of the Partnership Between N101 and S336 in Cl−-dependent 5-HT Transport
As noted above, our models suggest a critical relationship between N101 in TM1 and
S336 in TM6 on the coupling of Na+ and Cl− binding to 5-HT transport. To test this hypothesis,
we generated the Cys substitution S336C, reducing the length of the side-chain hydrogen bond
donor because our model proposes that this side chain directly coordinates Cl− as well as N368
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(Figure 16A) (Yamashita et al. 2005; Forrest et al. 2007). Indeed, although surface expression of
hSERT S336C was 70% of hSERT (Figure 17D), transport activity was only 11 ± 2.7% (n = 3)
that of wild type. Importantly, the residual 5-HT transport activity observed with S336C was
largely Cl−-independent and was actually enhanced by full anion replacement with acetate
(Figure 17, A–C).
The findings with S336C are similar to results obtained by Forrest et al. (Forrest et al.
2007), who proposed S372 was a Cl−-coordinating residue in SERT and found that mutation of
S372 to the negatively charged Asp or Glu yielded Cl− independence. However, unlike N101C,
S372C did not result in Cl−-independent uptake but rather yielded an increase in the
apparent Km value for Cl−. This difference in Cys substitution at these two sites in terms of
Cl− independence could be explained by the pKa at S336 and S372 in the absence of Cl−. C372 is
proposed to be in the noncharged SH form (Forrest et al. 2007). We constructed equilibrated
anminimized hSERT models in a solvated membrane system and used free energy perturbation
FEP analysis using dual topology methods (Simonson et al. 2004) to evaluate pKa shift upon
deprotonation for cysteines at the positions 336 and 372 relative to model solution
(150mM aqueous solution of NaCl). FEP simulations of the pKa shift for buried cysteines. These
analyses reveal that in the presence of Na+ in the Na1 site, C336 can be deprotonated at pH 7
with a large ΔpKa shift of approximately −5.0. The experimental pKa for the Cys side chain is
∼8.0, and therefore the pKa for C336 is ∼3.0, suggesting that there is a high probability that the
side chain of C336 is deprotonated with Na+ present at the Na1 site. However, analysis of C372
shows the resulting ΔpKa shift is approximately −0.9 and the net pKa for C372 is ∼7.1. The
reason for the apparent difference in protonation state at these two positions lies in the proximity
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Figure 17. Anion replacement impact on 5-HT transport and substrate induced current in
N101 and S336 mutants. [3H]5-HT (30 nM) uptake in HeLa cells was determined under Cl–replacement with the anions (A) acetate, (B) methanesulfonate and (C) D-gluconate in hSERT and
mutants as marked. Data were normalized to uptake of Cl–-containing buffer for each mutant. (D)
Western blot analysis was conducted to determine the surface expression of each hSERT mutant.
Surface proteins were labeled with a biotin tag, purified using neutravidin beads. hSERT was
detected using the monoclonal antibody ST51-1. Parental cells are included as a control.
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Figure 17 (continued). Anion replacement impact on 5-HT transport and substrate induced
current in N101 and S336 mutants. (E) TEVC analysis in oocytes of S336C (filled boxes),
N101A/S336C (open circles) and N101C/S336C (filled circles) double mutants plotting steadystate currents evoked upon application of 5 µM 5HT in response to Cl– concentration. Currents
were normalized to % current obtained with 120 mM Cl– at –60 mV.
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to bound Na+. MD simulations with C336− show that the negatively charged side chain partially
occupies the site for Cl− and could coordinate Na+ (with occupancy of ∼40%). C372 cannot
coordinate to the positive ion, and therefore its deprotonation in the low dielectric environment is
energetically unfavorable. These findings are consistent with the proposition that C336 acts
similar to charge-changing (Asp or Glu) mutations at the position 372 in providing a localized
negative charge and thereby results in Cl− independence. Whereas the convergence of free
energy simulations is known to be a bottleneck of the method, large shifts in pKa values are
suggestive of different propensities in the protonation states of these two cysteines (Li et al.
2008).
Interestingly, whereas in tissue culture studies S336C transported 5-HT at only ∼11% the
rate of wild type hSERT, introduction of N101A into the S336C background transport rate was
three times faster, similar to that of the N101A single mutant alone (Figure 18) (Henry 2003).
Like the N101 and S336 single mutants, 5-HT transport by the N101A/S336C and
N101C/S336C double mutants is Cl−-independent (Figure 18). Side-chain rotomer modeling of
S336C in both wild type and N101A mutant backgrounds suggest steric packing effects in the
Na1 ion-binding site were significant structural factors contributing to this phenotype (data not
shown; see (Henry et al. 2011)). Consistent with [3H]5-HT transport assays, TEVC analysis of
S336C single and N101A/S336C and N101C/S336C double mutants yields results similar to
N101A and N101C mutants, where 5-HT-induced currents are Cl−-independent (Figure 17E). As
with the N101C single mutant (Figure 14E), the N101C/S336C mutant shows a dose-dependent
reduction in observed current in response to increasing Cl− concentration suggesting the
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Figure 18. Kinetic analysis of 5-HT transport in hSERT S336C and N101A/ S336C
mutants. HeLa cells transiently expressing the hSERT N101A (open squares), hSERT
S336C (filled squares), or hSERT N101A/S336C (filled circles) mutants were evaluated for
dose-dependent 5-HT uptake after 10 min in NaCl containing buffer (n=3).
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possibility of Cl− co-transport in the N101C-containing mutant that could offset the
movement of positive (Na+) ions, appearing as a reduction in current.

Discussion
In previous biochemical analysis of hSERT TM1, it was suggested that the conserved
residue N101 was proximal to the substrate- and cocaine-binding sites (Henry 2003). A position
proximal to the substrate-binding site was later substantiated by the LeuT crystal structure
(Yamashita et al. 2005) and in relation to the competitive antagonist cocaine by subsequent LeuT
model-guided studies of dopamine transporter (Beuming et al. 2008). Interestingly, during the
substituted cysteine accessibility method analysis, we found N101C could be modified by the
positively charged reagent MTSET but not by the negatively charged MTSES (Henry 2003).
This distinction does not reflect a direct antagonism of MTSES by Cl− as N101 is not likely to be
directly involved in Cl− binding (Forrest et al. 2007; Ben-Yona et al. 2011; Tavoulari et al.
2011). In fact, Cl−-free conditions fail to promote MTSES inactivation of the N101C transporter
(Rudnick 2002). The inability of MTSES to inactivate the N101C mutant may arise from
repulsion by the transmembrane dipoles that are predicted to exist at the central unwound regions
in TM1 and -6 (Screpanti and Hunte 2007). Moreover, four recent reports that identify Cl−binding sites and the coordinating residues in SERT and GAT1 do not implicate N101 in this
role (Forrest et al. 2007; Zomot et al. 2007; Ben-Yona et al. 2011; Tavoulari et al. 2011).
In this study, we provide several lines of evidence regarding a critical role that N101
plays in coupling Cl− binding to the conformational changes that are essential for Na+-coupled 5HT transport. In particular, our substituted cysteine accessibility method analysis reveals that the
67

N101 mutants no longer require Cl− for 5-HT-induced conformational changes, providing more
specific evidence for the involvement of N101 in Cl− dependence. The N101 mutations increase
nonstoichiometric charge movements carried by hSERT, both in the presence and the absence of
5-HT, indicating uncoupled ion movements. Conversely, although N101 mutants transported 5HT at initial rates comparable with that of hSERT, steady-state 5-HT accumulation was reduced
∼90%, further indicating a loss of thermodynamic coupling between transmembrane gradients of
ions and 5-HT. This loss of coupling was even more severe than would be expected simply from
the contribution of a transmembrane Cl− gradient to 5-HT accumulation, which was less than 2fold in measurements with resealed vesicles expressing native SERT (Nelson and Blaustein
1982), suggesting a more profound defect in ion coupling in the N101 mutants.
Slight differences in the extent of Cl− substitution by the anions acetate (105%),
methanesulfonate (78%), and gluconate (70%) correlate with their Stokes diameters of 4.5, 5,
and 6.2Å, respectively, and suggest that N101 substitution may impart changes in anion
selectivity at the Cl−-binding site in SERT. These results indicate that anions may still interact
with hSERT in the N101 mutants and are consistent with the presence of all previously proposed
Cl−-binding site residues (Forrest et al. 2007; Zomot et al. 2007) in these mutants. Further
evidence comes from Cl− substitution with multivalent anions such as phosphate, resulting in
poor functional replacement compared with monovalent species (≤40% compared with Cl−containing conditions, data not shown). These data also suggest that the anion-binding site is still
available, and its functional role can be inhibited by multiple charged species. The N101/S336
double mutants appear less sensitive to the anion size in replacement of Cl− (Figure 17, B and C)
and Cl− substitution.
68

Further insight into the role of N101 and the impact of N101 substitutions derives from
our MD simulations. We utilized homology-based molecular modeling of hSERT using the
LeuT coordinates as well as small molecule docking of 5-HT with RosettaLigand. The results
predict that N101 extends into the substrate binding pocket where the side-chain carbonyl
oxygen, homologous to LeuT N27 (Yamashita et al. 2005; Kaufmann et al. 2009), as proposed
previously (Barker et al. 1999; Yamashita et al. 2005), places N101 in a critical position to
contribute to the stabilization of both Na+- and 5-HT-binding sites. Consistent with these
findings, a docking study by Celik et al. (Celik et al. 2008) identified a similar pose for 5-HT in
SERT as one of the three top-scoring clusters.
Ion and substrate dynamics are controlled by occupancy of Na1 and Cl− sites. The
mutations that affect ion binding to either site (S336 or N101) have a global impact on the entire
transport mechanism. For example, our MD analysis implicated S336 as an important residue in
the Cl− dependence of transport coupling. This residue was previously proposed to coordinate
Cl− in SERT (Forrest et al. 2007; Tavoulari et al. 2011) and GAT-1 (Zomot et al. 2007; BenYona et al. 2011), and we found that S336C exhibits the same insensitivity to MTSES as N101C
(Field et al. 2010). Experimental analysis of the hSERT S336C mutant subsequently revealed
that like in N101C, 5-HT transport by S336C was not dramatically stimulated by Cl−. However,
our MD pKa analysis suggests that this effect may also be due to replacement of Cl− by the Cys
thiolate anion, similar to replacement of other Cl−-coordinating residues with carboxylic amino
acids in SERT and GAT-1 (Forrest et al. 2007; Zomot et al. 2007). Finally, analysis of docking
conformations indicates that the coordination geometry of acetate in the wild type is less
favorable than in N101A and can explain why acetate can fully replace Cl− in an N101 mutant
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background but not in hSERT. In hSERT, acetate forms an H-bond with the C=O backbone of
S336 that would limit adoption of a Cl−-like geometry (data not included; see (Henry et al.
2011)). In N101A, the N368 amide side chain is no longer constrained by the H-bond network
imposed by N101 and is thus free to interact with acetate in a manner that reproduces the ion
coordination geometry of the WT NaCl model (data not included; see (Henry et al. 2011)).
More generally, our findings illustrate that both the direct interaction of N101 with N368
and the more indirect interaction with S336 via coordination of the NA1 sodium ion suggest that
establishment of physical interactions between TM1 and -6 is a critical facet of ion-coupled
substrate movement. This idea is further supported and expanded by our inter-helical interaction
energy analysis conducted on MD trajectories for WT and mutants (data not shown), which
suggests that Cl− removal has an adverse impact on transport by disruption of interactions
between TM1 and -3, TM1 and -6, and TM5 and -8. In contrast, the removal of Cl− is
energetically much less disruptive to inter-helical interactions in the N101 mutants. Recent
crystal structure and MD studies suggest that the primary transport mechanism for the LeuT
structural superfamily involves helical bundles that move relative to one another to allow entry to
and exit from the substrate- and ion-binding sites (Forrest et al. 2008; Ressl et al. 2009;
Shimamura et al. 2010; Watanabe et al. 2010) via gating residues originally described by
Yamashita et al. (Yamashita et al. 2005). However, disagreements do exist between the models,
and these differences may reflect mechanistic subtleties between transporters influenced by the
substrates and ions involved.
Within the SLC6 family, some bacterial, insect, and mammalian family members differ
in the identity of the residue homologous to hSERT N101 and contain instead a His, Ala, Cys,
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Gly, Thr, Ser, or Asp (Beuming et al. 2006), whereas all known Cl−-dependent SLC6
neurotransmitter transporters contain Asn at this site. This observation suggests that this residue
plays a critical role in promoting optimal coordination of sodium, Cl−, and substrate while
limiting movement of additional charges, a role that appears relaxed in the N101 mutants. As we
and others (Ingram et al. 2002; Quick 2003; Carvelli et al. 2004; 2008) have published that
serotonin and dopamine transporter charge flux is an important contributor to neuronal
excitability, we believe that the charge flux-limiting property of this residue is particularly
important at synapses.
Neurotransmitter transporters are now known to exist in regulated protein complexes that
can modulate multiple aspects of transport, including substrate affinity, membrane trafficking,
and ion conductance states. Our observation of a >7-fold increase in Na+ flux in the N101
mutants and the finding that syntaxin1A interaction with the N terminus of SERT can modulate
Na+ stoichiometry during the transport cycle (Quick 2003) raise the possibility that syntaxin1A
binding may modulate transporter conductance states by orienting residues in TM1, likely
including N101, to restrict nonstoichiometric ion flow during the transport cycle. Although Ala
(or Cys) can functionally replace N101, the loss of optimal coupling is accompanied by dramatic
increases in both leak and 5-HT-gated currents, properties that may be captured by syntaxin1Alinked regulatory mechanisms. The remarkable >2-fold increase in 5-HT efflux from cells
expressing the N101 mutants also supports the idea that precise orientation of the amide side
chain of this residue can control coupling between ion gradients and efflux of intracellular 5-HT.
In fact, initial cation replacement studies using NMDG-Cl suggests that Na+ dependence may be
altered in the N101 mutants (Figure 19). In addition, it has been shown that amphetamine71
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Figure 19. Na+ dependence of hSERT N101A and N101C mutants. Uptake of [3H]5-HT
(20 nM) after incubation for 15 minutes in medium with and without Na+ (replaced with
NMDG-Cl) is plotted as (A) percent uptake of Na+ containing buffer and (B) raw [3H] counts
per minute (CPM). CPMs for N101A and N101C in panel B are ~30% those of the hSERT
WT and are expected based upon the mutants surface expression relative to hSERT WT.
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induced efflux through dopamine transporter requires phosphorylation of its cytosolic Nterminus (Fog et al. 2006) as a result of CaMKII activation by amphetamine. Phosphorylation of
the N-terminus may propagate changes in structure upward to TM1, recapitulating the impact of
N101 mutants. Finally, high NE flux rates mediated by channel-like states have been identified
in the norepinephrine transporter (Galli et al. 1998). As these conductance states can be inhibited
by syntaxin1A (Sung and Blakely 2007), we speculate that the presence of the Asn in TM1 may
provide Cl−-coupled SLC6 transporters not only with the opportunity to more efficiently tap the
Na+ gradient for uphill transport but also allows transporters to move between coupled
transporter modes of substrate conduction and channel-like modes of neurotransmitter transport.
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CHAPTER III
THE TWO SODIUM SITES IN THE HUMAN SEROTONIN TRANSPORTER PLAY
DISTINCT ROLES IN THE ION COUPLING AND ELECTROGENICITY OF
TRANSPORT
Introduction
Secondary active solute transporters are a critical feature of biological systems that utilize
chemiosmotic gradients to support energetically unfavorable concentrative movement of
substrates across the plasma membrane. Evidence suggests that substrate translocation occurs via
an alternating access mechanism in which ion and substrate binding facilitate conformational
changes in the transporter allowing a central binding domain to be alternatively open to either
side of the membrane (Jardetzky 1966; Forrest et al. 2008; Forrest and Rudnick 2009). Recently,
a number of solute transporters from different families have been crystallized, providing critical
details about the structural features of these carriers (Yamashita et al. 2005; Faham et al. 2008;
Weyand et al. 2008; Gao et al. 2009; Ressl et al. 2009; Shaffer et al. 2009; Schulze et al. 2010;
Shimamura et al. 2010; Penmatsa and Gouaux 2013). Despite these transporters possessing little
to no sequence homology, all share a 5 + 5 arrangement of transmembrane helices termed the
FIRL (“five-transmembrane helix-inverted topology repeat, LeuT-like”) or “LeuT-fold”
(Khafizov et al. 2012), where the second bundle of five helices have inverted symmetry in
relation to the first group of five helices, supporting the idea of a conserved functional
mechanism (Abramson and Wright 2009; Forrest and Rudnick 2009; Krishnamurthy et al. 2009).
Importantly, a collection of crystal structures have been solved representing the “open-to-out”,
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“occluded,” and “open-to-in” conformations of the carriers, suggesting mechanisms that may
support substrate translocation (Yamashita et al. 2005; Zhou et al. 2007; Singh et al. 2008;
Krishnamurthy and Gouaux 2012; Piscitelli and Gouaux 2012). Unfortunately, these static poses
are limited in their ability to explain how ion binding is mechanistically and energetically
coupled to the conformationally mediated transport of substrate.
In this study, we focus on the human serotonin transporter (hSERT), a member of the
SLC6 family that plays a major regulatory role in synaptic transmission by clearing 5-HT from
the synaptic cleft, thereby terminating 5-HT receptor activation (Blakely et al. 1991; Hoffman et
al. 1991; Reith 2002; Beuming et al. 2006; Kristensen et al. 2011; Pramod et al. 2013). hSERT
has importance in human health, being the target of a number of therapeutic and illicit drugs,
including tricyclic antidepressants, selective serotonin reuptake inhibitors, cocaine, and 3,4methylenedioxymethamphetamine (“ecstasy”) (Ramamoorthy et al. 1993; Tatsumi et al. 1997;
McCann et al. 1998; Pramod et al. 2013). Although SERT shares only ∼21% overall sequence
identity with the SLC6 bacterial amino acid transporter LeuT, the residues in the core of the two
proteins, where substrate and ions bind, approach ∼60% identity, suggesting that the two Na+binding sites in LeuT, termed Na1 and Na2 (Yamashita et al. 2005), are conserved in hSERT
(Barker et al. 1999). Evidence for two Na+-binding sites in MATs was recently bolstered by the
solving

of

the

eukaryotic

Na+/Cl−-dependent

dopamine

transporter

from Drosophila

melanogaster (dDAT) with sodium-binding sites comparable with those in LeuT (Penmatsa and
Gouaux 2013). Crystal structures of dDAT and a LeuT Cl−-dependent mutant (E290S)
(Kantcheva et al. 2013) have greatly advanced our understanding of the Cl−-binding site in these
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proteins and support previous biochemical studies (Forrest et al. 2007; Zomot et al. 2007;
Tavoulari et al. 2011).
Interestingly, 5-HT uptake analysis indicates that during coupled transport, only one
Na+ is translocated per cycle (Sneddon 1969), suggesting that the Na1 and Na2 sites probably
have distinct but as yet unknown roles. Recent computational analysis of the Na2 binding site in
proteins with the LeuT-fold predicted that transition to an inward facing conformation
destabilizes Na+ coordination at Na2, resulting in Na+ release followed by substrate dissociation
(Noskov and Roux 2008; Shi and Weinstein 2010; Yu et al. 2010; Krishnamurthy and Gouaux
2012; Zdravkovic et al. 2012; Zhao et al. 2012). Were this true in hSERT, which appears to
translocate a single Na+ per transport cycle, the cation at Na1 would not be mobile. This surmise
is consistent with data from crystal structure and molecular dynamic analysis of the bacterial
galactose transporter, vSGLT, because this transporter possesses the homologous Na2 site but
lacks the Na1 site (Faham et al. 2008; Watanabe et al. 2010). Despite these implications,
however, the distinct role of the Na1 and Na2 in hSERT remains elusive. To understand the roles
that each bound Na+ performs in hSERT, we used site-directed mutagenesis in combination with
biochemical and electrophysiological analyses to characterize how alterations at either of the
Na+coordination sites affect ion dependence and selectivity as well as ion and 5-HT transport.
Using a mutation that alters Na1 coordination yet retains 5-HT transport, we uncovered distinct
roles for the Na1 and Na2 coordination sites as well as molecular interactions that appear to be
important in the 5-HT transport mechanism.
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Methodology
Site-Directed Mutagenesis
Mutagenesis of hSERT cDNA in pcDNA 3.1 was accomplished using the Change-IT
multiple mutation site-directed mutagenesis kit (Affymetrix, Cleveland, OH). Mutations were
verified by DNA sequencing via Northwoods DNA, Inc. (Bemidji, MN).
5-HT Uptake Analysis
All transport studies of the mutants were conducted using either HEK-293 cells
transfected with Trans-IT LTI (Mirus Inc.) in Opti-MEM medium as described previously
(Henry 2003) or stably expressing HEK-293 cells under G418 (800µg/ml) selection. Cell lines
were plated on 24-well poly-D-lysine-coated culture plates at a density of 50,000 cells/well and
maintained at 37°C, with 5% CO2 and under high humidity. Prior to uptake, plates were washed
using the appropriate buffer as follows. Standard complete buffer contained 120mM NaCl,
5.4mM KCl, 1.2mM CaCl2, 10mM glucose, 7.5mM HEPES, pH 7.4. Cation-only replacement
buffers were prepared by replacing NaCl with a specific cation, giving XCl, where X represents
Li+, K+, Ca2+, Mg2+, Ba2+, NH4+, N-methyl-D-glucamine (NMDG+), or choline+ (120mM for
single valence cations or 60mM for divalent cations). When Ca2+ was completely removed from
the buffer, 10mM mannitol was added to balance the osmolality. A small amount of cell
detachment was detected when assays were conducted in buffer lacking Ca2+, suggesting that
could be responsible for lower uptake activity under “Na+-only” conditions; however, cell
viability studies show that the cell wash off is minimal. Furthermore, a similar decrease in
activity was observed in the Na+-only buffer supplemented with 50µM Ca2+, which eliminated
detachment during uptake, indicating that any cell loss had little to no impact on the decreased
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activity observed in the Na+-only buffers. Buffers were adjusted to pH 7.4 using KOH or
NMDG. Anion replacement buffers were made similarly, with all buffer salts having
Cl− replaced by Y (120mM NaY, 5.4mM KY, 1.2mM CaY, where Y represents acetate, gluconate,
or sulfate). Assays measured transport of 50nM [3H]5-HT (5-hydroxy[3H]tryptaminetrifluoroacetate, 28.5Ci/mmol, PerkinElmer Life Sciences) as described previously (Henry
2003). Assays were conducted for 10 minutes in order to stay within the linear range of uptake,
with the exception of 5-HT saturation analysis (15 minutes) and 5-HT equilibrium analysis (2–90
minutes). Saturation assays were performed as described, except [3H]5-HT was diluted 50-fold
with non-radiolabeled 5-HT to achieve the highest concentration of 50µM. Washing with cold
assay buffer terminated transport assays. Cells were dissolved in Microscint 20 (PerkinElmer
Life Sciences) scintillation fluid, and counts/minute were determined using a TopCountNXT
(PerkinElmer Life Sciences). Basal activity from non-transfected (or parental) cells was
subtracted from experimental wells to obtain specific activity. Km, Vmax, and EC50 values were
calculated by fitting non-linear curves to the data as a function of 5-HT concentration (GraphPad
Software Prism 5). All experiments were conducted in triplicate and were independently
replicated a minimum of three times.
Protein Expression Analysis
Transporter surface expression was determined in stably expressing HEK-293 cells plated
on poly-D-lysine-coated 24-well plates at a density of 100,000 cells/well. 24–48 hours after
plating, cell surface proteins were biotinylated, quantitated, and analyzed using Western blotting
as described previously (Henry 2003).
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Cysteine Accessibility Analysis
HEK-293 hSERT cells were plated at 50,000 cells/well and transfected as described
above. Plates were washed with a cation-specific assay buffer, followed by treatment using the
same

buffer

supplemented

with

1mM (2-trimethylammonium)ethyl)methanethiosulfonate

bromide (MTSET) (Toronto Research Chemicals Inc.), 1mM MTSET + 20µM 5-HT, or vehicle.
In wells receiving 5-HT and MTSET, 5-HT was added 2 minutes prior to MTSET. Plates were
incubated at room temperature for 10 minutes. To terminate the reaction, MTSET was removed
via

multiple

washes

with

MKRH+G

(120mM NaCl,

4.7mM KCl,

2.2mM CaCl2,

1.2mM MgSO4, 1.2mM KH2PO4, 10mM Glucose, 10mM HEPES, pH 7.4). The remaining
transport activity was determined using 50nM [3H]5-HT as described previously.
Two-Electrode Voltage Clamp Analysis
cRNA preparation. Plasmids encoding hSERT were linearized and transcribed into
RNA with a T7 RNA polymerase kit mMessage mMachine (Ambion). A total of 5ng of cRNA
was microinjected into each oocyte. Electrophysiological recordings were performed 3–9 days
following injection.
Oocyte preparation. Xenopus laevis frogs (Nasco, Fort Atkinson, WI) were anesthetized
with ethyl 3-aminobenzoate methanesulfonate (FLUKA A5040) (2mg/ml in H2O). The frog was
decapitated, and the ovarian lobes were removed and transferred to sterile Ca2+-free OR2
solution (82.5mM NaCl, 2.5mM KCl, 2mM MgCl2, 10mM HEPES, pH adjusted to 7.4 with
NaOH). The lobes were manually dissected to produce groups of 5–10 oocytes and incubated in
OR2, containing 1mg/ml collagenase from Clostridium histolyticum (Sigma). Incubation for 45–
60 minutes at 18°C was sufficient to digest and remove the follicular layer. Oocytes were then
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selected and transferred to a Ringer solution (100mM NaCl, 2mM KCl, 1.8mM CaCl2,
1mM MgCl2, 5mM Hepes, pH adjusted to 7.6 with NaOH). Oocytes were kept at 18°C for a
minimum of 2 hours prior to injection. Injected oocytes were kept for 6–9 days at 18°C in a
Ringer solution containing 2.5mM Na+ pyruvate, 100µg/ml penicillin, 100µg/ml streptomycin.
Solutions were changed daily.
Electrophysiological recordings in X. laevis oocytes. A CA-1B high performance
oocyte clamp (Dagan Corp.) was employed for the measurements. The recorded signal was
digitized with a Digidata 13222A system (Axon Instruments). pCLAMP 9.2 (Axon Instruments)
was used for data acquisition. Borosilicate glass capillaries were pulled to a final resistance of
0.4–1.2 megaohms and filled with 3M KCl. Oocytes were impaled, and the membrane potential
was clamped to a holding potential of −60mV. For continuous superfusion with Na+ solution
(120mM NaCl, 2mM KCl, 1mM BaCl2, 1mM MgCl2, 10mM HEPES, pH adjusted to 7.4 with
NaOH) a gravity-driven superfusion system (Warner Instruments, Eight Channel Perfusion
Valve Control System (VC-8)) was used. For the Ca2+ solutions, NaCl was replaced by CaCl2.
The osmolarity of all solutions was kept the same. For measurements of the substrateindependent leak current, we used 10µM paroxetine. The leak was defined by subtraction of the
respective currents (INa+ − Iparoxetine). Recordings were started after a stable current base line had
been established. The current was sampled with 100Hz and low pass-filtered with 20Hz.
Whole Cell Patch Clamp
For patch clamp recordings, HEK293 cells stably expressing hSERT N101A were seeded
at low density for 24 hours before measuring currents. To measure substrate-induced hSERT
currents, cells were voltage-clamped using the whole cell patch clamp technique. Briefly, glass
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pipettes were filled with a solution consisting of 133mM potassium gluconate, 5.9mM NaCl,
1mM CaCl2, 0.7mM MgCl2, 10mM EGTA, and 10mM HEPES adjusted to pH 7.2 with KOH.
For some experiments, the internal Cl− concentration had to be increased. In these instances, the
pipette solution consisted of 133mM KCl, 5.9mM NaCl, 1mM CaCl2, 0.7mM MgCl2,
10mM EGTA, and 10mM HEPES adjusted to pH 7.2 with KOH. The cells were continuously
superfused with external solution: 140mM NaCl, 3mM KCl, 2.5mM CaCl2, 2mM MgCl2,
20mM glucose, and 10mM HEPES adjusted to pH 7.4 with NaOH. In those experiments where
external Na+ was replaced by Ca2+, we used the following solution: 15mM CaCl2, 150mM
choline chloride, 1mM MgCl2, and 10mM HEPES, adjusted to pH 7.2 with KOH.
Currents were recorded at room temperature (20–24°C) using an Axopatch 200B
amplifier and pClamp version 10.2 software (MDS Analytical Technologies). Cells were
voltage-clamped to potentials between −100 and −10mV, and 10µM 5-HT was applied for 5
seconds once every 60 seconds. Current traces were filtered at 1kHz and digitized at 2kHz using
a Digidata 1320A (MDS Analytical Technologies). The liquid junction potentials were
calculated, and measurements were compensated accordingly. Drugs were applied using a DAD12 device (Adams & List, Westbury, NY), which permits complete solution exchange around the
cells within 100ms. Current amplitudes in response to 5-HT application were quantified using
Clampfit version 10.2 software. Passive holding currents were subtracted, and the traces were
filtered using a 100-Hz digital Gaussian low pass filter.
Molecular Dynamic (MD) Simulations of hSERT·5-HT·Ion Complexes
MD simulations were conducted using hSERT and N101A mutant homology-modeled
structures complexed with 5-HT and ions. Homology models of hSERT were based on the “open
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to out” conformation of the leucine transporter (Protein Data Bank code 3F3A) and built using
Prime (Prime, version 3.1, Schrödinger, LLC, New York). The alignment obtained in the
structure prediction module of Prime was manually edited to match the comprehensive alignment
by Beuming et al. (Beuming et al. 2006; Kaufmann et al. 2009). The loops were modeled and
refined in Prime using an ab initio loop prediction method. Side chain optimization and
minimization was conducted on loop candidates, and the models were validated for quality based
on Ramachandran plots (Ramachandran et al. 1963) by PROCHECK validation (Laskowski et al.
1993) using the ADIT site. hSERT structural models were prepared for docking in the Protein
Preparation Wizard (Sastry et al. 2013) (Schrödinger Suite 2012 Protein Preparation Wizard,
Epik version 2.3, Schrödinger, LLC, New York; Impact version 5.8, Schrödinger, LLC, New
York; Prime version 3.1, Schrödinger, LLC, New York) using default options. Protonated 5-HT
conformers generated by LigPrep (LigPrep, version 2.5, Schrödinger, LLC, New York) were
docked into hSERT homology models containing various combinations of Na+, Ca2+, and
Cl− utilizing the induced fit docking protocol (Sherman et al. 2006). The best scoring 5-HTdocked hSERT and N101A complexes were placed in the center (along the z axis, coinciding
with the normal of the 1-palmitoyl-2-oleoyl-phosphatidylcholine bilayer) of the pre-equilibrated
1-palmitoyl-2-oleoyl-phosphatidylcholine lipid bilayer using the VMD visualization package
(Humphrey et al. 1996). The dimensions of the simulation box were 20 × 20 × 14Å, containing 1
protein, 1 ligand, and ~50,340 TIP3P water molecules and 222 1-palmitoyl-2-oleoylphosphatidylcholine molecules. 186 Na+ ions and 191 Cl− counterions were added to obtain an
electroneutral system with a salt concentration of 150mM. All calculations were carried out with
GROMACS version 4.5.4 (Hess et al. 2008), using a CHARMM27 force field under periodic
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boundary conditions. The topologies and parameters files for the ligand were generated by the
SwissParam tool (Zoete et al. 2011) based on the Merck molecular force fields that are
compatible with CHARMM and GROMACS. All simulations were performed in the NPT
ensemble with velocity scaling (V-rescale) thermostat and Parrinello-Rahman barostat. For the
CHARMM force field operating in GROMACS, electrostatics were calculated using particle
mesh Ewald with appropriate cut-offs: rlist = 1.3, rcoulomb = 1.3, rvdw = 1.2, vdwtype = switch,
rvdw_switch = 0.8. Fourier spacing of 0.12nm and a particle mesh Ewald order of 4 were
employed. V-rescale thermostat with a coupling constant of 0.1 ps was used to separately couple
protein, lipid, and solvent, including water and ions. The pressure was coupled using the
Parrinello-Rahman algorithm at 1 bar with a coupling constant ρ = 1 ps and a uniform
compressibility of 4.5 × 10−5 bar−1. The coordinates were saved every 100ps with an integration
time step of 2fs. The LINCS (linear constraint solver) algorithm was used to restrain all bond
lengths (Hess et al. 1997). The steepest descent algorithm in GROMACS was used to minimize
the energy of the 5-HT-docked and ion-incorporated WT and N101A mutant hSERT structures
in 1-palmitoyl-2-oleoyl-phosphatidylcholine bilayer followed by the equilibration phase. At the
temperature of 303K, the initial velocities were generated following a Maxwellian distribution.
The system was equilibrated for 1ns at a temperature of 303 Kby fixing the position of the
docked complex by applying position restraints of 1000 kJ mol−1 nm−2 on each heavy atom,
whereas lipids and water were allowed to move normally. After initial equilibration for 1ns, the
production runs were performed for 12ns. The pressure was maintained at 1 atmosphere using
semi-isotropic pressure coupling to a Parrinello-Rahman barostat with a coupling constant of
5ps. Conformations resulting from the production phase of each simulation were stored at
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intervals of 100ps and analyzed. PyMOL (DeLano 2010) was used to generate the molecular
graphic diagrams.

Results
N101 Mutation Specifically Modifies Cation Dependence, Allowing Ca2+ to Functionally
Replace Na+ for 5-HT Transport
Previously, we demonstrated that mutation of N101 to Ala or Cys conferred Cl−independent transport to hSERT (Henry et al. 2011) while maintaining little to no loss in
transport activity. Sequence analysis between hSERT and LeuT shows that the hSERT N101
residue corresponds to N27 in LeuT and N49 in dDAT, residues that directly coordinate Na+ at
the Na1 site. Direct coordination of N101 with Na+ at Na1 is further supported by the fact that
lengthening the side chain by one carbon through a N101Q mutation yields a non-functional
transporter, whereas smaller side chains are tolerated (Henry et al. 2011). We examined the
impact that mutations at N101 have on Na+ coupling to 5-HT transport in hSERT. First, we
looked for alterations in cation selectivity through measurement of [3H]5-HT uptake in cells
stably expressing the hSERT, hSERT N101A, or hSERT N101C mutant transporters in simple
buffers containing only a single cation, where the cation was either Na+, Ca2+, Li+, Ba2+, NH4+,
choline+, NMDG+, K+, or Mg2+ (Figure 20). Appreciable 5-HT transport was observed with
hSERT in the presence of Na+-only buffer, which was 85% ± 6.3% of the uptake observed with
complete buffer (see “Methodology”). Under the same conditions, the N101A and N101C
mutants yielded uptake levels of 69 ± 2.8 and 63 ± 2.3%, respectively (Henry et al. 2011). The
inability of K+, Li+, Mg2+, Ba2+, NH4+, choline+, and NMDG+ to functionally replace Na+ in the
N101 mutants for 5-HT uptake revealed that cation selectivity for 5-HT uptake is relatively
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Figure 20. 5-HT uptake by N101 mutants under cation substitution reveals Ca2+ can
functionally replace Na+ in 5-HT transport. Transport activity was measured in HEK cells
stably expressing hSERT, N101A or N101C. Initial transport rates (10 min.) were obtained in
complete buffer or in the presence of a cation-ONLY buffer as indicated on the x-axis.
Activity is given as percentage of uptake in complete buffer. A small amount of K+ (5.4mM)
was also added to each buffer, as transport activity was lost upon complete removal of K+.
Notably, K+ alone is unable to support 5-HT uptake. The Ca2+ effect on uptake by the N101
mutants was specific, as 5-HT transport was not observed in Ca2+ only buffers using the
parental cell line lacking hSERT. Each bar represents the mean and SEM of at least three
independent experiments, each of which was performed in quadruplicate. A two-way
ANOVA was performed on sample sets with a Bonferroni post-hoc test; *** = p < 0.001.
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Figure 21. 5-HT uptake in N101 mutants under cation and/or anion ion replacement.
Transport activity was measured in HEK cells stably expressing hSERT, N101A or N101C.
Initial transport rates (10 min.) were obtained in complete buffer or in the presence of a buffer
in which NaCl is replaced with 60mM CaCl2, 120mM Na-acetate, 60mM Ca-acetate or 60mM
Ca-gluconate. Activity was normalized to activity in complete buffer. Each bar represents the
mean and SEM of three separate experiments, each performed in quadruplicate. Data were
analyzed using a two-way ANOVA and Bonferroni post-hoc test.
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intact. In fact, replacement of Na+ with Ba2+ (hSERT), Li+ (N101 mutants), and K+ actually
inhibited 5-HT uptake to levels below those observed with NMDG+ (Figure 20). Remarkably,
whereas native hSERT exhibited only 5.2% ± 0.6% activity when Ca2+ replaced Na+, Ca2+ could
fully substitute for Na+ in the N101A mutant, exhibiting the same degree of uptake observed in
the Na+-only buffer. Likewise, Ca2+ could substitute for Na+ in the N101C mutant, albeit with
less efficacy (64.2 ± 2.9%), suggesting that Ca2+ coordination may be suboptimal in the N101C
mutant compared with N101A. Uptake of 5-HT under Ca2+-only conditions maintained the
Cl− independence observed in Na+-containing buffers (Figure 21).
Na+, but Not Ca2+, Imparts Conformational Changes in Native hSERT, whereas both
Na+ and Ca2+ Can Promote 5-HT-induced Conformational Changes in the N101A Mutant
The ability of Ca2+ to support 5-HT translocation by N101A and N101C mutants suggests
that Ca2+ binding to SERT induces conformational changes similar to those obtained with Na+.
Inactivation of SERT-mediated 5-HT transport by cysteine-directed methanothiosulfanate (MTS)
reagents (Chen 1997; Chen et al. 1997; Henry 2003) can be used as an indicator of
conformational changes in hSERT (Androutsellis-Theotokis et al. 2001; Ni 2001; AndroutsellisTheotokis and Rudnick 2002; Henry et al. 2011). We used the membrane-impermeant (MTS)
reagents MTSET to examine altered accessibility of residue C109 in the presence of Na+, Ca2+,
and the large monovalent cation, NMDG+, as well as the anions Cl− and acetate−. C109 is
positioned on the extracellular end of TM1, a domain thought to undergo significant
conformational change during substrate translocation (Krishnamurthy and Gouaux 2012). The
extent of inactivation of hSERT by MTS adduction at C109 can be modulated by both cation and
anion interactions with the transporter (Chen et al. 1997; Henry et al. 2011). In the presence of
NaCl, hSERT was relatively insensitive to 1mM MTSET, and co-incubation with 20µM 5-HT
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Figure 22. Ca2+ and Na+ alter C109 accessibility to MTSET, suggesting these cations
may promote similar conformational changes in the N101A mutant. HEK-293 cells
expressing hSERT or hSERT N101A were pretreated with 1mM MTSET in the absence (gray
bars) or presence (black bars) of 5-HT (20µM) and in the presence of Na+, Ca2+ or NMDG+.
Following treatment, 5-HT uptake assays were performed in complete buffer to quantitate
activity. Percent remaining activity is plotted and is defined as the amount of 5-HT uptake of
MTSET-treated cells as a percent of untreated cells. Each bar represents the mean and SEM of
at least three independent experiments, each of which was performed in quadruplicate. Panels
(A) & (B) depict results of MTSET treatment on (A) WT hSERT and (B) hSERT N101A in
each cation buffer. Panels (C) and (D) represent data from (A) and (B) replotted with respect
to genetic background and the presence or absence of Na+ (C) or Ca2+ (D). Panels (E) and (F)
highlight the effect of Cl– replacement under full Na+ (E) or full Ca2+ (F) buffer conditions. A
two-tailed t-test was performed on sample sets as indicated with brackets; *** = p < 0.001;
* = p < 0.05; n.s = not significant.
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had no detectable effect (Figure 22A). Substitution of Na+ with either Ca2+ or NMDG+ resulted
in a significant increase in sensitivity of hSERT to MTSET, while co-incubation with 20µM 5HT had no effect on sensitivity. In contrast, the N101A background revealed that C109 is highly
sensitive to MTSET treatment, giving an 83.5 ± 1.5% loss of 5-HT transport in Na+ buffer
(Figure 22B). Importantly, a C109A/N101A mutant is insensitive to MTSET inactivation (Henry
et al. 2011). Unlike in WT hSERT, co-incubation with 5-HT in the presence of Na+ or
Ca2+ significantly protected the N101A mutant from inactivation, yielding only a 55 ± 2.7 and 74
± 2.6% loss of activity, respectively. Co-incubation of 5-HT with NMDG+ did not afford the
same protection from MTSET (Figure 22B). Thus, in the N101A mutant, Na+ and Ca2+ are both
capable of promoting conditions that, together with 5-HT, result in conformational changes in
SERT. This effect was not observed with the larger NMDG+ ion, which due to its bulk is
unlikely to access the cation-binding site in hSERT (Mager et al. 1994). The data also reveal that
both Na+ and Cl− are necessary for protection from MTS inactivation at C109 in hSERT, as
removal of either ion results in a significant increase in sensitivity (Figure 22, C and E).
However, Ca2+ cannot afford protection in WT hSERT, as the absence or presence of Ca2+ does
not alter the sensitivity of C109 (Figure 22, D and F). In the N101A mutant, increased protection
from MTS inactivation was not dependent on Cl− but did require the presence of a cation (Na+ or
Ca2+) and 5-HT (Figure 22, C–F), suggesting that conformational changes normally mediated by
binding of only Na+ and Cl− require a cation and 5-HT in the N101A mutant.
hSERT N101 Mutants Display a Loss of Potency for Na+ to Drive 5-HT Transport
Given that LeuT residue N27 and dDAT residue N49 are homologous to hSERT N101
and they directly coordinate Na+ at the Na1 site (Yamashita et al. 2005; Penmatsa et al. 2013), it
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is reasonable that mutations at N101 would directly impact Na+ binding in hSERT. To evaluate
this possibility, [3H]5-HT uptake was measured using Na+ dose-response assays, where Na+
concentrations ranged from 0 to 120mM, and NMDG+ or Ca2+ was used to compensate for the
reductions in Na+. When NMDG+ was replaced by Na+, the dose-response curves for N101A and
N101C shifted rightward compared with WT, yielding increased EC50Na+ values of 10.2 ± 3.0
and 18.3 ± 4.7mM, respectively, compared with 3.8 ± 1.2mM in hSERT (Figure 23A). The loss
of N101 coordination of Na+, due to its mutation to Ala or Cys, is consistent with the observed
decrease of Na+ potency, as well as the reduced ability of the N101 mutants to efficiently couple
the Na+ chemiosmotic gradient to 5-HT transport (Figure 23D) (Henry et al. 2011). A similar
rank-order increase in the EC50Na+ values for the N101 mutants is observed upon substitution of
Na+ with Ca2+ (28 ± 3.7 and 47 ± 6.1mM for N101A and N101C, respectively, compared with 16
± 1.8mM for hSERT (Figure 23B)). Ca2+ has not previously been reported to modulate 5-HT
transport in SERT; however, we found that at low Na+ concentrations, Ca2+ was able to enhance
5-HT uptake (Figure 23B) in hSERT, whereas NMDG+ did not (Figure 23A). In contrast, the
presence of moderate to low levels of Ca2+ negatively affected 5-HT uptake as Na+ levels
increased, as evidenced by a shallower slope and increase in EC50Na+ values compared with
NMDG+ replacement. Taken together, these data indicate that Ca2+ may act in a competitive
manner to modulate the efficacy of Na+ to support 5-HT transport in native hSERT.
Finally, equimolar replacement of NMDG+ with Ca2+ yielded a dose-dependent increase
in 5-HT transport that reached levels that were ~50% (N101A) and ~35% (N101C) of transport
observed with 120mM Na+. In contrast, the WT displayed minimal uptake (~5%) even at the
highest Ca2+ concentration tested.
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Figure 23. Cation dependency and concentrative uptake studies. Cation dependence
analyses reveal N101 mutants display altered Na+ and Ca2+ efficacies in driving 5-HT
transport: Initial transport rates (10 min.) of [3H]5-HT (50nM) were obtained for HEK cells
stably-expressing hSERT (filled circles), N101A (open circles) or N101C (open diamonds)
over a range of Na+ concentrations (0 - 120mM) replaced with (A) NMDG+ or (B) or Ca2+.
Uptake was also measured (C) using Ca2+ concentrations (0 - 60mM) replaced by NMDG+.
Transport activity is expressed relative to that at maximal Na+ concentration. EC50 values
were determined by fitting data to a sigmoidal dose-response curve (variable slope). Steadystate uptake kinetics reveals loss of concentrative capacity in N101 mutants: [3H]5-HT uptake
by HEK cells stably-expressing hSERT (filled circles), N101A (open squares) or N101C
(open diamonds) in assay buffer containing (D) 120mM Na+ or (E) 60mM Ca2+ is monitored
over 120 min. Data are background subtracted using data from parental HEK cells. Data were
converted to amol 5-HT accumulated per cell unit time. The data were fit to a MichaelisMenten nonlinear regression equation using Prism 5. Each value represents the mean and
SEM of a minimum of three independent experiments, each of which was performed using
triplicate wells.
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Mutation at N101 Diminishes the Ability of the Transporter to Concentrate 5-HT
Because the N101A and N101C mutants display diminished capacity to couple transport
to the chemiosmotic gradients of Na+ and Cl−(Henry et al. 2011), we examined concentrative 5HT uptake under both Ca2+ and Na+ replacement conditions (Figure 23, D and E). As expected,
concentrative transport of 5-HT by hSERT was all but eliminated (95% reduction) in Ca2+ buffer
(Figure 23E). As previously demonstrated in chapter II (Henry et al. 2011), in Na+-only buffer,
concentrative uptake of 5-HT was significantly reduced in the N101A and N101C mutants
compared with hSERT (Figure 23D). In Ca2+buffer, concentrative uptake by the N101A and
N101C mutants was reduced 51 and 32%, respectively, compared with equilibrium levels
achieved with Na+, suggesting that the hSERT-Ca2+ interaction is less efficient than Na+ at
coupling the ion gradient to 5-HT transport. Previously, we reported that the N101A and N101C
mutants exhibit increased substrate efflux (Henry et al. 2011), which could account for part of
the dramatic decrease in concentrative uptake. Differences were also observed for the time
necessary to reach concentrative equilibrium. In Na+, the t½ for hSERT was 62 ± 10 minutes
compared with 16 ± 3.7 and 12 ± 3.1 minutes for N101A and N101C, respectively. The time for
the mutants to reach steady state in Ca2+ is more rapid than in Na+, with N101A reaching t½ at
5.4 ± 1.1 minutes and N101C at 7.3 ± 2.1 minutes, whereas in WT, the t½ is attenuated to 103 ±
59 minutes. To account for the fast saturation of the mutants, uptake assays were only 10 minutes
in length.
Ca2+ Decreases the Apparent Affinity of 5-HT in both hSERT and the N101 Mutants
Kinetic transport analysis in Na+ buffer yielded indistinguishable Km values for hSERT
(1.2 ± 0.4µM), N101A (1.6 ± 0.5µM), and N101C (1.2 ± 0.3µM). As stated above, 5-HT uptake
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by hSERT under Ca2+-only conditions retains ~5% activity, which is sufficient to measure
transport kinetics. Interestingly, Km values for 5-HT transport increased in all three transporters
by ~10-fold (hSERT, 14 ± 2.6µM; N101A, 18 ± 3.1µM; N101C, 11 ± 1.7µM). This equivalent
increase in Km for 5-HT in hSERT and the N101 mutants suggests that Ca2+ binds hSERT and
the N101 mutants in a similar manner. When taken together with the fact that the Na1 site is
thought to directly coordinate 5-HT, these data suggests that Ca2+ binds at Na1.
Mutations at Na2 Site Fail to Alter Cation Selectivity
Although the amino acid substitutions at N101 would directly implicate the Na1 site as
the target for Ca2+ activity in the mutants, studies have suggested that an extensive ion network
connects the Na1, Na2, Cl−, and 5-HT binding sites (Forrest et al. 2007; Zomot et al. 2007;
Henry et al. 2011; Zdravkovic et al. 2012). Therefore, it is possible that alterations in amino
acids and their coordination at Na1 could structurally influence ionic coupling at Na2, permitting
Ca2+ to bind at the Na2 site and activate transport. To investigate Ca2+ binding to Na2, amino
acid substitutions were introduced at residues D437 and S438 in the Na2 site to disrupt their side
chain carboxyl- and hydroxyl-mediated coordination with Na+. The other amino acids
comprising the Na2 site (G94, V97, and L434) were not mutated, because they coordinate the
Na+ion via backbone carbonyls. Functional characterization of the mutants with [3H]5-HT uptake
assays revealed that the conservative D437E mutant is non-functional, whereas the other
substitutions showed 16–93% activity (Table 2). Activity of S438 mutants ranged from 27 to
94%, with the highest activity exhibited by the conservative S438T mutant. None of the
substitutions at D437 or S438 conferred Ca2+-mediated 5-HT transport (Table 2).
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% Surface
Expression

Percent Activity
120 mM
Na+

60 mM Ca2+

0 mM Cl-

hSERT

100 ± 11

100 ± 4.7

3.23 ± 0.9

3.51 ± 0.4

N101A

77.7 ± 8.9

77.0 ± 4.2

68.9 ± 3.7

99.2 ± 8.5

N101C

62.4 ± 7.2

69.2 ± 5.3

42.5 ± 1.5

97.4 ± 5.5

D437A

115 ± 11

66.5 ± 7.8

6.53 ± 1.5

8.48 ± 2.0

D437C

109 ± 9.2

93.4 ± 5.4

6.91 ± 1.3

6.08 ± 0.8

D437E

N/A

N/A

N/A

N/A

D437T

85.7 ± 4.0

83.3 ± 5.6

5.64 ± 1.5

11.1 ± 1.6

D437V

78.7 ± 13

15.9 ± 4.3

5.93 ± 3.1

25.0 ± 6.1

S438A

101 ± 15

62.0 ± 6.5

6.08 ± 0.9

35.9 ± 3.4

S438C

105 ± 7.4

77.1 ± 4.1

1.97 ± 0.5

7.01 ± 1.4

S438T

131 ± 11

93.5 ± 5.6

4.18 ± 0.8

2.31 ± 0.3

S438V

48.0 ± 2.4

26.7 ± 5.1

5.13 ± 2.4

4.20 ± 1.3

Table 2. Determination of surface expression, transport activity and ion dependency for
the Na1 and Na2 site mutants. Surface expression was calculated by performing
densitometry of SERT bands from Western Blots of biotinylated surface proteins. Transport
activity was measured in HEK cells expressing hSERT or indicated mutants with assays
conducted in complete buffer. Activity of mutants in 120mM NaCl is expressed as percent of
hSERT WT activity. Activity under Ca2+ or Cl– replacement conditions is expressed as
percent uptake observed of the same construct in NaCl buffer. Each value represents the mean
and SEM of triplicate wells from independent experiments repeated at least three times. No
data is reported for D437E, as no measurable expression was present when transfected into
HEK cells.
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Figure 24. Introduction of the N101 mutations into the Na2 mutant backgrounds
restored Ca2+-dependent uptake activity. Transport activity was measured in HEK cells
transiently expressing hSERT or a N101/S438 double mutant. Initial transport rates (10 min)
were obtained in a Na+-containing buffer (120mM) or in a buffer in which Na+ was
completely replaced by Ca2+ (60mM) or NMDG+ (120mM). Each bar represents the mean and
SEM for a figure representing three separate experiments, each performed in quadruplicate.
Data were analyzed using a two-way ANOVA and Bonferroni post-hoc test; *** = p ≤ 0.001.
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Simultaneous mutation of residues N101 and S438 was not well tolerated, resulting in a
marked reduction in transport (1–12% remaining activity) (Figure 24). However, introduction of
N101A or N101C into either the S438T or S438A background restored Ca2+-supported
translocation, which is consistent with Ca2+ interaction at Na1. Notably, Ca2+ was superior to
Na+ in supporting uptake in transporters containing the N101A/S438A, N101A/S438T, or
N101C/S438A mutations. Conversely, the N101C/S438T mutant, which showed the most uptake
activity of the double mutants, had greater levels of transport in Na+ buffer compared with Ca2+,
but uptake in Ca2+ was still ∼6-fold greater than in NMDG buffer. These data further support the
idea that Ca2+-mediated influence on transport occurs through interaction at Na1 rather than Na2.
The Na1 Site Does Not Contribute to the Substrate-induced or Leak Currents in hSERT
SERT exhibits not only Na+-dependent Na+ and 5-HT flux but also 5-HT-gated
suprastoichiometric current (Mager et al. 1994). Because our data support binding of Ca2+ at the
Na1 site in hSERT, we surmised that analysis of the substrate-induced or leak currents in the
N101 mutants under Ca2+ replacement conditions would provide insight into the contribution of
the Na1-bound cation to the conductive states of hSERT. Therefore, we utilized two-electrode
voltage clamping studies to examine currents generated by 5-HT transport via the N101A mutant
in the presence of various concentrations of Na+ and Ca2+. Buffers containing different
concentrations of Na+, Ca2+, or both cations were perfused into the system and allowed to
equilibrate, after which 5-HT was added to induce transport-associated current. In the presence
of only Na+, an inward current of ∼−30nA is generated by the movement of a large amount of
Na+ ions through the WT transporter. When Na+ is partially replaced by increasingly larger
amounts of Ca2+, the inward current displayed by hSERT decreases in a dose-dependent manner
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(Figure 25A), whereas in the N101A mutant, the current persists; however, its magnitude is
slightly decreased (Figure 25B). The large transient current observed upon the first addition of
Ca2+ is not dependent on SERT and probably results from activation of endogenous channels
because the same transient can be seen in uninjected oocytes upon the addition of Ca2+ (Figure
25B, inset). Therefore, after the initial addition of Ca2+ to the buffer, readings were taken only
after a stable base line was reached.
Previous analysis of the N101 mutants in Na+ buffer revealed a reversal potential of
~+70mV (Henry et al. 2011), indicating that Na+ was the conducting ion. However, when we
fully replaced Na+ with Ca2+ in the N101A mutant, the reversal potential dropped to ~−30mV,
suggesting that Ca2+ does not carry the current when substituted for Na+, because we would
expect a more positive reversal potential if Ca2+ were now carrying the current (Figure 25C).
Remarkably, this indicates that, unlike Na+, Ca2+ does not seem to permeate through the
transporter, which may also explain why current levels decreased when Na+ was replaced by
Ca2+ (Figure 25B). Under full cation replacement with 80mM Ca2+, there is a prominent leak
current, as defined by current block with 10µM paroxetine. This leak current also reverses at
−30mV (Figure 25C). A similar reversal potential for the substrate-induced current and the leak
current is expected if both currents are carried by the same conformational intermediate, as
recently suggested by Schicker et al. (Schicker et al. 2011). The fact that the reversal potential
for I5-HT and Ileak occurs at ~-30mV suggests that Cl− is the permeating ion. Unfortunately, we
were unable to determine the I/V relationship for WT hSERT when Na+ was replaced with
80mM Ca2+ because the currents were <2nA at −60mV.
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Figure 25. Whole cell clamp electrophysiology studies. Replacement of Na+ with Ca2+: Shown
are representative current traces of (A) WT and (B) N101A, respectively, recorded from Xenopus
laevis oocytes using the two-electrode voltage clamp (TEVC) technique. The cells were clamped
to –60mV and currents were induced with 10µM 5-HT (black bars). The Ca2+ concentration was
successively increased and the Na+ concentration was simultaneously decreased as indicated.
Upon wash in 10mM Ca2+, a transient inward current was observed. The inset between panels (A)
and (B) depicts bars representative of substrate-induced current from oocytes expressing N101A
in the presence of Na+ (left bar) or Ba2+ (right bar). (C) Current amplitudes elicited by 10µM 5HT in WT (open circles) and N101A (filled circles) are plotted as a function of increasing Ca2+
concentrations (each data point is the average of 6 experiments). The remaining fraction of
normalized current in WT and N101A at 80mM Ca2+ was 0.12±0.35 and 0.30±0.30 respectively.
(D) The current-voltage dependence of 5-HT induced currents of the N101A mutant assessed in a
solution containing 80mM Ca2+ are plotted (N=5). For the Ca2+ solutions, NaCl was replaced by
CaCl2. Shown are the IV for the substrate-induced current and the IV for the substrate
independent leak in Na+. The leak was defined by the application of 10µM paroxetine.
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Figure 25 (continued). Whole cell clamp electrophysiology studies. (E) Shown is a
representative current trace recorded from HEK-293 cells expressing hSERT N101A in the
presence of physiological ion gradients. At –90mV, a 5 sec. application of 10µM 5-HT provoked
an inwardly directed current. (F) Current responses to 10µM 5-HT were also measured at
successively positive voltages. The currents were normalized to the maximum amplitude at –
90mV and plotted as a function of the respective holding potential. (G) A typical trace of a
current through hSERT N101A is shown in the absence of external Na+ but in the presence of
15mM external Ca2+. At –90mV the current induced by 10µM 5-HT was inwardly directed. (H)
However, this current reversed at around –60mV, when the inner Cl– concentration was low
(5mM) (open circles) or around 0mV at high (140mM) inner Cl– concentrations (filled boxes).
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Because Ca2+ does not appear to be transported and carry current, we wanted to see if the
addition of Ca2+could inhibit Na+-mediated currents by examining transport-mediated currents at
increasing concentrations of Ca2+ (Figure 25D). We found that hSERT exhibited a linear, dosedependent decrease in current as Ca2+concentration increased (and Na+ concentration decreased).
In contrast, N101A displayed a hyperbolic curve, indicating that Ca2+ reduces the amount of
Na+-generated current.
Finally, although Ba2+ can often functionally replace Ca2+ in channels (Partridge and
Leach 1991), Ba2+ was unable to support substrate-induced currents in the N101A mutant (data
not shown). This is consistent with the failure of Ba2+ to promote transport in radiolabeled 5-HT
uptake studies (Figure 20), revealing that Ca2+ binding is selective and is a prerequisite for
current generation.
Whole Cell Clamp of the N101A Mutant in HEK293 Cells Suggests That Cl− Is the Main
Charge Carrier When External Na+ Is Substituted by Ca2+
In order to further test if Cl− (and not Ca2+) is the main charge carrier by the N101A
mutant, we performed whole cell patch clamp analysis on HEK293 cells stably expressing
hSERT N101A. This technique allowed us to control the internal ion composition, thus
facilitating the interpretation of the reversal potential. When cells were recorded in the presence
of an external solution containing 152mM Na+, application of 10µM 5-HT for 5 seconds
provoked an inwardly directed current at a holding potential of −90mV (Figure 25E). Currentvoltage analysis in the presence of full external Na+ was performed (Figure 25F); however,
excessive noise occurred at voltages positive to −10mV (probably due to endogenous channels),
precluding analysis in that voltage range. When Na+ was removed from the external solution and
replaced with 15mM Ca2+ and 150mM choline, 10µM 5-HT was still able to induce current
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(Figure 25G). In HEK293 cells, unlike oocytes, full replacement of Na+ by Ca2+ (80 mM)
resulted in unstable electrical recordings. For this reason, we employed a solution containing
Ca2+ and choline that has been used in studies of voltage-gated Ca2+ channels (Bock et al. 2011).
Importantly, choline could not support 5-HT uptake in WT SERT or the N101A or N101C
mutants (Figure 20); therefore, the data represent the contribution of extracellular Ca2+. In this
buffer, application of 5-HT led to currents that were absent in cells expressing WT hSERT (data
not shown). Current-voltage relationships were recorded with 15mM external Ca2+ and two
internal Cl− concentrations. The current reversed at −55mV when the internal Cl− concentration
was 9.3mM compared with a reversal potential of ∼−5mV when internal Cl− was at
143.3mM (Figure 25H). These observed shifts in reversal potential in response to internal
Cl− concentration suggest that Cl− mediates the current in the N101A mutant when Ca2+ is the
supporting cation.
hSERT N101 Mutants Appear to Function as both Active and Passive Transporters
Comparison of 5-HT saturation uptake in hSERT with buffers containing either Na+ or
NMDG+ reveals that, when Na+ is completely replaced by NMDG+, increasing the amount of
extracellular 5-HT only marginally elevates substrate uptake in a dose-dependent manner (Figure
26). In contrast, both N101 mutants demonstrate enhanced substrate uptake in response to
increasing extracellular 5-HT, suggesting that the inside/outside gradient of 5-HT is better able to
drive transport in the mutants. Furthermore, the similar levels of uptake by the N101 mutants in
the presence or absence of Na+ suggest that the mutant transporters do not couple efficiently to
the Na+ gradient and may act more as passive-facilitative transporters when extracellular 5-HT
levels are high.
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Figure 26. N101 mutants exhibit increased in 5-HT dose-dependent levels of substrate
transport in the absence of Na+. HEK cells stably expressing the hSERT, N101A, or N101C
were evaluated for dose-dependent 5-HT uptake after 15 min in the presence (black bars) or
absence (gray bars) of Na+. Data was converted to fmol 5-HT transported per cell per minute.
Each bar represents the mean and SEM of a data set representing at least three independent
experiments, each of which was performed in triplicate. Numbers above gray bars indicate the
fold-decrease in activity when comparing the corresponding experimental condition in Na+ buffer.
A two-way ANOVA performed on sample sets with a Bonferroni post-hoc test revealed that all
mutant fold-decreases in activity were significantly different than the same experimental
paradigm in WT hSERT (p < 0.001).
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Molecular Dynamics Simulations Suggest a Mechanism for Ca2+ Gain-of-function
Phenotype
The dramatic impact the N101 mutation has on ion- and substrate-coupled translocation
suggested that mechanisms important to the translocation process could be revealed through
comparison of hSERT and the N101A mutant in molecular dynamic simulations. To carry out
these studies, 5-HT and ion-docked comparative models of hSERT and N101A were subjected to
12ns of MD simulations in a lipid bilayer system to investigate alterations in ion coordination
(Table 3). Simulations of hSERT Na1Na+, Na2Na+, and ClCl− with 5-HT bound revealed that
coordination of Na+ at Na1 was optimal, with a coordination number of 6 (CN:6) (Harding 2002)
(Table 3) and was identical to that shown for LeuT (Yamashita et al. 2005). Likewise,
coordination of Na+ at Na2 was similar to that in LeuT and dDAT except that the Oγ S438 (S335
in LeuT, S421 in dDAT) interaction with Na+ (expected by homology to LeuT) was varied based
on the system. Cl− coordination was similar to that reported by Tavoulari et al. (Tavoulari et al.
2011) with the addition of Gln-332 Nϵ (Ben-Yona et al. 2011; Tavoulari et al. 2011). dDAT
residue Gln-316, which is homologous to Gln-332, coordinates Cl− in the crystal structure
(Penmatsa et al. 2013). The Cl− ion was omitted from MD simulations with the N101A mutant,
because these transporters exhibit Cl− independence (Henry et al. 2011). As indicated by the
reduced potency for Na+ to support 5-HT uptake in the N101 mutants, the simulations reveal that
coordination of Na+ at Na1 in N101A is decreased to CN:5, due to the loss of the N101 Oδ
interaction.
Notably, we observed a correlation between transporter function and the coordination
state of the carboxyl side chain of residue D98 in Na1. 5-HT lacks the carboxyl group found on
amino acid substrates, such as leucine, and this Asp at position 98, which is strictly
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WT:
Na1:

A96 O,D98 Oδ, N101 Oδ, S336 O Oγ, N368 Oδ; n=6

Na2:

G94 O,V97 O, L434 O, D437 Oδ1 Oδ2; n=5

Cl:

Y121 HH, Q332 Nε, S336 Hγ, Ν368 Hδ, S372 Hγ; n=5

WT: without Cl
Na1:

A96 O,D98 Oδ1 Oδ2 (0.8), N101 Oδ, S336 O(0.5); n=5

Na2:

G94 O,V97 O, L434 O, D437 Oδ1 Oδ2; n=5

WT: with Ca, Na, & Cl
Ca1:

A96 O,D98 Oδ1 Oδ2, N101 Oδ, S336 O; n=5

Na2:

G94 O,V97 O, L434 O(0.9), D437 Oδ1 Oδ2; n=5

Cl:

Ca2+, N101 Oδ, S336 Hγ(0.9); L337 N (0.5); n=4

WT: without Cl, without 5HT
Na1:

A96 O, D98 Oδ1 Oδ2, N101 Oδ, S336 O (0.945), n=5

Na2:

G94 O,V97 O, L434 O (0.7), D437 Oδ1 Oδ2; S438 Oγ ; n=5.7

WT: without 5HT
Na1:

A96 O, D98 Oδ1 Oδ2 , N101 Oδ (0.9), S336 O (0.9), n=4.8

Na2:

G94 O ,V97 O, L434 O (0.8, D437 Oδ1 Oδ2 ; S438 Oγ(0.9) ; n=5.6

Cl:

Y121 HH, Q332 Nε , S336 Hγ, S372 Hγ; S369 Hγ (0.2); n=4.1

N101A: without Cl
Na1:

A96 O, D98 Oδ1 Oδ2(0.2), S336 O Oγ, N368 Oδ; n=5

Na2:

G94 O,V97 O, L434 O (0.5), D437 Oδ1 Oδ2; n=4.5

N101A: with Ca, without Cl
Ca1:

D98 Oδ1 Oδ2 (0.9), S336 O Oγ, N368 Oδ; n=5

Na2:

G94 O,V97 O, L434 O, D437 Oδ1 Oδ2; n=5

N101A: with Ca, without Na, without Cl
Ca1:

A96 O (0.6), D98 Oδ1 Oδ2, S336 O (0.6) Oγ (0.7), N368 Oδ; n=6

Table 3. Molecular dynamics simulation occupancies. Occupancies for atomic coordinations
were calculated over 12ns of simulation and are scaled from zero to one with one being 100%
occupancy within the designated distance cutoffs (Na+ 3.5 Å, Ca2+ 3.5 Å and Cl– 4.0 Å).
Occupancies that were not equal to one were notated in subscript parentheses.
104

Figure 27. Proposed model for the coupling of Na1, Na2 and Cl sites to substrate transport
in WT hSERT. Core regions of TMs 1, 6 (gray) and 7, 8 (white) of hSERT are displayed for
clarity. Highlighted residues D98, N368 and S438 are shown as sticks. 5-HT is depicted in ball
and stick representation. Na+, Ca2+ and Cl– ions are represented as blue, magenta and green
spheres, respectively. Red dashed lines indicate coordination. Panels demonstrate: 1. D98
coordination determines hSERT transport competency – D98 coordinates both Na1 and 5-HT
when hSERT is transport competent (B), while D98 exhibits bidentate coordination to Na1 when
simulations lack 5-HT (A) or Cl– (C), as well as when Ca2+ is placed at Na1 (D). 2. Bound 5-HT
alters S438 coordination of Na2 – In simulations lacking 5-HT, S438 interacts with Na2 (A),
whereas simulations with 5-HT bound reveal S438 does not coordinate Na+ at Na2 (B-D). 3.
N368 does not interact with Na1 in transport incompetent hSERT (A, C, D).
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conserved among MATs, is believed to serve as the functional correlate to the leucine carboxyl
group in support of Na+ and 5-HT binding. In the inhibitor bound dDAT structure, this conserved
Asp (D46) indirectly coordinates Na+ at Na1 through a water molecule (Penmatsa et al. 2013).
However, it is possible that direct Na+-Asp− interaction may occur in substrate-bound dDAT.
In the absence of 5-HT, the side chain of D98 in WT SERT exhibits bidentate
coordination (O∂1, O∂2) with the Na+ at Na1 (Figure 27A). However, in 5-HT-bound models,
D98 coordination to Na1 is monodendate, with one O∂ from the carbonyl participating in
coordination of the (+)-charged amine of 5-HT (Figure 27B). Simulations involving an empty Cl
site revealed that D98 retains bidentate coordination with Na1 and, importantly, lacks
coordination with 5-HT (Figure 27C). This apparent Cl−-dependent coordination of D98 to 5-HT
is consistent with previously published findings, where Cl−binding to hSERT decreased
the Km of 5-HT ∼4-fold (Nelson and Blaustein 1982; Henry et al. 2011; Koldsø et al. 2011). In
contrast, simulations with the N101A mutant with Na+ reveal that D98 (O∂) can coordinate the
amine of 5-HT even in the absence of Cl−. This loss of Cl−-dependent coordination of D98 in the
N101A background could explain why, under Cl−-free conditions, the N101A mutant exhibits
a Km for 5-HT that is comparable with values obtained with the Cl−-bound WT hSERT (Henry et
al. 2011).
Analysis of Ca2+ at Na1 revealed bidentate coordination between Ca2+ and the side chain
of D98 under all simulation conditions, which precludes D98–5-HT coordination (Figure 27D).
This loss of 5-HT stabilization is consistent with our finding that under Ca2+-only conditions,
WT hSERT as well as the N101 mutants exhibit a 10-fold increase in Km for 5-HT compared
with Na+-containing buffers. Evaluation of the transport-competent and -incompetent complexes
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with the non-functional transporters represented by hSERT without Cl− and hSERT with Ca2+ in
the Na1 site and Cl− in the Cl site revealed reorganization of residues S336 and N368 in the Na1
site. These amino acids have been reported to be critical for Na+ and Cl− coordination (Forrest et
al. 2007; Zomot et al. 2007; Ben-Yona et al. 2011; Tavoulari et al. 2011; Zdravkovic et al. 2012).
In the non-functional transporters, the side chain of residue S336 is oriented with Hγ pointing
away from the reported Cl−-binding site as per Forrest et al. (Forrest et al. 2007) (Figure 28A). In
contrast, all of the transport competent structures have the Hγ directed toward the Cl−-binding
site (Figure 28B). Likewise, N368, which normally coordinates the Na+ at Na1, as shown in the
transport-competent structures, is flipped away from the Na1 site in the non-functional models,
losing contact with both the Na1 and Cl−-binding sites. These data suggest that the availability of
S336 and N368 to participate in the Na1 and Cl coordination sites plays a critical role for
transport function and provide a mechanistic explanation for 1) the inability of Ca2+ to substitute
for Na+ in the WT transporter, 2) the loss of function of WT transporter in the absence of Cl−,
and 3) the gain of function by the N101A mutant to utilize Ca2+ or Na+ without Cl−.
Finally, we evaluated ion coordination at Na2 in our MD simulations, in light of our
biochemical data, to look for possible clues to the functional role of Na2 in transport. In
simulations lacking 5-HT, we found that the TM8 residue S438 coordinates the Na+ ion at Na2
(Figure 27A). However, in 5-HT-bound simulations, the S438 side chain reorients away and no
longer participates in coordination of the Na2 ion, suggesting that 5-HT binding may contribute
to destabilization of the Na2 site (Figure 27, B–D). Further analysis of the simulated transporter
systems revealed that transporters lacking coordination between S438 and Na+ at Na2 were
functionally competent in biochemical analysis, suggesting that loss of S438/Na2 coordination
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Figure 28. MD simulations of hSERT comparative models support a mechanistic role for
Na1 site coordinating residues. (Panels A and B) 5-HT-docked comparative hSERT models
were simulated in a lipid bilayer system for 12ns using GROMACS. Models were simulated with
various combinations of ions representative of our biochemical analyses. The constructs were
named using the convention where hSERT Na1Na+, Na2 Na+, ClCl– represents hSERT with Na+ at
Na1, Na+ at Na2 and Cl– at Cl. Empty ion binding sites are not listed. The peptide backbones are
shown as tubes colored as follows: [1] hSERT Na1-Na2-Cl (white), [2] hSERT Na1-Na2
(yellow), [3] hSERT Ca1-Na2-Cl (black), [4] N101A Na1-Na2 (orange), [5] N101A Ca1-Na2
(pink) and N101A Ca1 (green). The structures were aligned using Cαs in Pymol and for clarity
only TMs 1, 6 and 7 are shown. Na1Na+, Na2Na+, Cl– and Ca2+ are represented as blue, purple,
green and orange spheres, respectively. Panels are representative trajectories from simulations
under (A) transport incompetent and (B) competent conditions. Residues of interest are depicted
as sticks. The blue and green dashed ovals highlight the orientation of the S336 and N368 side
chains, respectively.
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may be important for progression through the transport process (Table 3 and Figure 27, A and
B). However, two simulated systems did not follow this rule. The WT hSERT, 5-HT, Na1Na+,
and Na2Na+, which lacks Cl− (Figure 27C), and the WT hSERT, 5-HT, Na1Ca2+, Na2Na+, and Cl−,
which has Ca2+ bound to Na1 (Figure 27D), are both functionally inactive yet lack the S438/Na2
interaction. This discrepancy can be explained if the loss of the S438/Na2 interaction disturbs the
hydrogen bond network linking Na2 to the Cl and Na1 sites, thereby disrupting their function as
molecular checkpoints and preventing translocation by the WT transporter unless the appropriate
ions and substrate are bound. In contrast, although the N101A transporter also exhibits Na2
destabilization due to loss of S438 interaction, substrate translocation can proceed relatively
unchecked because Na2 is uncoupled from the Na1 and Cl sites (as evidenced by functionality in
the absence of Cl− or when Ca2+ replaces Na+).

Discussion
This study presents biochemical, electrophysiological, and computational analyses of
mutations in a conserved Asn residue (N101) in TM1 of hSERT that is part of the proposed Na1
binding site. The findings of this work reveal that, in addition to the previously reported
Cl− independence afforded by mutation of N101 (Henry et al. 2011), the N101A and N101C
mutants can utilize Ca2+, in addition to Na+, to support 5-HT uptake. The unique properties
afforded by these substitutions at N101 have allowed us to uncover distinct roles for the Na1 and
Na2 sites in the 5-HT transport process.
Conformational studies based on TM1 sensitivity to MTS reagents support the Na+-like
behavior of Ca2+in the N101 mutants, because both Na+ and Ca2+, but not the large cation
109

NMDG+, impart conformational changes to the N101A mutant transporter. Also, Ca2+ alters the
dose dependence of Na+for 5-HT uptake and was able to support small but detectable 5-HTinduced currents in native hSERT. This suggests that Ca2+ can bind to WT hSERT but leads to a
primarily non-productive coordination state, one that can be overcome in the N101 mutant
background.
The functional interplay between the Na1, Na2, and Cl binding sites (Yu et al. 2010;
Zdravkovic et al. 2012; Zhao et al. 2012) presented a challenge to delineate where Ca2+ binds to
promote transport in the N101 mutants. However, we uncovered several lines of evidence
indicating that Ca2+ binds at Na1. First, mutation at N101 resulted in Ca2+-dependent transport,
whereas mutations at Na2 site residues failed to yield Ca2+-dependent uptake. (Interestingly, two
of the Na2 mutants displayed significant Cl− independence (Table 2)). Second, introduction of
N101A or N101C mutations into the Na2 mutant backgrounds yielded Ca2+-mediated transport.
Third, the Km of 5-HT for hSERT, as well as the N101 mutants, increases 10-fold in Ca2+-only
buffers. This decrease in apparent affinity of 5-HT is consistent with our MD analyses showing
that Ca2+ binding at Na1 results in bidentate coordination between Ca2+ and the conserved Asp
(D98) in TM1. The nature of this interaction precludes the ability of D98 to stabilize 5-HT
binding, by preventing the D98 side chain from interacting with the (+)-charged amine of 5-HT
in agreement with the increased 5-HT Km.
Remarkably, although our data suggest that Ca2+ binds to Na1, reversal potentials
from I/V analyses suggest that Cl−, and not Ca2+, is the major carrier of current in the N101A
mutant. Furthermore, Ca2+does not appear to permeate during transport in the N101 mutant. This
finding, combined with our evidence that Ca2+ binds at Na1, supports distinct roles for Na1 and
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Na2 in the translocation process. This assertion is strengthened by sequence comparison analysis
and crystal structures (Pramod et al. 2013), which reveal that Na2, in contrast to Na1, is
absolutely conserved among LeuT-like transporters and therefore probably serves to couple
substrate translocation to the Na+ gradient. This essential role of Na2 is also supported by inward
facing crystal structures (Krishnamurthy and Gouaux 2012) and molecular dynamic studies
(Watanabe et al. 2010; Koldsø et al. 2011), which indicate that the destabilization of Na2 and
release of its coordinated Na+ ion are critical steps for substrate release. Based on this
understanding, if Ca2+ were able to bind at Na2 in the N101 mutants, a Ca2+ ion would probably
be released into the cytoplasm during 5-HT translocation. However, our electrophysiological
data argue against contribution of Ca2+ to the substrate-induced or leak currents in the N101A
mutant under full replacement of Na2+ by Ca2+. Collectively, these findings support the binding
of Ca2+ to the Na1 site, which allows us to propose that the ion bound at Na1 (i.e. Na+ or Ca2+) is
not co-translocated during stoichiometric transport. However, we acknowledge that we may not
be able to detect low level Ca2+ flux. Nevertheless, such a mechanism, where only the Na+ at
Na2 is co-transported, agrees with the historical1Nain:15-HTin:1Clin:1Kout stoichiometry (Rudnick
and Nelson 1978; Nelson and Rudnick 1979; Quick 2003) and indicates that the Na1 site acts as
a molecular checkpoint for 5-HT binding, whereas Na2 primarily functions to couple the
Na+ gradient to transport.
Schicker et al. (Schicker et al. 2011) showed that substrate currents in SERT are probably
carried by a conducting state in equilibrium with the K+-bound inward facing conformation. In
the same study, a model was produced in which 5-HT-induced currents were explained by
conformational changes that increased the fraction of transporters in the conducting state. In this
111

model, currents induced by 5-HT were assumed to be carried by an intermediate from which 5HT had already dissociated. In addition, it was suggested that other known activities of SERT,
such as the substrate-independent leak current of Na+ or Li+, might also be explained by the same
conducting state. In this current study, we found that the leak current and the substrate-induced
current through hSERT N101A reversed at the same potential, consistent with the hypothesis that
both activities are related to the same conformational state. WT SERT cannot convert to the
inward facing conformation with 5-HT when external Na+ is absent. However, in hSERT N101A
Ca2+ supports this conversion. Therefore, if we assume that currents through WT and N101A are
mechanistically similar, hSERT N101A may serve as a resource to explore the conducting state
in a solution devoid of Na+. Additionally, our data support the idea that the conducting state is
capable of carrying Cl−, a conjecture that is difficult to test in WT SERT. However,
understanding this mechanism may provide insight into DAT function where Cl− has been
identified as the primary conducting ion in the transient channel mode (Ingram et al. 2002;
Carvelli et al. 2004; Meinild 2004).
The ability of the N101 mutants to utilize Ca2+ to support 5-HT uptake may indicate that
N101 mutations alter ion selectivity at Na1. However, we found that Ca2+ can bind to WT SERT
and promote low levels of substrate transport and ion currents. Also, although Ca2+ was able to
functionally replace Na+in the N101 mutant, other mono- and divalent cations could not. These
findings argue that the Ca2+-mediated transport gained in the N101 mutants does not originate
from altered ion selectivity. Rather, they suggest that the Na1 site has a molecular restriction that
prevents Ca2+ from permitting transporter activation. The N101 mutants appear to disrupt this
restriction by altering the ionic network connecting the Cl, Na1, and Na2 sites, revealing critical
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aspects of the molecular interactions between substrate and ions necessary for transporter
operation that have, until now, remained enigmatic.
Evaluation of the data from this study, in light of our previous analysis of the N101
residue (Henry et al. 2011), suggests critical mechanistic roles for a number of hSERT residues
in substrate binding and transport. Uptake studies have shown that, in the absence of Cl−,
the Km for 5-HT transport is increased significantly, indicating that Cl− binding alters the
apparent affinity of 5-HT for hSERT (Nelson and Blaustein 1982; Chang and Lam 1998; Henry
et al. 2011). Our MD studies link this positive impact of Cl− on the Km of 5-HT to the residue
D98. Under normal Na+ and Cl− conditions, we observed monodentate coordination of the D98
side chain carbonyl with the Na+ at Na1 and the amine of 5-HT. However, removal of Cl− in the
simulations resulted in a loss of N368 coordination with Na1, which is replaced by a bidentate
interaction of the side chain of D98 with Na1. This eliminates the D98–5-HT interaction,
providing a rational explanation for the observed increase in the Km for 5-HT. Likewise, the
absence of a cation at the Na1 site does not alter 5-HT binding (Chang and Lam 1998),
suggesting that, in the absence of Na+, the carboxyl side chain of D98 is available to stabilize 5HT binding, although it does not lead to productive transport. Therefore, we propose that upon 5HT binding, D98 transitions from bidentate to monodentate coordination of Na+ at Na1 and that
this change in coordination is critical to initiate transport. This is supported in our MD
simulations with Ca2+ bound at Na1, where D98 shows bidentate coordination with Na1 in both
WT and N101 mutant backgrounds. This lack of interaction between D98 and 5-HT would lead
to decreased stabilization of 5-HT binding. This is backed by uptake studies where
Ca2+ replacement of Na+ resulted in a ∼10-fold increase in the Km for 5-HT in both the WT and
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N101 mutant backgrounds. Therefore, the inability of D98 to interact with 5-HT would prevent
the side chain rearrangement in D98 that we speculate is important to initiate transport and
provides a rationale for the inability of Ca2+ to functionally replace Na+ in the WT transporter.
Given that our data reveal that Ca2+ can only bind to the Na1 site, this would suggest that
the N101 mutant transporters can function despite having an unoccupied Na2 site. This ability of
the transporter to function with Na2 in a bound or unbound state suggests at least partial
uncoupling of transport to the Na+ gradient, allowing the transporter to function in a “slippage”
mode. Support for this idea comes from our MD studies, where we propose that 5-HT binding to
SERT results in loss of S438 coordination of Na+ at Na2. Normally, in the absence of Cl− or the
presence of Ca2+, our proposed role for the Cl and Na1 sites as molecular checkpoints in WT
SERT would keep the transporter from cycling, although Na2 is destabilized by 5-HT binding.
However, in the N101A mutant, the regulatory role of the Cl and Na1 sites is uncoupled from
Na2, allowing 5-HT binding to destabilize Na2 via S438 and promote transport. This uncoupling
could also account for the large Na+ leak currents and increased efflux previously reported for
the N101 mutants (Henry et al. 2011) as well as the observed 5-HT dose-dependent uptake in the
absence of Na+ or Ca2+ described in this study. The N101A- and N101C-mediated disruption of
the Na1 and Cl sites to act as a molecular switch could explain how 5-HT binding alone to these
mutants can promote transport, although D98 has bidentate coordination to Na1 in absence of
Cl− or the presence of Ca2+. This uncoupled state could also explain our finding that 5-HT can
enhance its own uptake in a dose-dependent manner in N101 mutants, even when Na+ is replaced
by NMDG+.
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Additional support for uncoupling of substrate to ion binding in the N101 mutants comes
from our substituted cysteine accessibility method studies, which reveal differential
conformational changes proximal to C109 (extracellular vestibule end of TM1) under various ion
and substrate conditions. The findings show that in hSERT, Na+ and Cl−, but not 5-HT, are
sufficient and necessary to induce a vestibular conformational change involving TM1, indicating
that this movement is coupled to ion occupancy of the Na+- and Cl−-binding sites. In the N101A
mutant, however, neither Cl−, Na+, nor Ca2+, alone or in combination, support the vestibular
conformational change. Notably, 5-HT is able to promote a vestibular conformational change,
suggesting that, whereas cation and anion binding are no longer sufficiently coupled to bring
about conformational changes on their own, the uncoupled state can be overcome by 5-HT
coordination. Thus, 5-HT binding could act to orient TM1, -3, -6, and -8, allowing transport to
proceed, albeit less efficiently. In WT SERT, the absence of Na+ or Cl− in their binding sites
would inhibit the ability of 5-HT to engage transport, but in the uncoupled state of the mutant,
the ion binding sites no longer tightly regulate initiation of the transport cycle, permitting 5-HT
alone to activate transport.
The recent LeuT crystal structures supplement the collection of conformational
intermediates such that we now have structures spanning from the “apo open outward” to the
“apo open inward” conformations. Comparison of the findings from our study with these LeuT
transporter snapshots provides support for our proposed mechanism (Yamashita et al. 2005;
Singh et al. 2008; Krishnamurthy and Gouaux 2012). As LeuT transitions from the outward
facing to the inward facing structures, the residues that coordinate Na+ at Na1 (distances around
2.4Å) move further away from Na+(to around 3.4Å), becoming weaker, but notably still
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Figure 29. Alignment of LeuT crystal structures in poses associated with the translocation
mechanism support the purposed roles of hSERT N101 and N368. LeuT transporter crystal
structures representing "outward open" (white), "inward open occluded" (black) and "inward
open" (magenta) conformations. Na+ at Na1 is shown as blue spheres. Residues coordinating Na+
are shown in lines and sticks. Dashed-line boxes depict the reorientation of N27 (homologous to
hSERT N101; black sticks) and N286 (homologous to N368; magenta sticks) in "inward open
occluded" (black) conformation lacking sodium ion at Na2 site and "inward open" (magenta)
conformation with both Na+ sites unoccupied.
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coordinate Na+. However, more importantly, there is a large shift in the position of the A22,
N27, and N268 side chains in the Na1 site when LeuT transitions to an inward facing
conformation (Figure 29). These residues correspond to A96, N101, and N368, respectively, in
hSERT, which are highly conserved amino acids and may demonstrate a preserved role for these
residues in facilitating coupled transport in the SLC6 family. In fact, we found it intriguing that
in all of the MD simulations, N368 coordination of the cation bound at Na1 correlated with the
functionally competent transporter systems, whereas a lack of N368 coordination was observed
in all transporter systems that were non-functional. This is not too surprising, given that in
comparative models (Forrest et al. 2007; Henry et al. 2011) and by homology to dDAT
(Penmatsa et al. 2013), N368 is proposed to interact with Na1Na+, Cl−, N101, and S336 (which
directly coordinates Cl−).
Finally, the ability of the mutation at N101 to affect such a large number of SERT
biophysical properties emphasizes the requirement for proper communication between the ionand substrate-binding sites to provide efficient coupling of transport to the ionic gradients. To
that end, mutations such as N101 will offer powerful tools for future studies to gain a better
understanding of the molecular features necessary for secondary active transport.
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CHAPTER IV
ANTAGONIST-INDUCED CONFORMATIONAL CHANGES IN DOPAMINE
TRANSPORTER EXTRACELLULAR LOOP TWO INVOLVE RESIDUES IN A
POTENTIAL SALT BRIDGE
Introduction
DAT, like its MATs homologues SERT and NET, is composed of 12 transmembrane
spanning domains (TMs) connected by extracellular and intracellular loops (ELs and ILs)
(Figure 30) (Kristensen et al. 2011; Pramod et al. 2013). Substrates are translocated by an
alternating access mechanism in which the protein cycles through outwardly and inwardly facing
states that allow solutes to enter or exit the permeation pathway from opposite sides of the
membrane (Jardetzky 1966; Forrest and Rudnick 2009). These forms are generated by the
coordinated opening and closing of extracellular and intracellular gates that control substrate
access and direction of movement (Kniazeff et al. 2008). The structures of some of these
conformations have been captured through crystallization of LeuT in different phases of the
cycle, providing templates for computational modeling of DAT and other homologous
mammalian transporters (Yamashita et al. 2005; Singh et al. 2008; Zhou et al. 2009;
Krishnamurthy and Gouaux 2012). Recently, Drosophila DAT (dDAT) complexed with the
antidepressant nortriptyline was crystallized in an ‘outward-open’ conformation (Penmatsa et al.
2013), although stabilization of the protein for crystal formation required deletion of 43 amino
acids from EL2 and inclusion of five thermostable mutations. The modified dDAT was inactive
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Figure 30. Two-dimensional diagram of DAT. (A) Schematic diagram of rDAT
illustrating 12 transmembrane spanning domains, epitopes for N- and C-terminal tail
antibodies (green and yellow), and EL2 components including N-linked glycosylation
(branched structures), disulfide bond (solid line), Asp residues (red circles), D174 (large
red circle) and R218 (large purple circle). The full rDAT sequence was analyzed by
PsiPred and JUFO secondary structure prediction algorithms, which predicted the region
surrounding and including R218 is likely a helical structure (purple).
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for transport and lacked the functionally relevant zinc binding site present in mammalian DATs
formed by residues from EL2 and EL4 (Norgaard-Nielsen et al. 2002; Stockner et al. 2013),
which may limit the application of its structure to mammalian DAT. Recently, a valid
computational model of hDAT EL2 in the outward-facing transporter conformation has been
constructed using the molecular constraints provided by the zinc binding site and conserved
disulfide bond (Stockner et al. 2013).
Substrate binding in LeuT occurs in a pocket referred to as S1 that is formed between the
extracellular and intracellular gates (Yamashita et al. 2005). This site is formed from residues in
TMs 1, 3, 6, and 8, and similar regions of DAT, NET, and SERT have been implicated in
substrate binding and transport. Some findings also support the presence of an S2 substrate site
on the extracellular side of the extracellular gate in both LeuT and mammalian transporters
(Singh et al. 2007; Shi et al. 2008; Zhou et al. 2009; Piscitelli et al. 2010; Plenge et al. 2012;
Wang and Gouaux 2012). Findings obtained from mutagenesis approaches showing interaction
of DAT and SERT inhibitors with residues in TM1, TM3, TM6, and TM8 (Kitayama et al. 1992;
Chen et al. 1997; Henry 2003; Henry et al. 2006b; Beuming et al. 2008; Andersen et al. 2009;
Field et al. 2010), adduction of irreversible cocaine analogs to DAT near S1 residues in TM1 and
TM6 (Vaughan et al. 2005; Parnas et al. 2008), and molecular modeling of cocaine analog
binding (Beuming et al. 2008), strongly support the binding of neurotransmitter transport
inhibitors in S1. Further support for high-affinity antagonist binding to S1 comes from recent
crystal structures of a LeuT engineered with SERT residues in the central substrate binding
pocket (Wang et al. 2013) and from dDAT complexed with nortriptyline and cocaine (Penmatsa
et al. 2013; Wang et al. 2015). Some computational studies however, suggest that inhibitors can
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also bind at S2 (Plenge and Wiborg 2005; Shi et al. 2008; Huang et al. 2009; Hill et al. 2011;
Plenge et al. 2012).
The conformational changes that occur in DAT during the transport cycle establish the
transport kinetic rate, overall level of DA clearance, and strength of neurotransmission, and are
affected by regulatory mechanisms that may become disrupted in dopaminergic disorders and
drug abuse (Pramod et al. 2013; Vaughan and Foster 2013). These events are not fully explained
by information gleaned from static transporter crystal structures, and their elucidation remains an
important area of research. Biochemical and molecular approaches used to probe structural
rearrangements of neurotransmitter transporters include protease- and alkylation-protection
analyses and the substituted cysteine accessibility method (SCAM), (Reith et al. 1996; Ferrer and
Javitch 1998; Chen and Rudnick 2000; Reith 2001; Hastrup et al. 2003; Norregaard et al. 2003;
Chen et al. 2004; Loland et al. 2004; Wenge and Bönisch 2013). Our lab previously described a
pronounced reduction in the sensitivity of rat (r)DAT EL2 residue R218 to proteolysis by the
arginine/lysine specific protease trypsin in response to binding of uptake blockers that we
attributed to conformational movements generated during transport inhibition (Gaffaney 2004).
Here we continue our analysis of uptake blocker-induced changes in EL2 using the
aspartic acid specific enzyme endoproteinase Asp-N and identify ligand-induced conformational
sensitivity of D174, a residue just C-terminal to the extracellular end of TM3. Comparative
modeling of DAT and LeuT places D174 and R218 in close proximity, suggesting a structural
basis for their similar uptake inhibitor sensitivities and indicating their potential to form a salt
bridge. Using SCAM we examine the regions around rDAT D174 and human (h) DAT R219 and
identify conformational activity of hDAT V221. Similar to previous findings obtained with
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trypsin, we show that DA transport and cocaine analog binding activities are decreased after
Asp-N cleavage of EL2, suggesting a role for this domain in these functions. These findings
suggest that conformational changes in this region of EL2 following antagonist binding may
represent part of the transport inhibition mechanism and add to our understanding of an undercharacterized region of DAT.

Methodology
Tissue Preparation and Proteolysis
Male Sprague Dawley rats (175–300g) were decapitated and the striatum was quickly
removed, weighed, and placed in ice-cold sucrose phosphate buffer (SP) consisting of 0.32M
sucrose, 10mM sodium phosphate, pH 7.4. The tissue was disrupted with a Polytron
homogenizer and centrifuged at 20,000xg for 10 minutes at 4°C. The resulting membranes were
washed twice and resuspended to 20mg/ml original wet weight (o.w.w.) in ice-cold SP buffer.
Equal volumes of membranes and endoprotease Asp-N (1–5µg/ml final) prepared in SP buffer
were gently mixed and incubated for 45 minutes at room temperature. Proteolysis was stopped
by addition of 500 µl of ice-cold SP buffer, membranes were centrifuged at 15,000xg for 8
minutes at 4°C and the supernatant was removed. The resulting pellet was solubilized in sample
buffer (2% SDS, 10% glycerol, 100mM DTT, 60mM Tris–HCl, pH 6.8) at 20mg/ml o.w.w. and
subjected to electrophoresis and immunoblotting. For experiments testing the effects of ligands
on proteolysis, striatal membranes were incubated on ice for 1 hour in the presence or absence of
DAT uptake inhibitors (2µM), substrates (30µM), or ZnCl2 (10µM) followed by addition of AspN. For sodium replacement studies SP buffer was prepared with 10mM monobasic/dibasic
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potassium phosphate. Proteolysis of DAT was quantified as described below, with statistical
evaluation of proteolysis performed using ANOVA with significance set at p < 0.05. All
experiments were performed three or more times.
Immunoblot Analysis
Solubilized striatal membranes (25µl) were electrophoresed on 4–20% Tris/glycine
polyacrylamide gels and transferred to 0.2µm PVDF membranes. DAT and its proteolytic
fragments were detected by immunoblotting as previously described (Gaffaney 2004) with
mouse monoclonal antibody 16 (mAb16; EMD Millipore; 1:1000 dilution) generated against
rDAT N-terminal tail amino acids 42–59 or goat polyclonal antibody raised against rDAT Cterminal tail amino acids 601–619 (Research Diagnostic Inc.; 1:100 dilution). Bound antibodies
were detected with anti-mouse or anti-goat IgG 2°antibodies linked to alkaline phosphatase
(1:5000 dilution) and membranes were developed with the alkaline phosphatase substrate, 5bromo-4-choloro-3-indolyl phosphate/nitro blue (BCIP/NBT). Blots were dried, scanned, and
quantified using LumiAnalyst software (Roche/Boehringer- Mannhiem). Specificity of mAb16
immunostaining was verified by preabsorbing antibody with 30µg/ml peptide 16, using 30µg/ ml
peptide 5 (a.a. 225–236) as a negative control. Tissue linearity experiments verified that mAb16
signal intensity was linear between 0.1 and 10mg/ml tissue (not shown).
Quantification of DAT Proteolysis
Immunoblots were scanned at 600dpi with an Epson Perfection 12000U scanner and
saved as grey-scale images. Grey scale values were converted to Boehringer light units by
LumiAnalyst 3.0 software. Proteolysis of DAT was quantified dividing the immunoreactivity of
the 80kDa DAT form by the combined immunoreactivity of all DAT bands (full length protein
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and proteolytic fragments), with results converted to percent and subtracted from 100%. This
allowed for correction of low amounts of endogenous proteolysis observed in some experiments,
and served as an internal loading and transfer control. PeptideCutter (Expasy) was used to
determine the calculated Mr of peptide fragments.
Deglycosylation Analysis
DAT and DAT Asp-N fragments were immunoprecipitated with polyclonal antibody 16
as described previously (Foster et al. 2002). Protein A Sepharose beads containing the immune
complex were incubated with 1.5 units of glycopeptidase-F (PNGF) for 18 hours at 22°C to
deglycosylate DAT (Vaughan and Kuhar 1996). Beads were washed twice with
immunoprecipitation buffer (50mM Tris–HCl, 0.1% Triton X-100) and proteins were eluted with
sample buffer followed by immunoblotting with mAb16.
Asp-N Activity Assay
The Asp-N peptide substrate Azocoll® which generates a blue product when cleaved was
used to determine the activity of Asp-N in the presence or absence of 5µM cocaine, GBR 12909,
mazindol, benztropine, ZnCl2, dopamine, or amphetamine. Azocoll® was incubated with 1–
5µg/ml Asp-N at 37°C for 15 minutes in the presence of ligands, particulates were removed by
filtration through a Whatman No. 1 filter and the absorbance of the filtrate was measured at
520nm in a Molecular Devices SpectraMax 190 spectrometer. Absorbance was linear with
enzyme concentration and activity was not affected by any of the DAT compounds tested (not
shown).
[3H]CFT Binding and [3H]DA Uptake
For binding assays rat striatal membranes were treated with or without 5µg/ml Asp-N for
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45 minutes at 22°C, followed by addition of ice-cold SP buffer, centrifugation, and removal of
supernatant. Membrane pellets were resuspended in SP buffer to a concentration of 6mg/ml
o.w.w. and triplicate samples were incubated on ice with 2nM [3H]2b-carbomethoxy-3b-(4fluorophenyl)tropane ([3H]CFT) for 2 hours with non-specific binding determined by addition of
100µM (–)-cocaine. Reactions were terminated by rapid vacuum filtration using a Brandel tissue
harvester over Whatman GF/B glass fiber filters soaked in 0.1% BSA for 2 hours. Filters were
counted in a Beckman model 1600 scintillation counter. For uptake assays P2 synaptosomal
fractions were prepared in SP buffer from freshly dissected rat striatum (Krueger 1990), and
resuspended at 6mg/ml o.w.w. in ice-cold SP buffer. Aliquots were treated with or without
1µg/ml of Asp-N for 45 minutes and dispensed into assay tubes. Dopamine uptake assays were
performed in triplicate in modified Krebs phosphate buffer (16mM KPO4, 126mM NaCl, 4.8mM
KCl, 1.4mM MgSO4, 10mM glucose, 1.1mM ascorbic acid, and 1.3mM CaCl2, pH 7.4)
containing 10nM [3H]dopamine plus 100nM dopamine (Vaughan et al. 1997) with non-specific
uptake determined by addition of 100µM (–)-cocaine. Uptake assays were initiated by addition
of 100µl of synaptosomes to the reaction tube and conducted for 5 minutes at 30°C. Uptake was
stopped by addition of 5ml of ice-cold SP buffer and immediate vacuum filtration using a
Brandel tissue harvester over a Whatman GF/B filter soaked for 2 hours in 0.1% BSA. Filters
were counted using a Beckman model 1600 liquid scintillation counter. Aliquots of each sample
were subjected to immunoblotting to determine the extent of DAT proteolysis. Results were
analyzed by Student’s t-test with significance set at p < 0.05.
SCAM Analysis
The expression plasmid for hDAT E2C with two extracellularly facing Cys residues (C90
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and C306) mutated to Ala was the generous gift of Dr. Jonathan Javitch, Columbia University
and was used for analysis of R219 and flanking residues. The homologous rDAT E2C (C90A,
C305A) was generated in our lab for analysis of D174 and flanking residues. E2C and Cys
mutations in the E2C background were made using the Stratagene QuikChange kit with codon
substitution verified by sequencing (Alpha Biolabs; Northwoods DNA). For production of
human stable transformants, GripTight cells™ (Invitrogen) were transfected using FuGENE,
(Roche Applied Bioscience) and pooled lines were maintained under selection with 250µg/ml
Hygromycin. For production of stable rat transformants, Lewis Lung Carcinoma Porcine Kidney
(LLC-PK1) cells were transfected using X-tremeGENE, (Roche Applied Bioscience) and pooled
lines were maintained under selection with 800µg/ml G418. For Western blotting, cells were
lysed with solubilization buffer (25mM Tris–HCl, 150mM NaCl, 1mM EDTA, 5mM NEM, and
1% Triton X-100), protein content was determined using the BCA method and 10µg of total
protein was immunoblotted with mAb16 for rDAT or mAb369 (Chemicon; Temecula, CA) for
hDAT.
For activity assays cells expressing h/rDAT E2C or E2C Cys mutants were grown on 12or 48-well plates to 90–95% confluency. Cells were washed 2x with Krebs–Ringer HEPES
buffer (25mM HEPES, 1.2mM KH2PO4, 125mM NaCl, 4.8mM KCl, 1.2mM MgS04, 5.6mM
glucose, and 1.3mM CaCl2, pH 7.4). For binding assays cells were incubated with 1nM (12-well)
or 10nM (48-well) [3H]CFT for 2 hours on ice, rinsed twice with ice-cold KRH, and solubilized
in 1% SDS. For uptake assays, cells were incubated for 10 minutes at 37°C with 10nM [3H]DA
plus 3µM DA. Non-specific binding and transport were determined using 100µM (–)-cocaine.
Cells were washed twice with ice-cold KRH, solubilized in 1% SDS, and analyzed for
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radioactivity by scintillation counting. Uptake and binding values were normalized for protein
content and results for mutants are indicated as percent of E2C activity set to 100%. For SCAM
analysis MTSET, MTSES, or MTSEA (Biotium; Hayward, CA) were prepared immediately
prior to use, and added to the cells (1mM final) for 10 minutes at room temperature. For cocaine
protection assays cells were incubated with 10µM (–)-cocaine for 10 minutes prior to MTSET
addition. Following incubation the cells were washed 3 times with KRH and assayed for
[3H]CFT binding or [3H]DA transport.
Molecular Modeling
To determine distance between residues L126 and S150 that are homologous to D174 and
R218 in rDAT, the X-ray coordinates for the second extracellular loop (EL2) of LeuT were
analyzed from the crystal structures representing the ‘apo-out’ (PDBID: 3TT1), ‘open-to-out’
(3F3A), ‘outward-occluded’ (2A65), ‘outward-occluded’ (3TU0), ‘apo-in’ (3TT3), and
‘occluded with sertralinebound’ (3GWU). With the exception of the apo-inward structure,
residues 132 through 135 were unresolved and were therefore re-built using Prime 3.1 in
Schrödinger suite (Schrödinger LLC), with the native crystal structures as templates. The
resulting structures differed only 0.000–0.005 RMSD from their respective templates. The
mutations L126D and S150R were introduced and EL2 structures modeled using Rosetta
Backrub which allows for focused flexible backbone modeling (Smith and Kortemme 2008). The
top scoring Backrub models were analyzed for distances between D126 and R150. Possible
backbone-dependent rotamers for D126 and R150 were analyzed in PyMol. Figures were
generated using PyMol. (The PyMOL Molecular Graphics System (Schrödinger, LLC)).
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Results
Endoproteinase Asp-N Digestion of rDAT
In a previous study we found that in situ proteolysis of

32

PO4-labeled rat striatal

membranes with Asp-N generated a phosphorylated 19kDa DAT fragment that precipitated with
N-terminal polyclonal Ab16 (Foster et al. 2002), suggesting that Asp-N could provide a suitable
enzyme for analysis of DAT proteolysis. In the N-terminal region of the protein rDAT contains
two Asp residues (D68 and D79) that are embedded in TM1 and inaccessible to protease during
in situ treatments, and six that are in EL2 (D174, D191, D199, D205, D230 and D231) (Figure
30). To develop an immunoblot assay for detection of Asp-N fragments that could be used to test
effects of ligands we examined the overall Asp-N digestion pattern using both N-terminal (mAb
16) and C-terminal (a.a. 601–619) antibodies (Figure 31, left). In control membranes both
antibodies detected full length DAT migrating at ~80kDa (arrow a). In Asp-N treated membranes
the primary N-terminal proteolysis product was a 19kDa fragment (arrow d) that corresponded to
the phosphorylated peptide we identified by immunoprecipitation, and a lower intensity 32kDa
cleavage product (arrow b) was also produced in some but not all experiments. Because there are
no Asp residues in EL1, IL1, or the N-terminal tail and those in TM1 are protected from
proteolysis, these fragments extend from the transporter N-terminus to the cleavage site. The
mass of the 19 kDa band is thus consistent with proteolysis at D174 (calculated Mr 19,243),
while that of the 32 kDa band is consistent with proteolysis at D191 or D199, which would
generate fragments of calculated protein Mr 21,244 and 22,032 with the remaining mass
contributed by N-linked carbohydrates on N181, N188, or N196 (Figure 31). The 32 kDa
fragment was not more prominent than the 19kDa fragment at lower Asp-N doses or
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Figure 31. Characterization of DAT Asp-N fragments. Rat striatal membranes were
treated with (+) or without (–) 1µg/ml Asp-N and analyzed as indicated. Left panel,
immunoblotting of samples with N- and C-terminal specific DAT antisera: (arrow a) fulllength DAT; (arrows b and d) 32 and 19kDa fragments detected by mAb 16; (arrow c)
30kDa fragment detected with C-terminal antibody. Middle panel, immunoblotting of
Asp-N treated samples with mAb16 containing no addition (control), 30µg/ml peptide 16
(p16), or 30µg/ml peptide 5 (p5). Right panel, DAT and DAT Asp-N fragments were
immunoprecipitated with polyclonal antibody 16 and treated with or without 1.5 units
PNGF, followed by immunoblotting with mAb16.
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treatment times, or seen in its absence, suggesting that D174 is the preferred site of proteolysis
with occasional missed cleavages producing the larger peptide. Immunoblotting of Asp-N digests
with the C-terminal mAb detected a 30kDa fragment (arrow c) that is similar in mass to a 32kDa
C-terminal fragment produced by cleavage of R218 (Vaughan and Kuhar 1996; Gaffaney 2004),
and is thus consistent with proteolysis of D205, D230, or D231.
The specificity of N-terminal fragment immunoreactivity was confirmed by preabsorbing
mAb16 with its antigenic peptide (peptide 16), which blocked staining of full-length DAT and
all fragments (Figure 31, middle), while inclusion of peptide 5 (rDAT a.a. 225–236) had no
effect. To further characterize the fragments we treated control and Asp-N proteolyzed DATs
with glycopeptidase-F to remove N-linked carbohydrates (Figure 31, right). This reduced the
mass of the full-length protein by ~20–25kDa as previously shown (Vaughan 1995; Li et al.
2004), but did not affect the mass of the 19kDa fragment. This result strongly indicates that the
19kDa fragment is produced by cleavage of D174, which is the only Asp residue in EL2 that is
N-terminal to all glycosylation sites. We note that we have been unable to drive in situ
proteolysis of heterologously expressed DATs and thus have not been able to confirm usage of
protease sites by site-directed mutagenesis.
Uptake blockers reduce Asp-N proteolysis
To determine if uptake blockers or substrates affect the Asp-N sensitivity of DAT, rat
striatal membranes were incubated with various DAT ligands during protease treatment (Figure
32). In control membranes, Asp-N treatment caused robust production of the 19kDa fragment
(Figure 32A), with DAT proteolysis levels averaging 62 ± 4% (Figure 32B). Incubation of
membranes with the DA uptake inhibitors (–)-cocaine, GBR 12909, mazindol, nomifensine, or b130

Figure 32. Effect of ligand binding on Asp-N proteolysis. Rat striatal membranes
incubated in the absence (control) or presence of 2µM uptake blockers, 30µM substrates, or
10µM Zn2+, were treated with vehicle or 1µg/ml Asp-N and immunoblotted with mAb16.
(A) Representative immunoblot showing full-length DAT and 19kDa Asp-N fragments
produced in indicated conditions. (B) Quantification of DAT proteolysis in the presence of
tested compounds. Bars indicate the fraction of DAT digestion in the presence of vehicle
(black bar), uptake blockers or Zn2+ (hatched bars), or substrates (gray bars). Values shown
are means ± S.E.M. of three independent experiments. * = p < 0.05, ** = p < 0.01, *** = p
< 0.001 relative to control by ANOVA with a Dunnett’s multiple comparison post hoc test.
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CFT strongly inhibited production of the 19kDa fragment, with proteolysis levels ranging from
12 ± 5% to 33 ± 6% (all p < 0.05 to p < 0.001 relative to control). Proteolysis was not affected by
the inactive cocaine stereoisomer (+)-cocaine or by the NET inhibitor desipramine (not shown),
demonstrating the pharmacological specificity of the effect. In contrast to the effects of transport
inhibitors, incubation of membranes with the substrates DA, AMPH, or METH, or with Zn2+, did
not affect DAT proteolysis (all p > 0.05 relative to control) (Figure 32, A and B).
To further verify that the reduced proteolysis of DAT was due to ligand binding, we
tested for the effects of Asp-N in the absence of Na+ (Figure 33), which significantly reduces the
affinity of DAT for cocaine (Wang et al. 2003). In Na+-containing buffer, DATs showed robust
proteolysis that was strongly inhibited by uptake blockers (Figure 33, A and B). However, when
K+ was substituted for Na+, uptake blockers did not prevent proteolysis, consistent with reduced
ligand affinity resulting in lack of transporter conformational change. No difference was found in
the levels of control DAT proteolysis in the presence or absence of Na+, indicating that Na+
binding alone does not induce transporter conformational changes detectable with this assay.
Finally, as an additional control, we determined that none of the DAT blockers or substrates
tested affected Asp-N cleavage of a synthetic substrate (not shown), indicating that reduced
production of DAT fragments by ligands was not the result of Asp-N inhibition. Together these
results demonstrate that binding of uptake blockers but not substrates or Zn2+ leads to reduced
proteolysis of D174.
Asp-N treatment disrupts DAT function
To determine if proteolysis of EL2 affects DAT function, rat striatal membranes or
synaptosomes were treated with Asp-N followed by assessment of [3H]CFT binding
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Figure 33. Uptake ligand-induced protease resistance requires Na+. Rat striatal
membranes suspended in buffer containing either Na+ or K+ were incubated with
uptake blockers (2µM) or substrates (30µM) and treated with vehicle or Asp-N
followed by immunoblotting with mAb16. (A) Representative immunoblot. (B)
Quantification of DAT proteolysis (means ± S.E.M.) in the presence of Na+ (black
bars) or K+ (hatched bars). ** = p < 0.01, *** = p < 0.001 relative to control by
ANOVA with a Dunnett’s multiple comparison post hoc test.
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(Figure 34A) or [3H]DA transport (Figure 34B). Immunoblotting of membranes and
synaptosomes confirmed production of Asp-N fragments with proteolysis levels averaging 18 ±
3%. After Asp-N treatment, binding and transport activities of DAT were reduced by 31 ± 6%
and 20 ± 4%, respectively, roughly correlating with the extent of digestion, and suggesting that
loss of EL2 integrity leads to reduction of DAT transport and binding functions.
SCAM analysis of EL2 residues
We then performed SCAM analysis of the regions around rDAT D174 and hDAT R219
to further assess the conformational sensitivity of these residues and to examine flanking
sequences. For analysis of the N-terminal side of EL2 we generated an rDAT E2C construct as
the background for insertion of Cys mutations at residues 171–177 (F171, T172, M173, D174,
L175, P176, and W177) (Figure 35). The corresponding human sequence (FTTELPW) differs
slightly but retains conservation of the negative charge at Glu174. rDAT E2C displayed uptake
and binding activities that were similar to those of the WT protein (not shown). Immunoblotting
showed that all mutants expressed full-length DAT at ~20–100% of E2C levels except for
W177C, which showed no mature protein (Figure 35A). A pronounced band that migrated at
~200 kDa was present in T172C, M173C and D174C forms. As surface projections indicate that
these residues are at the transporter surface (not shown), this suggests the possibility for disulfide
bond formation to occur between DAT monomers via the inserted cysteines. [3H]DA uptake and
[3H]CFT binding activities of these mutants roughly paralleled their expression levels,
suggesting that kinetic properties were not strongly altered by the mutations. Consistent with its
lack of expression, W177C showed ≤5% of E2C levels of transport and binding activity (Figure
35B), and could not be further analyzed. The remaining mutants were analyzed by SCAM using
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Figure 34. Asp-N treatment disrupts binding and transport activities. (A) Rat
striatal membranes or (B) rat striatal synaptosomes were treated with (+) or without (–)
5µg/ml Asp-N followed by assessment of (A) [3H]CFT binding or (B) [3H]DA uptake.
Left panels show verification of proteolysis by immunoblotting. Histograms show
quantification of uptake or binding (means ± S.E.M.). * = p < 0.05, ** = p < 0.01
relative to control by Student’s t-test.
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Figure 35. SCAM analysis of the N-terminal region of EL2. Cells expressing the
indicated rDAT mutants were analyzed by (A) immunoblotting or (B) [3H]DA transport
(black bars) and [3H]CFT binding (gray bars). (C) Cells were incubated with vehicle (black
bars) or 10µM (–)-cocaine (gray bars) followed by addition of 10mM MTSET prior to
binding analysis. The histogram shows percent changes in [3H]CFT binding for each form
(means ± S.E.M, n = 3). Treated and untreated samples were not significantly different.
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[3H]CFT binding as the functional read-out. Treatment of cells with the positively charged MTS
reagent MTSET caused only slight (~5–20%) reductions in binding for mutants at positions 172–
176 and larger but more variable reduction (31 ± 19%) for F171C, none of which were
significantly different from E2C (all p > 0.05), and inclusion of (–)-cocaine during the treatment
did not alter these effects (Figure 35C). [3H]DA transport activity of D174C was also not
affected by MTSET, and [3H]CFT binding activity for D174C was not significantly affected by
the negatively and positively charged MTS reagents MTSES and MTSEA (not shown). Pull
down experiments showed that MTSEA biotin reacted with D174C (not shown) indicating that
the residue was accessible to the reagent. These results thus suggest that binding and transport
activities of these DAT forms were not affected by modification of the inserted cysteines.
For analysis of the C-terminal side of EL2 we used the hDAT E2C construct (Loland et
al. 2004) as the background for insertion of Cys mutations at residues 210–226 (Figure 36). This
sequence is identical in hDAT and rDAT. The mutants were analyzed by immunoblotting and
[3H]CFT binding, and in some cases for [3H]DA transport (Figure 36, A and B). E215C, Y216C
and F217C forms showed little to no expression, [3H]DA uptake, or [3H]CFT binding, and could
not be analyzed by SCAM. The remaining mutants showed ~15–100% of E2C levels of [3H]CFT
binding (Figure 36B), which roughly corresponded to the protein expression levels, suggesting
that the mutations did not strongly impact binding characteristics. The proportionally lower
uptake levels for E218C and R219C compared to binding could be consistent with impairments
in transport or surface expression, although further work will be necessary to confirm the
mechanism. Using [3H]CFT binding as the functional read-out, we found that MTSET caused
~60% reduction in binding for A213C; ~20–30% reductions in binding for R219C, G220C,
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Figure 36. SCAM analysis of the C-terminal region of EL2. Cells expressing the
indicated hDAT mutants were analyzed by (A) immunoblotting or (B) [3H]DA
transport (black bars) and [3H]CFT binding (gray bars).
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Figure 36 (continued). SCAM analysis of the C-terminal region of EL2. (C) Cells
were incubated with vehicle (black bars) or 10µM (–)-cocaine (gray bars) followed by
addition of 10mM MTSET prior to binding analysis. Responses for R219C and V221C
are indicated in blue (vehicle) or red (cocaine) for clarity. Results show percent
changes in [3H]CFT binding for each form (means ± S.E.M.). * = p < 0.05, ** = p <
0.01, *** = p < 0.001 relative to E2C by ANOVA with a Dunnett’s multiple
comparison post hoc test; † = p < 0.05, ††† = p < 0.001 for indicated forms relative to
the absence of cocaine by Student’s t-test. n = 3–5 for all forms except T211C (6),
P212C (6), A213C (6), E218C (8), R219C (10), and H223C (6).
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V221C, L222C, and H223C; ~10–15% increases in binding for T211C, P212C, L224C, and
Q226C; and lesser changes for the remaining residues (Figure 36C). Statistically different
changes relative to that of E2C were seen for A213C (p < 0.001), R219C (p < 0.01), and V221C,
L222C, and H223C (p < 0.05), indicative of modifications that altered binding. Inclusion of (–)cocaine during the MTSET treatment did not alter the binding changes at most of these residues,
but significantly reduced the inhibition of binding at R219C (p < 0.001) and V221C (p < 0.05)
(Figure 36C), confirming the conformational sensitivity of R218/219 to cocaine and identifying
cocaine-induced conformational changes at V221.
Molecular modeling
To further understand the significance of these findings we performed molecular
modeling of D174 and R218 using homology to LeuT structures solved in the ‘apo-out’, ‘opento-out’, ‘outward-occluded’, ‘apo-in’, and ‘occluded with sertraline-bound’ forms that represent
different states of the transport cycle (Yamashita et al. 2005; Singh et al. 2008; Zhou et al. 2009;
Krishnamurthy and Gouaux 2012) (Figure 37). The LeuT residues homologous to D174 and
R218 are L126 and S150, and their positions have been solved in all LeuT crystal structures,
providing a reasonable template for low level modeling of D174 and R218. The results revealed
that L126 and S150 were present within ~11Å of each other (Figure 37A), but showed no
significant differences in proximity or orientation in any of the transporter forms (Figure 37B),
consistent with a lack of movement during transporter cycling or ligand binding in LeuT. We
then substituted LeuT residues L126 and S150 in silico with D and R to model D174 and R218
positions. The structures were subjected to refinement using Rosetta Backrub, which is designed
to sample and energy-minimize local backbone and side chain conformations following residue
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Figure 37. Comparative modeling of D174 and D218 from LeuT EL2 crystal
structures. (A) Ribbon diagram of LeuT EL2, highlighting positions and calculated
distance between L126 and S150 (dashed line). (B) Superimposed ribbon diagrams of
EL2 coordinates from LeuT forms ‘apo-out’ (pink); ‘open-to-out’ (orange); ‘outwardoccluded’ (brown, green); ‘apo-in’ (gray); and ‘sertraline-bound’ (cyan), show
minimal changes in overall domain structure or L126 and S150 distances. (C) Ribbon
diagram of LeuT with in silico mutation of L126 and S150 side chains to D and R.
Energy minimization using Rosetta Backrub revealed several conformations in which
the residues are close enough to form a salt bridge (dashed line).
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Figure 37 (continued). Comparative modeling of D174 and D218 from LeuT EL2
crystal structures. (D) Superimposed ribbon diagrams of EL2 from LeuT forms listed
above with DAT substitutions reveal no significant alteration in D174/R218 side chain
orientation or distance. (E) Ribbon diagram of dDAT EL2 with in silico mutation
S142D. Manual rotamer search of D142 and R218 were chosen in PyMol. Measured
distance between the side chains is indicated (dashed line).
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substitution (Smith and Kortemme 2008). A manual backbone-dependent rotamer search
revealed that the longer R and D side chains can come within 2.9Å of one another (Figure 37C),
suggesting the possibility of an ionic interaction between these two residues in DAT. Similar to
the endogenous LeuT residues, however, the relative positions of D174 and R218 side chains
showed no significant variations across the in silico mutated models (Figure 37D).

Discussion
Our findings from protease and SCAM analyses suggest that rDAT/hDAT EL2 residues
D174, R218/219, and V221 undergo conformational changes in response to binding of uptake
blockers or achieve protection indirectly through conformational changes of nearby residues.
Because the effects were not obtained with substrates, it is possible that the changes may
contribute to the mechanism of transport inhibition, for instance by promoting outward
conformations thought to bind to or be stabilized by cocaine (Loland et al. 2004), or by otherwise
impacting structural rearrangements needed for transport. Comparative modeling places these
residues in close three-dimensional proximity, which could provide a structural basis for their
similar sensitivities to uptake blockers, and indicates the potential for D174 and R218 to form a
salt bridge. We found no ability of substrates to induce protease resistant forms, but because
substrates were analyzed in binding rather than transport conditions, it cannot be excluded that
these states might exist during post-binding phases of the transport cycle. Similar to our previous
results with tryptic proteolysis of R218, we found no induction of D174 resistance to Asp-N by
Zn2+, which slows DA transport by suppressing conformational movements needed for substrate
translocation (Norregaard et al. 1998; Stockner et al. 2013). This suggests that inhibition of
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transport induced by Zn2+ and by pharmacological blockers occurs via distinct mechanisms that
might be therapeutically exploited if more fully understood.
It is not known how the conformational information from ligand binding is transmitted to
these residues or if the D174 and R218 changes occur independently or via charge interactions.
TM3 directly interacts with uptake blockers (Chen et al. 1997; Henry 2003; Penmatsa et al.
2013), suggesting the likelihood for direct transmission of ligand-induced conformational
changes to D174, although the specific nature of these changes is unknown. R218 and V221 are
predicted by PsiPred and JUFO to be present in an a-helical conformation (Figure 30). In LeuT
crystal structures, the homologous helical domain undergoes significant compression and
rotation during the ‘apo-out’ to ‘apo-in’ transitions (Krishnamurthy and Gouaux 2012) that could
alter accessibilities of constituent residues. Although modeling in LeuT templates supports
D174–R218 salt bridge interactions in all transporter states, leak conductance (Mager et al. 1994)
and SCAM studies of SERT (Chen et al. 1997) indicate the occurrence of dynamic
conformational changes in the absence of substrate. Similar reorientations in resting DATs could
intermittently alter D174 and R218 interactions to allow protease access, while inhibitors that
block transport may stabilize a conformation that locks the D174–R218 interaction. Because
Asp-N and trypsin require binding of the charged side chains to position the scissile bond in the
catalytic site, formation of the salt bridge could suppress enzyme recognition. Such alterations in
trypsin resistance and sensitivity in response to salt bridge formation and disruption have been
reported (Rajabi et al. 2008).
Whatever the mechanism responsible for D174 and R218 protease resistance, our
findings indicate that molecular modeling of D174 and R218 in LeuT templates, which identifies
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no significant structural alterations of these residues, does not accurately represent the properties
of DAT, in which these residues clearly undergo either direct or indirect ligand-induced
alterations. These inconsistencies may result from differences between DAT and LeuT in EL2
structure and/or ligand binding site. EL2 of DAT differs considerably from that of LeuT by
containing 21 additional residues, a disulfide bond, multiple N-linked glycosylation sites, and
Zn2+-coordinating residues (Norgaard-Nielsen et al. 2002; Li et al. 2004; Meinild 2004; Chen et
al. 2007; Stockner et al. 2013). Few of these elements have been solved at high resolution, and
their contributions to EL2 structure are incompletely understood. It is conceivable that given
these large differences, EL2 of DAT may undergo distinct or greater conformational changes
than that of LeuT and that even small rotations in connecting elements could alter D174–R218
interactions. Such conformational changes in EL2 are supported by computational models of this
domain based on well-defined molecular constraints which show that the zinc binding site
present in the outward-facing form of DAT is destabilized in the inward-facing structure, due in
part to movement of EL2 (Stockner et al. 2013). In addition, in the sertralinebound form of LeuT
the ligand is complexed at low affinity in the S2 site, which may not accurately represent
structures produced by high affinity and/or S1 binding of cocaine or other inhibitors in DAT.
Dose–response studies of antagonist-induced R218 protease resistance showed strong agreement
with published ligand affinities, indicative of responses to high affinity binding (Gaffaney 2004).
Previously the only insight into competitive binding at S1 was the Trp-bound LeuT co-crystal
(Singh et al. 2008), presenting the possibility that binding of larger molecules such as cocaine at
S1 could induce distinct conformational changes in EL2. In fact, in the dDAT-nortriptyline cocrystal (Penmatsa et al. 2013) the residues homologous to D174 and R218 are almost twice as far
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apart (19.7Å) as compared to LeuT (11.1Å) (Figure 37E), suggesting differences between DAT
and LeuT in EL2 structure or conformational responsiveness. While the distance between D174
and R218 in this inhibitor-bound dDAT structure is too great to allow salt bridge interactions, it
is possible that the native EL2 structure is not accurately represented due to the removal of 43
residues needed to crystalize the protein. In addition, the dDAT residue homologous to rDAT
D174 is Ser, which may also impact the final loop structure and the potential for this site to
interact with R218. Thus many questions remain to be addressed with respect to these issues.
Our current and previous findings that conditions that cleave EL2 but leave the resulting
N- and C-terminal segments of the protein largely intact lead to reductions of DA transport and
CFT binding suggest that EL2 is important for overall transporter structure and/or contributes a
functional property that is lost after proteolysis. A connection between EL2 and transport
inhibitor binding was also recently identified in hNET (Wenge and Bönisch 2013). Alkylation of
hNET EL2 residue His222 suppressed binding of the uptake inhibitor [3H]nisoxetine, although
mutation of this residue was without effect. This suggested that the residue was not directly
involved in binding but that its alkylation sterically blocked access of nisoxetine to its binding
pocket, implicating its proximity to the binding pathway or the binding site. This residue is
conserved in r/hDAT (H224/225) and is just downstream of R218/219 in the EL2 α-helix,
suggesting a potential structural similarity and further supporting a mechanistic connection
between this region of EL2 and uptake inhibitor binding.
High-resolution insight into neurotransmitter transporter molecular mechanisms has been
obtained by homology comparison to the LeuT and dDAT ligand binding sites, but lack of
information on EL and IL structures has delayed progress in understanding the roles of these
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domains. Though EL2 has typically been thought to serve a supportive structural role rather than
being directly involved in transport or ligand binding functions (Koldsø et al. 2013), our results
now begin to identify functional properties associated with the region. In addition, because our
protease resistance findings differentiate responses of these residues to antagonists and
substrates, they suggest this region as a possible target for development of reagents to reduce
inhibitor binding without directly impacting the substrate site.
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CHAPTER V
THE FORMATION OF A PUTATIVE SALT BRIDGE AT THE EXTERNAL GATE OF
THE SEROTONIN TRANSPORTER IS IMPORTANT FOR AMPHETAMINE
TRANSLOCATION AND THE INDUCTION OF SUBSTRATE EFFLUX
Introduction
The serotonin (5-HT) transporter (SERT) is a twelve transmembrane á-helical protein
responsible for the termination of serotonergic signaling by removing 5-HT from the synaptic
cleft (Gu et al. 1994). Serotonergic signaling is involved in a number of physiological functions
including the regulation of appetite, mood, libido, and memory (Amara 1993; Kristensen et al.
2011; Pramod et al. 2013). Alterations in serotonergic signaling have been implicated in
disorders like addiction, autism and depression (Owens and Nemeroff 1994; Hahn and Blakely
2002; Veenstra-VanderWeele et al. 2012). Moreover, SERT is the target of many illicit and
therapeutic substances, including cocaine, amphetamine (AMPH), and most antidepressants
(Tatsumi et al. 1997; Amara and Sonders 1998; Owens et al. 2001).
Like 5-HT, AMPH is a substrate for human SERT and induces an outward movement, or
efflux, of 5-HT from the cytoplasm through SERTs (Rudnick and Wall 1992a; 1992b; Sitte et al.
1998). This AMPH-induced substrate efflux is also seen in vivo, as AMPHs are known to
increase extracellular levels of 5-HT, dopamine, and norepinephrine, resulting in the euphoric
effects observed with amphetamine use (Rudnick and Wall 1992a; 1992b). The increase in
synaptic 5-HT is thought to be prompted by the transport of AMPH into synaptic vesicles by
vesicular monoamine transporters (VMAT), whereby increased vesicular AMPH concentration
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results in the dissipation of the vesicular proton gradient causing VMAT transport to reverse
direction and precipitating the emptying of 5-HT from the synaptic vesicles into the cytoplasm.
Once in the cytoplasm, 5-HT is then reverse transported by SERT back into the synaptic cleft, a
process termed efflux (Wall et al. 1995; Petersen and DeFelice 1999; Sulzer et al. 2005; Sitte and
Freissmuth 2015). Currently, the molecular mechanism by which AMPH promote this nonvesicular, SERT-mediated 5-HT efflux is not well understood (Scholze et al. 2000; Sitte et al.
2000; 2001).
Previous studies in our laboratory demonstrated dramatic differences in the efflux
properties between Drosophila SERT (dSERT) and human SERT (hSERT) (Rodriguez et al.
2003). dSERT has an increased rate of basal 5-HT efflux in the absence of efflux-inducing
AMPH, in contrast to hSERT which exhibits little to no basal efflux activity. However, 5-HT
release via hSERT occurs readily upon exposure to AMPH. Notably, AMPH-induced efflux is
not observed with dSERT (Rodriguez et al. 2003), suggesting that variation in the primary amino
acid sequence of hSERT and dSERT results in this different phenotypic response to AMPH.
Electrophysiological studies in Xenopus oocytes revealed that upon perfusion with AMPH,
currents are elicited through hSERT similar to those that are classically observed upon challenge
with substrates. However, these currents were not observed when dSERT was challenged with
AMPH, suggesting AMPH acts as a substrate at hSERT but not dSERT (Rodriguez et al. 2003).
In the MATs, the outer gate is an important structure which, when open, allows substrate
and ions to enter and bind to the transporter. Binding of the ions and substrate results in closure
of the gate to an occluded state necessary for the translocation step. Analysis of a multiple
sequence alignment of the Na+-dependent neurotransmitter transporters revealed that an acidic
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residue is highly conserved at the extracellular and intracellular gates. For example, the
extracellular gate of hSERT is composed of Arg 104 and Glu 493. However, in dSERT the acidic
gating residue is replaced with the polar amino acid Asn yielding an Arg 99 and Asn 484 pair,
which would be unable to form a salt bridge interaction. We hypothesized that the loss of a
strong charge/charge interaction at the extracellular gate could contribute to the observed
differences in the efflux properties of hSERT and dSERT and the transporters recognition of
AMPH as a substrate.
Further analysis of the sequence alignment of the SLC6 family of proteins revealed that a
vast majority (nearly 90%) of transporters contain an Asp at the external gate position on TM10
(Beuming et al. 2006). Conversely, only ~4% of SLC6 proteins have a Glu at this same position
in TM10, most of which (~80%) are species variants of SERT, and even less, ~2% of the SLC6
proteins, possess an Asn. Based on the 90% prevalence of Asp in the outer gate of SLC6
proteins, we also characterized the SERT from C. elegans (ceSERT), as it has an Asp (D517)
across from the Arg (R125) at the extracellular gate. Consistent with our hypothesis that the
presence of residues capable of forming a salt bridge at the outer gate are important for AMPHinduced efflux by SERT, we found that ceSERT is capable of mediating AMPH-induced efflux.
Here we utilized species scanning mutagenesis, a process by which two outer gate
mutants were generated for each SERT background that structurally mimic the outer gate
composition found in the other respective SERT species variants. This allowed us to examine
how the size and charge of the outer gate residue in TM10 effects MDMA interaction with the
transporter, which could provide evolutionary and functional significance for both the presence
and the identity of an acidic residue at the extracellular gate of SERT. This study reveals that the
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molecular composition of the extracellular gate impacts the interaction of the transporter with
MDMA, whereby recognition of MDMA as a substrate and subsequent efflux promotion are
largely inhibited without the presence of the residues capable of forming a putative salt bridge at
the outer gate. This may suggests that the presence of a salt bridge at the outer gate could be
important in initiating or stabilizing key mechanistic steps needed during transport of and efflux
induced by MDMA.

Methodology
Site-Directed Mutagenesis
hSERT, dSERT and ceSERT mutants were constructed using the QuikChange
mutagenesis kit (Stratagene, La Jolla, CA). Additionally, an HA-tag was added to the C-terminal
tail of the ceSERT plasmid for detection in Western blots. Analysis of the effect of HA-tag
addition revealed no significant alterations in transporter function or expression (data not
shown). Site-directed mutants were identified by screening for co-introduction of a silent
restriction site verified by sequencing of the entire open reading frame (Eurofins MWG Operon).
[3H]5-HT Uptake Assay
HEK-GripTite® cells (Invitrogen) were plated on 24-well culture plates and transiently
transfected 24 hours later using the Genecellin DNA transfection reagent (Bulldog BioCells). A
group of untransfected parental cells served as a negative control. 24-36 hours after transfection,
cells were washed with a modified Krebs-Ringer-HEPES buffer (MKRH) (120mM NaCl,
4.7mM KCl, 2.2mM CaCl2, 10mM HEPES, 1.2mM KH2PO4, 1.2mM MgSO4 10mM D-glucose,
pH 7.4). For competition assays, drugs were added and allowed to equilibrate. 50nM [3H]5-HT
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(Perkin Elmer, Waltham, MA) was added to sample wells and incubated for 10 minutes at 37ºC.
Cells were washed three times with ice-cold MKRH, solubilized with Microscint-20 (Perkin
Elmer), and counted on a PerkinElmer TopCount NXT scintillation counter to quantitate the
accumulated [3H]5-HT.
For saturation transport assays, transiently transfected cells were challenged with a range
of concentrations from a mixture of [3H]5-HT and non-labeled 5-HT (0.001 – 5µM) at 37ºC for
12 minutes. Cells were washed and accumulated [3H]5-HT was determined as described above.
For amphetamine-and substrate-induced exchange assays, transiently transfected HEKGripTite® cells were prepared as previously described. Cells were washed once with MKRH and
then preloaded with 50nM [3H]5-HT for 20 min at 37ºC. Preloaded cells were washed twice with
MKRH and challenged with a concentration range of cold 5-HT or MDMA. Efflux proceeded
for 10 minutes at 37ºC before being terminated by washing 3X with ice-cold MKRH buffer.
Cells were solubilized and remaining [3H]5-HT was counted as previously described.
Amphetamine- or substrate-induced efflux was calculated by determining the amount of efflux in
terms of percent 5-HT remaining in pre-loaded cells treated with a substrate compared with those
treated with 10µM paroxetine.
Basal efflux was determined in 24-well plates with transiently transfected GripTite®
cells. Cells were preloaded with 50nM [3H]5-HT for 30 minutes. Cells were washed twice with
MKRH to remove excess [3H]5-HT and incubated in MKRH from 0.5 to 10 minutes. The assay
was terminated by two washes with ice cold MKRH. The [3H]5-HT remaining in the cell was
determined by scintillation counting. Results were evaluated as the percentage of [3H]5-HT
remaining after incubation compared with cells treated with 10µM paroxetine.
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Surface Expression Analysis via Surface Biotinylation
To determine transporter surface expression transiently transfected HEK-GripTite® cells
were plated on 24-well plates at a density of 100,000 cells/well. 24–48 hours later, cell surface
proteins were labeled with NHS-SS-biotin (Thermo Scientific) and affinity purified using
neutravidin agarose beads (Thermo Scientific). A BCA protein assay was used to determine total
protein concentrations. Equal amounts of protein were processed by SDS-PAGE and Western
blotting to determine the relative amount of surface and total transporter pools(Henry 2003).
hSERT, dSERT, and ceSERT were detected using the ST51-2 monoclonal antibody (MAb
Technologies), an anti-Drosophilla-SERT polyclonal antibody (Alpha Diagnostic International),
and an anti-HA-tag monoclonal antibody (Thermo Scientific), respectively.
Whole-Cell Radioligand Binding Assay
HEK-GripTite® cells were plated in 24-well plates and were transiently transfected with
SERT cDNA using Genecellin. 48 hours post-transfection, cells were washed once with MKRH.
The assay was then carried out in MKRH using 10 µM paroxetine to define nonspecific binding.
Equilibrium binding was carried out by incubating with 10nM [3H](S)-citalopram (hSERT and
ceSERT backgrounds) or 20nM [3H]mazindol (dSERT background) binding at 4ºC for 1 hour.
Cells were washed twice with ice-cold MKRH and accumulated [3H](S)-citalopram or
[3H]mazindol was determined using scintillation counting as described above.
Two-electrode Voltage Clamping of Xenopus Oocytes
cRNA preparation. Plasmids were linearized and transcribed into RNA with a T7 RNA
polymerase kit mMessage mMachine (Ambion). A total of 5-50ng of cRNA was microinjected
into each oocyte. Electrophysiological recordings were performed 4–8 days following injection.
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Oocyte preparation. Xenopus laevis frogs (Nasco, Fort Atkinson, WI) were anesthetized
with ethyl 3-aminobenzoate methanesulfonate (FLUKA A5040) (2mg/ml in H2O). The frog was
decapitated, and the ovarian lobes were removed and transferred to sterile Ca2+-free ND-96
solution (96mM NaCl, 2mM KCl, 5mM MgCl2, 5mM HEPES, pH adjusted to 7.5 with NaOH).
The lobes were manually dissected to produce groups of 5–10 oocytes and incubated in ND-96,
containing 1-2mg/ml collagenase from Clostridium histolyticum (Sigma). Incubation for 60-90
minutes at room temperature was sufficient to digest and remove the follicular layer.
Defoliculated ocytes were selected and transferred to a fortified ND-96 buffer (96mM NaCl,
2mM KCl, 0.6mM CaCl2, 5mM MgCl2, 5mM HEPES 1mM Na-pyruvate, 100µg/ml
streptomycin, 50µg/ml tetracycline, 3% dialyzed horse serum, pH adjusted to 7.5 with NaOH).
Oocytes were kept at room temperature for a minimum of 2 hours prior to injection. Injection
was completed using the Nanoject II (Drummond Scientific). Injected oocytes were kept for 4–8
days at 18°C the fortified ND-96 buffer. Solutions were changed daily.
Electrophysiological recordings in X. laevis oocytes. A high performance oocyte clamp
OC-725C (Warner Instruments) was employed for the measurements. The recorded signal was
digitized with a PowerLab 8/35 system (AD Instruments). LabChart (AD Instruments) was used
for data acquisition. Borosilicate glass capillaries (Drummond Scientific) were pulled (Sutter
Instruments, model P-87) to a final resistance of 0.4–1.2 megaohms and filled with 3M KCl.
Oocytes were impaled, and the membrane potential was clamped to a holding potential of
−60mV. For continuous superfusion with unfortified ND-96 solution (96mM NaCl, 2mM KCl,
0.6mM CaCl2, 5mM MgCl2, 5mM HEPES, pH adjusted to 7.5 with NaOH) a gravity-driven
superfusion system (Warner Instruments, Eight Channel Perfusion Valve Control System) was
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used. The osmolarity of all solutions was kept equal by supplementation with mannitol.
Recordings were initiated after a stable current base line had been established. The current was
sampled with 100Hz and low pass-filtered with 20Hz.

Results
Disruption of hSERT External Gate Abolishes Transport
To determine the role of the external hSERT gating residues R104 and E493 in
amphetamine-induced efflux, a double mutant (R104E/E493R) was engineered to determine if
swapping the position of the charge could restore function. However, this reciprocal mutant
completely disrupted substrate transport (Figure 38) suggesting these residues likely participate
in interactions with other residues that are important in structure and/or function of the
transporter. Notably, the single mutants hSERT R104E and hSERT E493R were also nonfunctional. Expression of the single and double mutants at the cell surface were confirmed using
Western blotting and radioligand binding analysis (data not shown).
Species-Scanning Mutagenesis of the External Gate Yields Little Effect on 5-HT Transport
or Protein Trafficking
As swapping the two charged residues of the outer gate was unsuccessful, we performed
species-scanning mutagenesis with dSERT and ceSERT to introduce less disruptive mutations at
the external gate. Species-scanning mutagenesis is a strategy whereby species variants of a
protein are analyzed by multiple sequence alignment to identify alternative residues that
naturally occur at a specific position (Henry et al. 2006b). The native residues identified through
this technique are: hSERT, hE493D and hE493N, dSERT, dN484D and dN484E and ceSERT
ceD517E and ceD517N. These mutations were engineered and examined for changes in transport
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Figure 38. 5-HT transport activity of hSERT gating mutants. HEK-293 cells transiently
expressing hSERT or an hSERT gating mutant were assayed for [3H]5-HT uptake. Here,
results are graphically represented as the amount of [3H]5-HT uptake normalized to the level
of uptake in WT hSERT. Data represent mean ± SEM for at least three independent
experiments performed in triplicate.
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Table 4. Summary of transporter kinetics, activity and surface expression levels for each
SERT species variant and their respective outer gate mutants. Shown are relative
transport activity, surface expression, KM and Vmax values for each SERT species and their
respective external gate mutants. Transport activity values and surface expression are
normalized to the WT value in each respective species grouping.
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activity or kinetics and surface expression (Table 4). Only the ceD517N mutant exhibited a
change in functional activity compared to wild type (~29% decrease in transport activity and a
~3 fold increase in KM) indicating the naturally occurring variations at the TM10 gating residue
were well tolerated.
The Acidic TM10 Gating Residue is Important for the Ability of the Transporter to
Mediate MDMA-Induced Exchange
5-HT efflux occurs readily through hSERT and ceSERT in response to AMPH
application, whereas in dSERT, AMPHs elicit little or no efflux (Rodriguez et al. 2003). One of
the hallmarks of a SERT substrate is its ability to induce the efflux of preloaded substrate in
neurons or cultured cells (Fuller 1980; Rudnick and Wall 1992a; 1992b; Sitte et al. 1998). Thus,
the ability of MDMA to evoke 5-HT efflux was accessed in order to explore the importance of
the acidic amino acid at the outer gate in the recognition of AMPH as a substrate (and thus its
capacity to induce efflux) (Rudnick and Wall 1992a; 1992b). When HEK-GripTite® cells
expressing either hSERT, dSERT, ceSERT or one of their respective outer gate mutants were
preloaded with [3H]5-HT and challenged with non-labeled 5-HT to induce substrate-mediated
efflux there was significant release of [3H]5-HT (Figure 39).
Similarly, when the cells were challenged with MDMA, robust release of [3H]5-HT was
observed consistent with the properties of a substrate. However, little to no exchange was
observed in either dSERT or hSERT E493N (Figure 40, A and B). This suggests that the
presence of a negative charge at the outer gate is critical for the proper recognition and induction
of the MDMA transport mechanism. Notably, the ceD517N mutant (Figure 40C) also displayed
significant loss of MDMA-induced exchange (~41% decrease when compared with wild-type
ceSERT). However, unlike with dSERT or hSERT E493N, lack of a negative charge at the
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Figure 39. 5-HT can induce substrate efflux in transporters with either a negative
charge or a polar Asn at the external gating position on TM10. Substrate efflux assay:
HEK-GripTite® cells transiently expressing a SERT species variant or a SERT external gate
mutant were preloaded with [3H]5-HT. Loaded cells were challenged with various
concentrations of cold 5-HT in order to induce substrate-mediated efflux. After 10 minutes,
the assay was terminated by washing with ice-cold buffer and the amount of [3H]5-HT
remaining in the cell was quantified. Results for (A) hSERT, (B) dSERT and (C) ceSERT,
along with each set of respective external gate mutants for each, are represented in two ways:
(left) as a dose-response curve and (right) as a bar graph of results when 1mM 5-HT was used
to induce substrate efflux; n = 2.
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Figure 40. The presence of an Asn at the external gate of SERT results in diminished
MDMA-induced substrate efflux when compared with transporters that contain an
acidic amino acid at the homologous position. Substrate efflux assay: HEK-GripTite® cells
transiently expressing a SERT species variant or a SERT external gate mutant were preloaded
with [3H]5-HT. Loaded cells were challenged with various concentrations of MDMA in order
to induce substrate-mediated efflux. After 10 minutes, the assay was terminated by washing
with ice-cold buffer and the amount of [3H]5-HT remaining in the cell was quantified. Results
for (A) hSERT, (B) dSERT and (C) ceSERT, along with each set of respective outer gate
mutants for each, are represented in two ways: (left) as a dose-response curve and (right) as a
bar graph of results when 1mM MDMA was used to induce substrate efflux. A one-way
ANOVA was performed for each SERT grouping; ** p < 0.01, *** p < 0.001; n = 4.
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TM10 outer gate residue did not abolish MDMA-induced exchange suggesting there may be
other yet to be identified residues that are also important for MDMA recognition as a substrate.
If the presence of an acidic amino acid at the outer gate is important for AMPH-induced
exchange, introduction of an acidic residue into the TM10 gating residue in dSERT would likely
result in a gain-of-function, such that MDMA could induce release of internal substrate. To
evaluate this prediction, [3H]5-HT pre-loaded HEK Griptite culture cells expressing the dSERT
N484D or dSERT N484E mutants were exposed to MDMA (Figure 40B) 5-HT release was
observed at levels similar to wild-type hSERT (Figure 40A). Decreasing the bulk of the acidic
residue in hSERT by engineering an hSERT E493D mutant resulted in a ~38% loss of MDMAinduced exchange when compared to wild-type hSERT (Figure 40A) suggesting that the
positional length of the negative charge may be of importance. In ceSERT, where the presence of
an acidic residue was not absolutely required, altering the identity of the acidic residue in
ceSERT (D517E) yielded no effect on MDMA-induced exchange (Figure 40C), again suggesting
the substrate recognition mechanism in ceSERT may be partially or fundamentally different than
in hSERT and dSERT. These observations support our hypothesis, that the presence of an acidic
amino acid at the outer gate is important, and even critical to hSERT and dSERT critical for
propagating AMPH transport and promoting efflux.
Mutation at the Outer Gate does not Significantly Alter MDMA Potency
The inability of MDMA to induce substrate-like effects in dSERT could occur if lack of
an acidic residue significantly reduces or completely eliminates the binding of MDMA to the
transporter. Therefore, we performed [3H]5-HT competition uptake analysis to determine if
mutation of the acidic residue at the extracellular gate impacted the ability of MDMA to bind to
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Figure 41. The ability of MDMA to block 5-HT transport is not significantly different
when comparing transporters with an acidic amino acid at the outer gate to those that
have an Asn. Competitive uptake assay: HEK-GripTite® cells transiently expressing a SERT
or SERT outer gate mutant are simultaneously challenged with [3H]5-HT (50nM) and
concentrations of MDMA ranging from 10pM – 100µM. After 10 minutes, the assay was
terminated by washing with ice-cold buffer and results were quantified. Results are depicted
as a dose-response curve for (A) hSERT, (B) dSERT and (C) ceSERT, along with the external
gate mutants for each SERT; n ≥ 3.
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MDMA EC50 (µM)
hSERT

4.35 ± 1.9

hSERT E439D

5.91 ± 2.4

hSERT E439N

10.3 ± 2.8

dSERT

47.5 ± 8.1

dSERT N484D

17.5 ± 5.9

dSERT N484E

10.2 ± 5.2

ceSERT

17.3 ± 4.4

ceSERT D517E

19.5 ± 6.8

ceSERT D517N

56.8 ± 9.6

Table 5. Estimated EC50 values from [3H]5-HT competition
uptake analysis. Relative MDMA potency (EC50) values for
hSERT, dSERT, ceSERT or an external gate mutant from one
of the respective SERT species variant backgrounds. EC50
values represent mean ± S.E.M. of a minimum of three separate
experiments performed in triplicate.
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the transporter, and thus account for the inability of MDMA to act as a substrate (Figure 41).
Transporters possessing an Asn at the external gating position on TM10 demonstrated a trend
toward decreased MDMA potency, with the wild-type dSERT and the ceSERT D517N mutant
exhibiting a ~3.5- and ~3.1-fold decrease in their ability to block [3H]5-HT uptake, respectively,
when compared to the transporters from the same background with acidic amino acids at their
outer gate (Table 5). For the hSERT E493N mutation, this effect was less pronounced (~2.1-fold
decrease in MDMA potency). Despite a trend towards reduced MDMA potency in transporters
with an Asn at the outer gate, these transporters remain capable of binding and blocking [3H]5HT uptake. This does not completely rule out the presence of an acidic amino acid being
important for the composition of the MDMA binding site, however it does suggest that MDMA
still binds to transporters with an Asn at the outer gate, but that these transporters are
mechanistically incapable of transporting MDMA.
The Generation of MDMA-Induced Current by SERT is Dependent on the Presence of the
Acidic TM10 Gating Residue
Along with inducing efflux, substrates are known to elicit currents when applied to cells
expressing SERT. To measure this effect, two-electrode voltage-clamp (TEVC) studies in
Xenopus laevis oocytes injected with SERT cRNA are used, whereby SERT-expressing oocytes
challenged with 5-HT or MDMA exhibit substrate-induced currents if the ligand is recognized as
a substrate. Previously, we have shown that, for hSERT, similar current amplitudes are observed
for 5-HT and the AMPH-like derivative 5-Methoxy-6-methyl-2-aminoindane (MMAI); however,
for dSERT, current is observed only in response to 5-HT (Rodriguez et al. 2003).
Using the TEVC methodology, we examined hSERT, dSERT, ceSERT and the two
respective outer gate mutants in each background (hSERT E493D and E493N; dSERT N484D
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and N484E; ceSERT D517E and D517N) to determine the ability of each to mediate 5-HT
and/or MDMA-induced current (Figure 42 and Table 6). In direct support of the results from the
[3H]5-HT efflux studies, both the wild-type dSERT and the hSERT E493N mutant exhibited 5HT-induced current but were unable to mediate significant MDMA-induced currents, even at
high MDMA concentrations (MDMA-induced currents in hSERT E493N and dSERT were not
significantly different than the response to equal MDMA concentrations in water-injected control
oocytes). Similarly, the ceSERT D517N mutant showed a sizable decrease (~45%) when
comparing its respective MDMA:5-HT-induced current ratio with wild-type ceSERT, however
this was not the complete lack of MDMA-induced current that was found with wild-type dSERT
or the hSERT E493N mutant, further supporting a difference in the role of the outer gate in each
SERT background.
Also in direct support of the [3H]5-HT exchange studies, both dSERT N484D and
dSERT N484E demonstrate a gain of function compared to the wild-type dSERT, where both
mutants exhibit MDMA-induced currents for which the wild-type dSERT is unable to mediate
(Figure 42). Moreover, while the identity of the acidic amino acid does not alter the generation or
magnitude of MDMA currents induced in the dSERT or ceSERT mutants, hSERT demonstrates
a distinct preference for the presence of a Glu residue over an Asp as MDMA-induced current
for hSERT E493D is reduced by ~58% compared with the wild-type hSERT (after first being
normalized to each 5-HT-induced current, respectively, to control for differences in expression).
Our competitive binding data revealed that MDMA maintains the ability to bind and
inhibit 5-HT uptake in dSERT or hSERT E493N transporters that possess a polar Asn rather than
an acidic amino acid at the outer gate (Figure 41). Furthermore, MDMA should inhibit 5-HT165

Figure 42. The effect of outer gate composition on 5-HT and MDMA-induced currents.
Xenopus oocytes injected with mRNA transcripts that code for hSERT, dSERT, ceSERT or
one of each species’ respective outer gate mutants were examined for substrate-induced
currents four-seven days post-injection. Oocyte membranes were held at –60mV and were
challenged with either 10µM 5-HT (black bars) or 2, 10 or 20µM MDMA (gray bars). Traces
were smoothed and analyzed using LabChart (AD Instruments). Each trace is representative
of a much larger data set, where n ≥ 11. A summary of the average results for each construct
can be found in table 6.
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Table 6. Summary table for TEVC analysis of 5-HT and MDMA-induced currents. Listed are the average
magnitudes of currents generated under each listed condition when Xenopus oocytes expressing a SERT or SERT
outer gate mutant were challenged with 5-HT or MDMA. Each IMDMA value is listed and is also normalized to the
average I5-HT produced by that same transporter (column to the right of each IMDMA column). The N value listed for
each transporter is the number of individual oocytes tested under each condition. These oocytes are all taken from a
single Xenopus frog, but are representative of data from three frogs in total.

induced current in transporters that either lack or exhibit reduced MDMA-induced current. To
address this prediction, we used the TEVC method while simultaneously perfusing 0.5µM 5-HT
and a range of MDMA concentrations (Figure 43).
Whereas transporters containing an acidic amino acid at the outer gate all demonstrated
substrate-induced currents under all the tested conditions, with wild-type dSERT and the hSERT
E493N mutant we observe that higher concentrations of MDMA are capable of blocking the 5HT-induced current (Figure 43). Similarly, the ceSERT D517N mutant exhibits greatly reduced
5-HT-induced currents in the presence of increased MDMA concentrations, although the
substrate-induced current is not completely eliminated, as a small but significant MDMAinduced signal can be detected. A similar effect is seen with the hSERT E493D mutant, whereby
increasing the concentration of MDMA results in a decrease in the magnitude of the induced
current due to the decreased capacity of the hSERT E493D transporter to transport MDMA.
Overall though, increased concentrations of MDMA are capable of diminishing or even
eliminating the 5-HT-induced current in transporters with reduced MDMA transport capacities,
suggesting that MDMA remains capable of binding to transporters with and Asn at the outer gate
but that once bound the transporter is unable to initiate or complete the translocation mechanism.

Discussion
The use of species variants in the primary amino acid sequence of MATs to discern the
functions of individual residues has been a well-utilized and beneficial methodology (Barker et
al. 1994; 1999; Adkins et al. 2001; Henry et al. 2006b). Here, we demonstrate that the presence
of an acidic amino acid at the outer gate is vital for the ability of SERT to transport MDMA and
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Figure 43. MDMA binds and blocks 5-HT transport in transporters with an Asn at the
TM10 external gating position – (A) TEVC analysis, where the cell membrane was held at –
60mV and oocytes were simultaneously challenged with 1µM 5-HT and the amount of MDMA
labeled under each respective trace. Curves labeled control were only challenged with 5-HT.
Each trace is a representation of a much larger data set, where n ≥ 8. (B) Graphical
representation of TEVC data in (A), where each bar denotes the magnitude of the average
current induced at each tested condition as a percentage of the average magnitude generated
under the control (5-HT only) condition. A one-way ANOVA was performed for each
construct, and significant differences from the control are denoted with brackets above the bars.
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to mediate the process of MDMA-induced efflux.
The acidic amino acid found in the external gating position in TM10 of hSERT (E493) is
highly conserved throughout the SLC6 family (Beuming et al. 2006). Crystal structures from a
bacterial homolog of the MATs, LeuT, as well as a crystal structure of the dDAT provide direct
evidence that this acidic residue (an Asp in both LeuT and dDAT) forms an important interaction
with an Arg (homologous to R104 in hSERT) located at the cytoplasmic end of TM1, which aids
in stabilizing the formation of an outer gate (Yamashita et al. 2005; Singh et al. 2008; Penmatsa
et al. 2013). In most crystal structures, interaction between D404 (LeuT numbering) and R30
(LeuT) is shown to be water mediated, however in an inward-facing conformation of LeuT, there
is a direct ionic interaction between the two residues (Krishnamurthy and Gouaux 2012). This
provides strong evidence that the R30-D404 salt bridge produces a stronger and/or tighter seal to
effectively block access between the extracellular milieu the inside of the cell during the
translocation process.

In addition, such a bond would likely stabilize the inward-facing

conformation. The findings we present here indicate the importance of a negative charge at the
TM10 external gating position to the mechanism of MDMA transport in SERT (Figures 42 and
40), and therefore it is tempting to speculate that the formation of a salt bridge with R104
(hSERT) at the outer gate is a critical step of the MDMA translocation process.
Both charged gating residues form multiple interactions that are highly important to the
translocation mechanism. For instance, the well conserved gating residue R30 (LeuT numbering)
has been reported to form two additional hydrogen bonds with TM10 mediated through the polar
side chain of T409 and the backbone carbonyl of G408 (LeuT numbering; T497 and G498 in
hSERT), along with the salt bridge with the acidic residue on TM10 when the external gate is
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closed. Therefore, our substitution of this Arg with an acidic amino acid (Figure 37) likely
resulted in a disruption of the interactions that are necessary for the composition of the
extracellular gate, thereby destroying proper functionality of the transport mechanism. Our
findings are consistent with work on the GABA transporter GAT-1, where even the conservative
replacement of this TM1 Arg with a Lys completely eliminating substrate uptake activity
(Pantanowitz et al. 1993). This same conservative mutation in hSERT (R104K) retains
functionality, though it does impart a ~5-fold decrease in the Vmax for 5-HT transport and causes
a drastic decrease in allosteric potency of both the SSRI (S)-citalopram and the TCA
clomipramine (Plenge et al. 2012).
Analysis of the inward-facing crystal structure of LeuT suggests that, in addition to
preventing the access of extracellular milieu to the binding region when the transporter is facing
the cytoplasm, the salt bridge at the extracellular gate may also be important in the stabilizing of
TM1b during the process of structural rearrangement when moving to the inward-facing
conformation. This is consistent with the “rocking bundle” mechanism purposed by Forrest and
Rudnick, where TMs 1, 2, 6 and 7 act as a moving bundle against the stationary scaffold
composed of TMs 3, 4, 5, 8, 9 and 10, allowing the transporter to modulate through the outward,
occluded and inward states (Forrest and Rudnick 2009). In this way, the extracellular salt bridge
acts as an anchor, which tethers TM1b to TM10 (Figure 8) and keeps their position relatively
stable. This allows TM1a to pivot outward at a specific hinge point in the unwound region of
TM1 (Krishnamurthy and Gouaux 2012). The position of these hinge structures has profound
consequences for the substrate and both Na+ ion sites (termed Na1, the site adjacent to the
substrate binding site, and Na2, the site that is slightly more distal from the bound substrate)
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when the transporter is in the inward-open state. The hinge for TM1a is located at Leu25, which
is considerably more central than the Na2 binding site, leading to separation of residues on TM1a
from the static TM8 as TM1a undergoes a large shift away from the scaffold domain in order to
open the permeation pathway to the cytoplasm. This dramatic shift in the position of TM1a
relative to the scaffold domain effectively destroys the Na2 site and demonstrates how the
release of this Na+, the movement of TM1a and the opening of the transporter to the cytoplasm
are coupled. A similar mechanism has been suggested for the V. parahaemolyticus
sodium/galactose transporter (vSGLT) (Shimamura et al. 2010) and supported through both
biochemical and computational studies of SERT (Koldsø et al. 2011; Felts et al. 2014).
Likewise, there are two hinge residues in TM6, S256 in TM6a and F259 in TM6b. During
dynamic movement to the inward-facing conformation, these hinge regions remain relatively
static by comparison to residues at the ends of TMs 1 and 6. Therefore, because the hinge
residues undergo little displacement during the transition to the inward facing conformation,
many of the substrate binding residues on TMs 3 and 8 that are in close proximity to these hinge
regions remain unperturbed, maintaining the structural integrity of the aliphatic portion of the
substrate-binding pocket. Thus, although dramatic movements in positioning of TM1 and TM6
affect residues coordinating the amino group of the substrate (allowing for the dissociation of
substrate into the cytoplasm), a considerable portion of the substrate-binding pocket is retained in
the inward-open state, possibly preserving the ability of the transporter to bind substrate under
conditions of reversed substrate flux.
Similarly, the tethering of TM1b to the scaffold domain during the MDMA translocation
process may be crucial for the conformational shift to an inward facing pose. In fact, the overall
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stabilization of TM1b that is brought about by formation of the salt bridge at the outer gate could
have conformational consequences in the N-terminal tail, thereby allowing kinases to access
specific phosphorylation sites whose modification have been linked to the efflux mechanism
(Khoshbouei et al. 2004; Sucic et al. 2010; Cremona et al. 2011; Pizzo et al. 2013). Changes to
the conformation of the N-terminal tail could be substrate-dependent, as molecules of different
sizes and chemical groups could impart distinct inward-facing conformations, which may impact
the ability of the transporter to be post-translationally modified (ie phosphorylation). Likewise,
increased stability of the inward-facing conformation mediated by the external salt bridge or
alternative states resulting from MDMA transport could alter the conformational equilibria of the
transporter, resulting in an increase in the population of transporters facing the cytoplasm. Such
changes in the conformational equilibria of the transporter have previously been associated with
the uncoupled flux of Na+ ions, as it is the presence of these suprastoichiometric Na+ ions in the
cytoplasm that are thought to thermodynamically drive efflux (Scholze et al. 2000; Sitte et al.
2000; Schicker et al. 2011). Furthermore, changes in the conformational equilibria of the
transporter are altered by interaction of the phospholipid PIP2 with the N-terminus, a connection
that, when impeded, modifies the magnitude of uncoupled current flux through SERT
(Buchmayer et al. 2013) and eliminates the ability of DAT to mediate efflux (Hamilton et al.
2014).
Recently, Blakely and colleagues described a DAT mutation, A559V, which is found in a
small population of humans diagnosed with attention deficit hyperactivity disorder (ADHD)
(Mazei-Robison et al. 2008). Studies revealed that DAT A559V exhibits enhanced non-vesicular,
DAT-dependent DA release and unexpectedly DA efflux is actually blocked by AMPH as
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opposed to enhancing efflux as seen with wild-type hDAT. Likewise, the presence of an Asn at
the TM10 gating position in dSERT and the hSERT E493N mutant (rather than an acidic amino
acid), yielded a transporter where MDMA functions as an antagonist rather than a substrate. In
addition, we found that Asn at the outer gate increases the rate of basal efflux through SERT to a
level comparable to the hDAT A559V mutant (data not shown). Therefore, it is possible that the
effect of the DAT A559V mutation on the overall structural dynamic of the transporter may
result in a similar alteration of conformational equilibria, thereby producing a similar phenotype.
Currently, the molecular components and interactions necessary to engage the
translocation mechanism remain poorly understood and even controversial. Evidence from Shi et
al. that suggests that an additional molecule of substrate may be requisite to trigger the
completion of the translocation mechanism of SLC6 transporters (Shi et al. 2008). This study in
LeuT employed biochemical techniques in concert with molecular dynamic simulations to
propose the existence a second substrate-binding site (termed S2) just above where the salt
bridge divides the extracellular vestibule from the core-binding region of the transporter (S1).
Although a crystal structure showing substrate bound to this S2 site has not been discovered and
these claims of an S2 site are contested by studies from the Goaux lab, several studies from the
Javitch group have presented compelling evidence for its existence (Zhou et al. 2007; Singh et al.
2008; Zhou et al. 2009). Javitch and colleages suggest that the S2 site is obstructed from
substrate binding during crystallography by requisite detergents used in the process of crystal
formation, which occupy the S2 site and outcompete leucine binding (Quick et al. 2009; 2012).
However, this putative S2 site shares many of the same attributes as S1, such as the hydrophobic
pocket, which accommodates the aliphatic substrate side chain, and an “ionic cleft” formed by
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the gating residues D404 and R30, which coordinate with the carboxyl and amine groups of the
substrate (Shi et al. 2008). Reportedly, binding of substrate at S2 occurs once the outer gate is
closed and the transporter is in an occluded conformation. MD simulation data, as well as several
eloquent biochemical assays, demonstrated that the two molecules of substrate are capable of
binding to LeuT at the same time and that occupancy of the S2 site by leucine is critical for
substrate translocation. These data lead the authors to purpose a mechanism, whereby the
binding of substrate to S2 is critical for triggering the release of one of the Na+ ions (Na1) and
the substrate bound at S1 into the cytoplasm. To our knowledge, no one has looked to determine
if such a model holds true with MDMA or AMPH.
Nevertheless, assuming that the two-site model is correct, 5-HT can bind to both S1 and S2
and act as a substrate even if the TM10 gate residue is Asn (Table 4). However, it is possible that
the size or chemical makeup of MDMA prohibits it from binding to the S2 site without an acidic
residue to support its coordination. Under these conditions, 5-HT would bind both sites and
promote translocation but MDMA would be incapable of engaging the transport process, as it
could only bind the S1 site. Our [3H]5-HT competitive uptake data demonstrates that MDMA
acts as an antagonist at dSERT and hSERT E493N, which lack the acid gate residue (Figures 41
and 43). This would explain why AMPH remains capable of binding with relatively high potency
to transporters containing an Asn at the external gate, as the S1 site would be unperturbed by
alterations at the outer gate. However, our current analysis lacks the resolution to determine if
MDMA is biding to S1, S2 or both. Future work will involve targeting the S2 site to characterize
its involvement in the recognition of MDMA as a substrate.
In summary, our work demonstrates that the presence of an acidic amino acid at the outer
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gate is critical for the recognition of MDMA as a substrate and the induction of the efflux
machinery. This study is the first, to our knowledge, in eukaryotic transporters to demonstrate
how a single mutation can completely alter the ability of the transporter to recognize a ligand as
either an agonist or antagonist. Previous work by Piscitelli et al also characterize a single
mutation that alters ligand recognition, whereby the introduction of the I359Q mutation in the
binding site of LeuT resulted in the recognition of the classical LeuT antagonist tryptophan as a
functional substrate (Piscitelli and Gouaux 2012). Both of our studies emphasize how even a
single mutation can completely alter the functionality of the transporter, highlighting the intricate
nature of the transport machinery. In the case of the acidic residue on TM10 that we characterize
here, we speculate that the presence of a negative charge at the external gate is likely important
because it allows for the formation of a salt bridge with an Arg on TM1, which is critical for the
maintenance of a closed outer gate. The formation of this salt bridge may also be mechanistically
important for the stabilization of a critical intermediary step in the MDMA translocation process,
and play a role in mediating other SERT functions, such as the uncoupled flux of Na+ ions and
the AMPH-induced efflux of substrate.
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CHAPTER VI
NOVEL AZIDO-IODO PHOTOAFFINITY LIGANDS FOR THE SEROTONIN
TRANSPORTER BASED ON THE SELECTIVE SEROTONIN REUPTAKE
INHIBITOR (S)-CITALOPRAM
Introduction
The serotonin transporter (SERT) is a member of the solute carrier 6 (SLC6) family of
transporters that functions to regulate serotonin neurotransmission and homeostasis(Kristensen et
al. 2011; Pramod et al. 2013; Rudnick et al. 2014). In particular, selective serotonin reuptake
inhibitors (SSRIs) and tricyclic antidepressants (TCAs), widely prescribed medications for
treatment of anxiety and major depressive disorders, principally work by binding to SERT and
inhibiting serotonin reuptake into presynaptic neurons (Gillman 2007; Pastoor and Gobburu
2014). Notably, (S)-citalopram (Escitalopram, Figure 44) binds with high affinity and selectivity
to hSERT. However, despite its well-documented clinical success, the molecular interactions
between (S)-citalopram and hSERT that determine its reuptake inhibition potency and selectivity
over other monoamine transporters (i.e., the norepinephrine transporter (NET) and dopamine
transporter (DAT)) remain poorly understood.
The 3-D structure of SERT, as well as its structure, function, and regulation, including
oligomerization and distribution in cells or brain tissue, have been studied with small molecular
probes containing electrophiles (e.g. N3, NCS) and radiolabels (e.g. 3H,

125

I) (Smith and Collins

2015). In particular, the well-known technique of photoaffinity labeling utilizes molecular probes
that contain a functional group capable of forming a covalent bond to a biological target upon
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Figure 44. Chemical structures of (S)-citalopram and known DAT and/or SERT
inhibitor PALs. Depicted are a two-dimensional representation of the chemical
structures for (1) (S)-citalopram, (2) RTI-82, (3) MFZ 2-24, (4) JHC 2-48, (5)
paroxetine, (6) 2-nitroimipramine and (7) the arylazido derivative of serotonin, 3-(fl(4-azidobenzami- dino)ethyl)-5-hydroxyindole (SABA).
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photoactivation (Chuang and Otagiri 2013). Of the numerous photoreactive functional groups
that can be employed in the design of photoaffinity ligands (PALs) (e.g., benzophenones,
aliphatic and aromatic diazirines, etc.), aryl azides are most effectively used given their relatively
small size, ease of synthetic incorporation, and chemical stability (Lochner 2010).
Numerous [125I]-radiolabelled-arylazido analogs of dopamine transporter (DAT)
inhibitors including cocaine (Carroll et al. 1992; Zou et al. 2001; Lever et al. 2005; Newman et
al. 2006), GBR12909 (Grigoriadis et al. 1989; Sallee et al. 1989; Dutta et al. 2001; Cao et al.
2004), benztropine (Agoston et al. 1997; Zou et al. 2001; 2003), pyrovalerone (Lapinsky et al.
2009; 2012), bupropion (Lapinsky et al. 2012), and methylphenidate (Lapinsky et al. 2011) have
been developed to elucidate molecular components of the ligand-binding site and mechanisms
underlying uptake inhibition. The 4’azido, 3’-iodo-substituted phenyl ring is a common
structural motif found in many PALs that bind DAT irreversibly upon photoactivation (e.g., RTI
82, MFZ 2-24 and JHC 2-48; Figure 44) (Carroll et al. 1992; Zou et al. 2001; Lever et al. 2005;
Newman et al. 2006). Specifically, the tropane-based PALs RTI-82 and MFZ 2-24 have been
instrumental in defining drug-protein interactions at the molecular level and thus further defining
the structural components of DAT that are critical for transport inhibition by cocaine (Vaughan
et al. 1999; Parnas et al. 2008; Dahal et al. 2014).
In contrast to DAT PALs, the development of SERT selective PALs has been more
limited.

To the best of our knowledge, only a few PALs have been synthesized and

experimentally validated to label SERT (Figure 44). Although the tropane-based PALs bind to
SERT as well as DAT, to date, only MFZ 2-24 has been used to photolabel the hSERT
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Figure 45. Substitutions at the C-1 and C-5 position on the (S)-citalopram
structure for the PALs VK03-51, VK03-83 and NYDU-2-24. Shown is the basic
parental structure of (S)-citalopram (left) and a table that defines the chemical
constituents found at the C-5 (R1) and C-1 (R2) positions for (S)-citalopram, VK03-51,
VK03-83 and NYDU-2-24, respectively.
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(Zou et al. 2001; Lever et al. 2005; Henry et al. 2006b). Other inhibitor-based ligands that
photolabel SERT include the aryl-azido derivative of the SSRI paroxetine (Chudzik et al. 1995)
and a tricyclic antidepressant-based PAL, [3H]-2-nitroimipramine that showed covalent
incorporation into SERT present in membrane homogenates of rat brain and liver, and human
platelets (Rehavi et al. 1983; Wennogle et al. 1985). Finally, photoinactivation of serotonin
uptake has been demonstrated by an azidobenzamidine derivative of serotonin (Ransom et al.
1985). However, to date none of these SERT PALs have been used to define the structural basis
of their binding interactions at the hSERT.
Based on the successful application of PALs (Vaughan et al. 1999; Parnas et al. 2008;
Dahal et al. 2014) in elucidating drug-binding site interactions at DAT our concept for the
present study was that appending the 4’-azido, 3’-iodo aryl moiety onto different positions of the
(S)-citalopram base might reveal different sites of adduction on hSERT that would enable a
clearer understanding of the (S)-citalopram binding mechanism. Extensive structure-activity
relationships have been described with analogs of citalopram that suggest positions C-1 and C-5
can accommodate significant steric bulk without appreciable loss in hSERT binding affinity
(Zhang et al. 2010; Banala et al. 2013; Kumar et al. 2014). Herein, described is the
pharmacological evaluation of three novel C-1 or C-5 substituted 4’-azido, 3’-iodo- analogues of
(S)-citalopram (named NYDU-2-24, VK03-51 and VK03-83; Figure 45) and demonstrated is
their ability to covalently label hSERT upon photoactivation.
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Methodology
Whole-cell Competition Uptake Assay
HEK-293 GripTite™ cells

(Invitrogen) were plated in 24-well Culturplates

(PerkinElmer) at 50,000 cells/well and transiently transfected with wild-type hSERT or hSERT
S438T-conttaining pcDNA3 based plasmid constructs using the Trans-IT LTI transfection
system (Mirus Bio). Assays were conducted 36-48 hours after transfection where cells were
washed using MKRHG buffer (5mM Tris, 7.5mM HEPES, 120mM NaCl, 5.4mM KCl, 1.2mM
CaCl2, 1.2mM MgSO4, 10mM Dextrose, pH 7.4), preincubated with the competitor compounds
for 5 minutes followed by addition of [3H]5-HT at a final concentration of 50nM. Uptake was
allowed to proceed for 10 minutes and then terminated by washing twice with ice-cold MKRHG.
[3H]5-HT uptake was quantified by dissolving cells in Microscint-20 (PerkinElmer) and using
the Packard TopCount NXT (PerkinElmer) to measure radioactivity (CPM). Data were
normalized to percent activity in the absence of a drug competitor for each form. Assays were
carried out in triplicate and were repeated at least four times. Ki values were determined using
Prism 5 (GraphPad).
hSERT Photoaffinity Labeling
Photoaffinity labeling of hSERT was performed using methods that have been verified
previously for assessing irreversible adduction of a variety of ligands for both DAT and SERT
(Agoston et al. 1997; Vaughan et al. 1999; Lever et al. 2005; Newman et al. 2006; Henry et al.
2006b; Parnas et al. 2008; Lapinsky et al. 2009; 2011; 2012; Dahal et al. 2014). These
procedures were performed using LLCPK1 cells stably expressing HA-hSERT (generous gift of
Dr. James Foster) and with untransfected parent LLCPK1 cells for negative controls. Cells were
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grown to 90% confluence in 12-well plates and washed with KRH buffer. [125I]VK03-51,
[125I]VK03-83 and [125I]NYDU-2-24 were added to a final concentration of 10nM and incubated
for 1.5 hours at 4ºC. In some experiments, hSERTs were irreversibly labeled in parallel with
[125I]MFZ 2-24 as a positive control (Henry et al. 2006b). For pharmacological displacement,
10µM (S)-citalopram was added 30 minutes prior to addition of the radioligands. Cells were
irradiated with shortwave ultraviolet light (254nm, Fotodyne UV Lamp model 3-6000) for 5
minutes at a distance of 15–20mm to photoactivate the radioligand, washed twice with 1mL of
ice-cold KRH buffer and lysed by addition of 0.5mL of RIPA buffer (50mM NaF, 2mM EDTA,
125mM Na3PO4, 1.25% Triton X-100, and 1.25% sodium deoxycholate) containing protease
inhibitors for 30 minutes on ice. Lysates were centrifuged at 20,000 x g for 15 minutes at 4ºC to
remove insoluble material and subjected to immunoprecipitation and immunoblotting using antiHA monoclonal antibody (Covance) or anti-SERT antibody ST51 (mAB Technologies) as
previously described (Henry et al. 2006b). Immunoprecipitated samples were separated on 420% SDS-polyacrylamide gels followed by autoradiography (Hyperfilm MP film; GE
Healthcare) for 1-3 days at –80ºC. For immunoblotting, cell lysates were separated on 4–20%
SDS-polyacrylamide gels transferred to 0.45mm polyvinylidene difluoride membranes and
probed for hSERT with anti-HA antibody.

Results
Pharmacological properties of NYDU-2-24, VK-03-51 and VK-03-83
Inhibition of [3H]5-HT uptake by WT hSERT and the hSERT S438T mutant was
evaluated to determine inhibitory constants for NYDU-2-24, VK03-51, VK03-83, and (S)183

citalopram. When tested against WT hSERT the C-5 substituted PALs NYDU-4-24 and VK0383 showed affinities of 24nM and 38nM, respectively, values that were reduced by 11-fold and
17-fold compared to that of (S)-citalopram (Ki = 2.2nM) (Figure 46, Table 7). In contrast, the C-1
substituted PAL VK03-51 showed a greater reduction in affinity (Ki = 227nM, 100-fold)
compared to (S)-citalopram, which is in accord with structure-activity relationships previously
described (Banala et al. 2013). When tested against hSERT S438T, all four compounds showed
dramatic rightward shifts in inhibitory potency (Figure 46, dashed lines) with Ki values ranging
from 3.8 to 9.9µM (Table 7). These findings are consistent with previous reports that S438 is a
key residue for high-affinity binding of many hSERT antagonists and that its mutation to Thr
results in significant loss in potency for (S)-citalopram and many other hSERT inhibitors
(Andersen et al. 2009). Interestingly, the C-1-substituted PAL VK03-51 demonstrated
significantly lower affinity than (S)-citalopram or the other PALs for WT hSERT, but an affinity
that trended higher for the S438T mutant. Moreover, the difference in binding affinities between
the mutant and WT hSERT for VK03-51 was only 17-fold, as compared to the significantly more
dramatic shift for the parent ligand, (S)-citalopram (~3600-fold).
Photoaffinity labeling experiments with hSERT
Next, we tested [125I]VK03-51, [125I]VK03-83 and [125I]NYDU-2-24 for irreversible labeling of
HA-hSERT upon photoactivation (Figure 47). For these studies, HA-hSERT LLCPK1 cells were
incubated with the PALs in the presence or absence of (S)-citalopram as indicated, and irradiated
with UV light to cross link the ligand to the protein. Lysates were immunoprecipitated with antiHA or anti-hSERT antibodies, and samples analyzed by SDS-PAGE and autoradiography. These
methods, have been used to verify photolabeling of DAT and SERT by numerous structurally
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Figure 46. [3H]5-HT uptake inhibition analysis for (S)-citalopram, VK0351, VK03-83 and NYDU-2-24. HEK-293 Griptite™ cells expressing hSERT
(solid lines) or hSERT S438T (dashed lines) were assayed for [3H]5-HT
uptake in the presence of the indicated concentrations of (S)-citalopram (filled
circles), VK03-51 (open squares), VK03-83 (open circles) or NYDU-2-24
(filled squares). Data shown are means ± SEM of transport activity for each
form in the absence of competitor, set to 100%. Assays were conducted in
triplicate and were repeated at least four times.
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hSERT (Ki ,nM)

hSERT S438T (Ki ,nM)

(S)-citalopram

2.2 ± 0.17

7879 ± 1300*

VK03-51

227 ± 23#

3811 ± 590*

VK03-83

38 ± 2.9#

9879 ± 1200*

NYDU-2-24

24 ± 2.2#

5697 ± 745*

Table 7. Inhibitory constants of (S)-citalopram, VK03-51, VK03-83
and NYDU-2-24 for [3H]5-HT transport by hSERT and hSERT
S438T. Data are Ki values (nM) (means ± SEM) for the ability of the
(S)-citalopram-based PALs to inhibit uptake of [3H]5-HT as shown in
Figure 6.3. Ki values were calculated using the Cheng-Prusoff equation
in GraphPad Prism 5. Data were analyzed by paired t-tests for
statistical significance where * denotes the Ki value obtained with the
hSERT S438T mutant is significantly different than the Ki for WT
hSERT (p < 0.001) and # indicates that the Ki value for the analog is
significantly different than the Ki for (S)-citalopram obtained with WT
hSERT (p < 0.001). The Ki values obtained with hSERT S438T for the
analogs and (S)-citalopram were not statistically different from one
another.
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NYDU-2-24

VK03-83

VK03-51

MFZ-2-24

Figure 47. Photoaffinity labeling of hSERT. HA-hSERT LLCPK1 cells or
nontransfected (parent) LLCPK1 cells were incubated with the indicated ligands in the
absence (–) or presence (+) of 10µM (S)-citalopram (S-Cit). Cell lysates were
immunoprecipitated with Anti-HA antibodies followed by SDS-PAGE and
autoradiography to detect [125I] radiolabeled proteins (upper panels) or were analyzed
by immunblotting (IB) with anti-HA to detect total hSERT (lower panels). Results
are representative of three independent experiments.
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diverse tropane and non-tropane based ligands (Agoston et al. 1997; Vaughan et al. 1999; Lever
et al. 2005; Newman et al. 2006; Henry et al. 2006b; Parnas et al. 2008; Lapinsky et al. 2009;
2011; 2012; Dahal et al. 2014). The results show that [125I]VK03-51, [125I]VK03-83 and
[125I]NYDU-2-24 all covalently label a protein of the expected hSERT molecular mass of ~100
kDa when using HA-hSERT cells, but that this band was not obtained from non-transfected
hSERT-null parent cells (upper panels), supporting the identity of the band as hSERT.
Immunoblotting (lower panels) verified the presence and absence of hSERT in transfected and
untransfected cells, respectively. The photoaffinity labeled proteins were immunoprecipitated
using anti-HA antibody (Figure 47), as well as with the anti-hSERT antibody ST-51 (not shown),
but were not precipitated with non-immune IgG (not shown), also supporting the identity of the
bands as hSERT. Similar results were obtained using the tropane PAL MFZ 2-24, which was
previously demonstrated to photolabel hSERT (Henry et al. 2006b). Together these results
demonstrate that hSERT protein is irreversibly labeled with [125I]VK03-51, [125I]VK03-83 and
[125I]NYDU-2-24, providing the first demonstration of photoaffinity labeling of hSERT by
analogs of (S)-citalopram.
For pharmacological characterization of irreversible labeling, HA-hSERT-LLCPK1 cells
were incubated with either vehicle or 10µM (S)-citalopram prior to addition of the radioiodinated
PALs. Incorporation of [125I]VK03-83 and [125I]NYDU-2-24 was blocked by >99% (Figure 47,
left and center-left panels), demonstrating that (S)-citalopram fully displaces these C-5
substituted radioligands prior to photoactivation, further supporting the identity of this protein as
hSERT. Similar results were obtained for displacement of hSERT labeling by [125I]MFZ 2-24, as
we previously demonstrated (Henry et al. 2006b). In contrast, 10µM (S)-citalopram inhibited
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[125I]VK03-51 labeling of hSERT by only ~30%, suggesting that this C-1-substituted PAL
possesses a different pharmacological profile than the two C-5-substituted ligands. In a previous
SAR study wherein (S)-citalopram was modified by N-substitution at the C-5 position with a
second molecule of (S)-citalopram to create a homobifunctional ligand, binding data suggested
simultaneous interaction of the ligand with the S1 and S2 binding sites (Banala et al. 2013). (S)citalopram binds to both S1 and S2 sites, however, its affinity for S2 is much lower than for S1
(Plenge et al. 2012). Thus it is conceivable that [125I]VK03-51 may be binding to both S1 and S2
sites and the latter might not be fully inhibited by 10µM (S)-citalopram (Plenge et al. 2012;
Banala et al. 2013).

Discussion
So far, two binding sites have been identified in the crystal structures of inhibitor-bound
LeuT: the centrally located substrate S1 binding pocket and the extracellular vestibule, which
contains the putative S2 binding site (Singh et al. 2007; Zhou et al. 2007; Singh et al. 2008; Zhou
et al. 2009). The equivalent regions in SERT are natural candidates for harboring ligand-binding
sites. Indeed, re-evaluation of extensive mutational analysis shows that the majority of residues
that are critical for recognition of inhibitors are located in the TM and loop regions that
contribute to the formation of the extracellular permeation pathway and the substrate binding
pocket (Chen and Rudnick 2000; Goldberg et al. 2003; Neubauer 2006; Henry et al. 2006b;
Andersen et al. 2009; 2010; Koldsø et al. 2010; Sinning et al. 2010).
Since the co-crystallization of LeuT with a set of noncompetitive inhibitors, including
TCAs and SSRIs (Singh et al. 2007; Zhou et al. 2007; 2009), we now know that antagonists may
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function in a more non-competitive mechanism as well as in a classic competitive manner (Zhou
et al. 2007; 2009). Despite this, the majority of biochemical evidence indicates that the primary
high-affinity binding site for TCAs and SSRIs, including those co-crystallized with LeuT, likely
occurs in the S1 site of SERT (Henry et al. 2006a; Gouaux 2009). However, some studies have
found that TCAs and SSRIs, in addition to binding to a high-affinity binding site, may also bind
to a low-affinity allosteric site in SERT (Sette et al. 1983; Plenge and Mellerup 1985; Segonzac
et al. 1985; Wennogle et al. 1985; O'Riordan et al. 1990; Plenge et al. 1991; Chen et al. 2005a).
Binding to this allosteric site markedly increases the off-rate of the inhibitor bound to the highaffinity binding site. It has been suggested that the allosteric site is situated corresponding to a
suggested oligomeric interface in the transporter (Neubauer 2006); however, it is tempting to
speculate that the allosteric site could be situated in the S2 vestibule outside the primary S1
binding pocket.
While irreversible labeling by the C-5 substituted [125I]VK03-83 and [125I]NYDU-2-24
was completely eliminated by pre-incubation with (S)-citalopram, irreversible labeling by the C1 substituted [125I]VK03-51 was reduced by only ~30% with (S)-citalopram pre-incubation. The
inability of (S)-citalopram to completely block [125I]VK03-51 hSERT photolabeling indicates
that this PAL has complex hSERT binding properties compared to the C-5-substitituted PALs,
[125I]VK03-83 and [125I]NYDU-2-24. Indeed, one explanation for this nuance between the C-1
and C-5 analogue binding profiles could be a preference by the C-1 substituted VK03-51 for the
S2 site over the high-affinity S1 site. This concept is further supported by the fact that VK03-51
exhibits a ten-fold increase in Ki when compared with the C-5 substituted VK03-83 and NYDU4-24. If VK03-51 does preferentially coordinate within the S2 site, this would mean that
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characterization of the point of covalent attachment following photolabeling could provide the
first direct evidence of an antagonist coordinating with a residue in the extracellular vestibule
when bound. Likewise, use of the two C-5 substituted photolabeled analogues could also help
determine the orientation of bound citalopram in the S1 site. Together, these findings would
represent a huge step forward in our understanding of the inhibitory mechanisms, both
competitive and non-competitive, employed by the highly SERT selective inhibitor (S)citalopram.
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